<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4687717</article-id><article-id pub-id-type="pmid">26683658</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0145322</article-id><article-id pub-id-type="publisher-id">PONE-D-15-45236</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer</article-title><alt-title alt-title-type="running-head">Signature Pathways of Human Prostate Cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Myers</surname><given-names>Jennifer S.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>von Lersner</surname><given-names>Ariana K.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Robbins</surname><given-names>Charles J.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sang</surname><given-names>Qing-Xiang Amy</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Chemistry and Biochemistry, Florida State University, Tallahassee, Florida, United States of America</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Institute of Molecular Biophysics, Florida State University, Tallahassee, Florida, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Cao</surname><given-names>Jian</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Stony Brook University, UNITED STATES</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: QXAS JSM. Performed the experiments: JSM AKVL CJR. Analyzed the data: QXAS JSM AKVL CJR. Contributed reagents/materials/analysis tools: QXAS JSM AKVL CJR. Wrote the paper: QXAS JSM AKVL CJR.</p></fn><corresp id="cor001">* E-mail: <email>qxsang@chem.fsu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>12</issue><elocation-id>e0145322</elocation-id><history><date date-type="received"><day>14</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>2</day><month>12</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Myers et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Myers et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0145322.pdf"/><abstract><p>Genomic technologies including microarrays and next-generation sequencing have enabled the generation of molecular signatures of prostate cancer. Lists of differentially expressed genes between malignant and non-malignant states are thought to be fertile sources of putative prostate cancer biomarkers. However such lists of differentially expressed genes can be highly variable for multiple reasons. As such, looking at differential expression in the context of gene sets and pathways has been more robust. Using next-generation genome sequencing data from The Cancer Genome Atlas, differential gene expression between age- and stage- matched human prostate tumors and non-malignant samples was assessed and used to craft a pathway signature of prostate cancer. Up- and down-regulated genes were assigned to pathways composed of curated groups of related genes from multiple databases. The significance of these pathways was then evaluated according to the number of differentially expressed genes found in the pathway and their position within the pathway using Gene Set Enrichment Analysis and Signaling Pathway Impact Analysis. The &#x0201c;transforming growth factor-beta signaling&#x0201d; and &#x0201c;Ran regulation of mitotic spindle formation&#x0201d; pathways were strongly associated with prostate cancer. Several other significant pathways confirm reported findings from microarray data that suggest actin cytoskeleton regulation, cell cycle, mitogen-activated protein kinase signaling, and calcium signaling are also altered in prostate cancer. Thus we have demonstrated feasibility of pathway analysis and identified an underexplored area (Ran) for investigation in prostate cancer pathogenesis.</p></abstract><funding-group><funding-statement>This work was in part supported by the Leslie N. Wilson-Delores Auzenne Graduate Assistantship for Minorities awarded to JSM by the Florida State University Graduate School, the Research Experience Program of Women in Math, Science, and Engineering of Florida State University to AKVL, and grants from the Florida State University and an Endowed Chair Professorship in Cancer Research from anonymous donors to QXAS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="8"/><page-count count="27"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Prostate cancer is the second most diagnosed cancer among American men, with over 220,000 new cases predicted in 2015 [<xref rid="pone.0145322.ref001" ref-type="bibr">1</xref>]. Prostate-specific antigen (PSA) has been the cornerstone of prostate cancer screening for decades. However PSA is not an ideal biomarker and widespread use of PSA-screening is falling out of favor [<xref rid="pone.0145322.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="pone.0145322.ref004" ref-type="bibr">4</xref>]. Reliance on PSA screening is problematic because false positives result from benign prostatic hyperplasia or prostatitis and because PSA fails to discriminate indolent disease, leading to overdiagnosis. The expansion of genomic and proteomic technology and methodology has improved the characterization of tumor biology, driving the search for more accurate cancer biomarkers. Gene and protein expression differences between normal and malignant prostate tissues have been well documented and serve as a pool for putative diagnostic, prognostic, and risk stratification biomarkers [<xref rid="pone.0145322.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0145322.ref024" ref-type="bibr">24</xref>]. Gene mutations, epigenetic changes, and microRNA expression changes that occur in cancer initiation and progression have also been studied with the goal of biomarker discovery [<xref rid="pone.0145322.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0145322.ref029" ref-type="bibr">29</xref>]. Yet there remain several substantial obstacles in biomarker implementation. Low reproducibility across laboratories, differences in experimental platforms and techniques, the inherent heterogeneity of prostate cancer, and insignificant clinical utility or small gains in sensitivity and specificity beyond PSA hampers the identification, validation, and implementation of biomarkers [<xref rid="pone.0145322.ref030" ref-type="bibr">30</xref>&#x02013;<xref rid="pone.0145322.ref035" ref-type="bibr">35</xref>].</p><p>Previous work has focused on the selection and validation of individual genes as biomarkers. Yet the heterogeneity of prostate cancer makes it extremely unlikely to find a single gene that is a representative marker [<xref rid="pone.0145322.ref036" ref-type="bibr">36</xref>]. Screening panels formed by the combination of multiple genes have been used to increase predictive power for cancer detection, recurrence, relapse, and survival beyond the use of PSA or Gleason score alone [<xref rid="pone.0145322.ref037" ref-type="bibr">37</xref>&#x02013;<xref rid="pone.0145322.ref040" ref-type="bibr">40</xref>]. The success of the biomarker panel approach is evidenced by the commercial launch of several screening tests which have found clinical usefulness: ProMark [<xref rid="pone.0145322.ref041" ref-type="bibr">41</xref>], Oncotype DX [<xref rid="pone.0145322.ref042" ref-type="bibr">42</xref>], Prolaris [<xref rid="pone.0145322.ref043" ref-type="bibr">43</xref>], and Decipher [<xref rid="pone.0145322.ref044" ref-type="bibr">44</xref>]. These panels may be pulled from molecular classifications studies that use differential expression to craft a signature for cancer.</p><p>However molecular classifications and gene signatures are not always stable in the sense that multiple signatures can be found for cancers. Large discrepancies between lists of differentially expressed genes (DEGs) from microarray data have been highlighted [<xref rid="pone.0145322.ref045" ref-type="bibr">45</xref>]. In some cases the overlap between microarray datasets was as low as 5% [<xref rid="pone.0145322.ref046" ref-type="bibr">46</xref>]. So for each set of DEGs, a different signature could be found. Thus biomarkers selected from these lists would perform with varying degrees of success. Taking the list of DEGs and correlating them to a prognostic marker may generate a more useful putative biomarker pool because then only genes correlated with prognosis would comprise the molecular signature. However, Ein-Dor <italic>et al</italic>. showed that in breast cancer, there was no single, unique set of genes that predicted survival because altering the patient population could produce multiple sets of genes of equal prognostic ability in predicting survival [<xref rid="pone.0145322.ref033" ref-type="bibr">33</xref>]. Furthermore, correlation with survival was not required for prognostic ability [<xref rid="pone.0145322.ref033" ref-type="bibr">33</xref>]. So it is likely that many panels exclude a number of other genes that could be potential biomarkers because the panel was derived from one body of samples (although it may be large) and considered only strongest correlations.</p><p>An alternative approach is pathway-based analysis. In pathway analysis, a collection of related genes from the same pathway or network of interaction is assessed instead of examining a group of potentially unrelated genes that optimize sensitivity and selectivity of diagnosis or prognosis. There is increased overlap between data at the pathway level compared to overlap between lists of DEGs [<xref rid="pone.0145322.ref046" ref-type="bibr">46</xref>, <xref rid="pone.0145322.ref047" ref-type="bibr">47</xref>]. Pathway analysis does not neglect the cooperative nature of genes and considers that oftentimes genes involved in the same process are often deregulated together. By looking at the pathway, minor variations in instrumentation or method are less likely to impact results, leading to more consistent results across different sets of data [<xref rid="pone.0145322.ref048" ref-type="bibr">48</xref>]. Thus the pathway approach yields more robust results, improves disease classification, and may reveal novel insights about a disease [<xref rid="pone.0145322.ref049" ref-type="bibr">49</xref>&#x02013;<xref rid="pone.0145322.ref051" ref-type="bibr">51</xref>]. One type of pathway analysis starts with a differentially expressed gene and correlates the expression of genes involved in the same pathway or similar process with a particular diagnostic or prognostic outcome [<xref rid="pone.0145322.ref052" ref-type="bibr">52</xref>&#x02013;<xref rid="pone.0145322.ref054" ref-type="bibr">54</xref>]. A similar iteration starts with a pathway of known importance in cancer initiation or progression and evaluates the prognostic power of its individual components. This has been done for the mitogen-activated protein kinase (MAPK) pathway [<xref rid="pone.0145322.ref055" ref-type="bibr">55</xref>], Akt [<xref rid="pone.0145322.ref056" ref-type="bibr">56</xref>], mTOR pathway [<xref rid="pone.0145322.ref057" ref-type="bibr">57</xref>, <xref rid="pone.0145322.ref058" ref-type="bibr">58</xref>], Toll-like receptor signaling pathway [<xref rid="pone.0145322.ref059" ref-type="bibr">59</xref>], and other oncogene signatures [<xref rid="pone.0145322.ref060" ref-type="bibr">60</xref>].</p><p>In this paper, comprehensive gene expression in human prostate cancer was characterized using an unbiased pathway approach. Next generation sequencing was used to obtain a profile of the differences in RNA expression between human tumors and non-malignant tissue from patients. Pathway analysis included Gene Set Enrichment Analysis and Signaling Pathway Impact Analysis. Two pathways were significantly associated with human prostate tumors&#x02014;&#x0201c;Ran regulation of mitotic spindle formation&#x0201d; pathway and &#x0201c;transforming growth factor-beta (TGF-&#x003b2;) signaling&#x0201d; pathway.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><sec id="sec003"><title>RNA sequencing data</title><p>Level 3 de-identified data for prostate cancer samples and all available non-malignant samples from these prostate cancer patients was downloaded from The Cancer Genome Atlas (TCGA) data portal (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/">https://tcga-data.nci.nih.gov</ext-link>). Level 3 describes data that has been processed and aggregated to give gene expression signals for a sample. For each sample, the data contains expression counts for up to 20,531 coding and non-coding RNA transcripts plus clinical information such as age, stage, Gleason score, PSA level, and race/ethnicity. Before analysis, tumor and non-malignant samples were randomly pulled to achieve an age- and stage-matched pool of 225 samples (<xref rid="pone.0145322.s004" ref-type="supplementary-material">S1 Table</xref>). A total of 173 prostate cancer samples and 52 non-malignant samples from 204 unique patients were analyzed. The patient clinical information is presented in <xref rid="pone.0145322.t001" ref-type="table">Table 1</xref>.</p><table-wrap id="pone.0145322.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0145322.t001</object-id><label>Table 1</label><caption><title>Prostate cancer patient clinical information from TCGA.</title></caption><alternatives><graphic id="pone.0145322.t001g" xlink:href="pone.0145322.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Characteristics</th><th align="left" rowspan="1" colspan="1">Samples (n = 225)</th><th align="left" rowspan="1" colspan="1">Tumor (n = 173)</th><th align="left" rowspan="1" colspan="1">Non-Malignant (n = 52)</th><th align="left" rowspan="1" colspan="1">Fisher&#x02019;s Exact Test P-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Age</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c; 65</td><td align="left" rowspan="1" colspan="1">155</td><td align="left" rowspan="1" colspan="1">121</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">0.609</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x02265; 65</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Pathological T stage</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">T1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.649</td></tr><tr><td align="center" rowspan="1" colspan="1">T2</td><td align="left" rowspan="1" colspan="1">113</td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">T3</td><td align="left" rowspan="1" colspan="1">103</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">T4</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Unspecified</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Race</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.701</td></tr><tr><td align="center" rowspan="1" colspan="1">Black</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Unspecified</td><td align="left" rowspan="1" colspan="1">126</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ethnicity</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Not Hispanic</td><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Unspecified</td><td align="left" rowspan="1" colspan="1">129</td><td align="left" rowspan="1" colspan="1">122</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gleason Score</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">&#x02264; 6</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0.00168</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">129</td><td align="left" rowspan="1" colspan="1">89</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">8&#x02013;10</td><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec004"><title>Differential Gene Expression</title><p>The R programming environment (version 3.1.2) [<xref rid="pone.0145322.ref061" ref-type="bibr">61</xref>] was used to process raw data, perform statistical calculations, and perform differential expression analysis. After age- and stage-matching, 393 transcripts were removed because they lacked expression in the 225 samples comprising the dataset. The RNA counts for the remaining 20,138 transcripts were rounded to the nearest whole number and compiled into a matrix to build the dataset. The magnitude of expression changes relative to non-malignant samples was also calculated by taking the base 2 logarithm of the tumor/non-malignant mean expression ratio. For genes with no expression in either the tumor or non-malignant samples, the log<sub>2</sub> fold changes were adjusted by adding one to each mean and then calculating the ratio. All log<sub>2</sub> values quoted are values after any such adjustments. Negative fold changes indicated down-regulation in tumor samples whereas positive values indicated up-regulation. The R package DESeq2 (version 1.6.3) [<xref rid="pone.0145322.ref062" ref-type="bibr">62</xref>] was used to identify DEGs in the TCGA patient RNA data. The computing was done on the Florida State University High Performance Computing Cluster. DESeq2 returned a P-value determined by Wald statistics and an adjusted P-value (Q-value) to correct for multiple comparisons testing using the Benjamini-Hochberg method to determine the false discovery rate (FDR). DEGs were defined as genes different with a FDR less than 1% (Q &#x0003c; 0.01).</p><p>To evaluate the significance of the identified DEGs, analyses were conducted to search for overrepresented pathways, gene set enrichment, and signaling pathway impact. First, overrepresented elements were identified among the DEGs. The Protein ANalysis THrough Evolutionary Relationships (PANTHER) Classification System and analysis tools were used to categorize DEGs by PANTHER protein class, Gene Ontology (GO) Molecular Function, and GO Biological Process to then determine if any of these classes or GO terms were overrepresented [<xref rid="pone.0145322.ref063" ref-type="bibr">63</xref>]. The PANTHER Overrepresentation Test (release 20150430) was used to search the data against the PANTHER database (PANTHER version 10.0 Released 2015-05-15) and the GO database (Released 2015-05-09) to identify either protein classes or GO annotations overrepresented in our data when compared to a reference human genome. P-values were adjusted using a Bonferroni correction.</p></sec><sec id="sec005"><title>Pathway Analysis</title><p>Gene Set Enrichment Analysis (GSEA) [<xref rid="pone.0145322.ref064" ref-type="bibr">64</xref>] was used to identify groups of genes enriched in either the tumor or non-malignant condition. The GSEA analysis tool (version 2.2.0) was downloaded from the Broad Institute website (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gsea/index.jsp">http://www.broadinstitute.org/gsea/index.jsp</ext-link>). Curated gene sets of BioCarta and Reactome pathways were downloaded from the Broad Institute&#x02019;s Molecular Signatures Database. An additional gene set was constructed from Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways [<xref rid="pone.0145322.ref065" ref-type="bibr">65</xref>]. Pathways with the least relevance to prostate cancer were excluded. The KEGG pathways included in the analysis are listed in the Supporting Information (<xref rid="pone.0145322.s005" ref-type="supplementary-material">S2 Table</xref>). The entire RNA expression count matrix was loaded into the GSEA application without limiting the input to only DEGs. Both small (&#x0003c; 5 genes) and large (&#x0003e; 500 genes) gene sets were excluded from the analysis.</p><p>Signaling Pathway Impact Analysis (SPIA) was used to assess the importance of enriched pathways in terms of their impact and ability to activate or inhibit a pathway [<xref rid="pone.0145322.ref066" ref-type="bibr">66</xref>]. SPIA analysis was accomplished using the R package &#x0201c;SPIA&#x0201d; (version 2.18.0) [<xref rid="pone.0145322.ref067" ref-type="bibr">67</xref>]. Entrez IDs, log<sub>2</sub> fold changes, and Q-values for all genes were compiled. The differential expression cut-off used in the SPIA algorithm was based on the FDR-adjusted Q-value. The analysis was run using the same tailored list of pathways as used in GSEA (<xref rid="pone.0145322.s005" ref-type="supplementary-material">S2 Table</xref>) and updated versions of these pathways were download prior to running the analysis (accessed 7/29/2015).</p></sec></sec><sec sec-type="results" id="sec006"><title>Results</title><p>Using a 1% FDR (Q &#x0003c;0.01), DESeq2 analysis marked 11,115 genes and transcripts as statistically different between tumor samples and non-malignant samples in our TCGA dataset (<xref rid="pone.0145322.s006" ref-type="supplementary-material">S3</xref> and <xref rid="pone.0145322.s007" ref-type="supplementary-material">S4</xref> Tables). This covers 55% of the genes and transcripts sequenced. The number of down-regulated genes and transcripts totaled 5,379 and the number of up-regulated genes and transcripts totaled 5,736. Overall the largest changes observed were in the down-regulation of genes and transcripts (<xref rid="pone.0145322.g001" ref-type="fig">Fig 1</xref>). The magnitude of the up-regulation of genes and transcripts was smaller than the magnitude of down-regulated genes and the range of expression was also smaller. The twenty most down-regulated and the twenty most up-regulated genes are presented in <xref rid="pone.0145322.t002" ref-type="table">Table 2</xref> and <xref rid="pone.0145322.t003" ref-type="table">Table 3</xref>.</p><fig id="pone.0145322.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0145322.g001</object-id><label>Fig 1</label><caption><title>Magnitude of gene expression differences between tumor and non-malignant human prostate cancer samples.</title><p>In this one-dimensional scatter plot the magnitude of gene expression changes represented by log<sub>2</sub> fold ratios are shown. Each point represents a gene or transcript. Significantly differentially expressed genes and transcripts are shown as solid red diamonds.</p></caption><graphic xlink:href="pone.0145322.g001"/></fig><table-wrap id="pone.0145322.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0145322.t002</object-id><label>Table 2</label><caption><title>Twenty largest decreases in RNA expression between prostate tumor and non-malignant TCGA samples.</title></caption><alternatives><graphic id="pone.0145322.t002g" xlink:href="pone.0145322.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene Symbol</th><th align="left" rowspan="1" colspan="1">Name</th><th align="left" rowspan="1" colspan="1">Log<sub>2</sub> Fold Change</th><th align="left" rowspan="1" colspan="1">P-value</th><th align="left" rowspan="1" colspan="1">Q-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>WFDC9</italic></td><td align="left" rowspan="1" colspan="1">Protein WFDC9</td><td align="right" rowspan="1" colspan="1">-11.89</td><td align="right" rowspan="1" colspan="1">1.98E-04</td><td align="right" rowspan="1" colspan="1">4.30E-04</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>DEFB125</italic></td><td align="left" rowspan="1" colspan="1">Beta-defensin 125</td><td align="right" rowspan="1" colspan="1">-10.91</td><td align="right" rowspan="1" colspan="1">4.30E-04</td><td align="right" rowspan="1" colspan="1">8.89E-04</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>EDDM3B</italic></td><td align="left" rowspan="1" colspan="1">Epididymal secretory protein E3-beta</td><td align="right" rowspan="1" colspan="1">-10.85</td><td align="right" rowspan="1" colspan="1">4.64E-09</td><td align="right" rowspan="1" colspan="1">1.96E-08</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>PAEP</italic></td><td align="left" rowspan="1" colspan="1">Glycodelin</td><td align="right" rowspan="1" colspan="1">-10.82</td><td align="right" rowspan="1" colspan="1">3.47E-16</td><td align="right" rowspan="1" colspan="1">3.78E-15</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>SEMG2</italic></td><td align="left" rowspan="1" colspan="1">Semenogelin-2</td><td align="right" rowspan="1" colspan="1">-10.64</td><td align="right" rowspan="1" colspan="1">1.98E-63</td><td align="right" rowspan="1" colspan="1">2.36E-60</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>PATE4</italic></td><td align="left" rowspan="1" colspan="1">Prostate and testis expressed protein 4</td><td align="right" rowspan="1" colspan="1">-10.48</td><td align="right" rowspan="1" colspan="1">2.26E-55</td><td align="right" rowspan="1" colspan="1">1.54E-52</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>EDDM3A</italic></td><td align="left" rowspan="1" colspan="1">Epididymal secretory protein E3-alpha</td><td align="right" rowspan="1" colspan="1">-10.45</td><td align="right" rowspan="1" colspan="1">5.77E-13</td><td align="right" rowspan="1" colspan="1">4.05E-12</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>CRISP1</italic></td><td align="left" rowspan="1" colspan="1">Cysteine-rich secretory protein 1</td><td align="right" rowspan="1" colspan="1">-9.58</td><td align="right" rowspan="1" colspan="1">1.17E-25</td><td align="right" rowspan="1" colspan="1">5.02E-24</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>PATE1</italic></td><td align="left" rowspan="1" colspan="1">Prostate and testis expressed protein 1</td><td align="right" rowspan="1" colspan="1">-9.53</td><td align="right" rowspan="1" colspan="1">3.27E-27</td><td align="right" rowspan="1" colspan="1">1.76E-25</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>DEFB127</italic></td><td align="left" rowspan="1" colspan="1">Beta-defensin 127</td><td align="right" rowspan="1" colspan="1">-9.52</td><td align="right" rowspan="1" colspan="1">1.06E-04</td><td align="right" rowspan="1" colspan="1">2.41E-04</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>AQP2</italic></td><td align="left" rowspan="1" colspan="1">Aquaporin-2</td><td align="right" rowspan="1" colspan="1">-9.50</td><td align="right" rowspan="1" colspan="1">1.94E-57</td><td align="right" rowspan="1" colspan="1">1.69E-54</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TMEM114</italic></td><td align="left" rowspan="1" colspan="1">Transmembrane protein 114</td><td align="right" rowspan="1" colspan="1">-9.35</td><td align="right" rowspan="1" colspan="1">1.19E-15</td><td align="right" rowspan="1" colspan="1">1.21E-14</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>GRXCR1</italic></td><td align="left" rowspan="1" colspan="1">Glutaredoxin domain-containing cysteine-rich protein 1</td><td align="right" rowspan="1" colspan="1">-8.75</td><td align="right" rowspan="1" colspan="1">5.95E-19</td><td align="right" rowspan="1" colspan="1">9.64E-18</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>SPINT3</italic></td><td align="left" rowspan="1" colspan="1">Kunitz-type protease inhibitor 3</td><td align="right" rowspan="1" colspan="1">-8.23</td><td align="right" rowspan="1" colspan="1">2.11E-24</td><td align="right" rowspan="1" colspan="1">7.48E-23</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>CLDN2</italic></td><td align="left" rowspan="1" colspan="1">Claudin-2</td><td align="right" rowspan="1" colspan="1">-8.02</td><td align="right" rowspan="1" colspan="1">2.11E-75</td><td align="right" rowspan="1" colspan="1">6.72E-72</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>SULT2A1</italic></td><td align="left" rowspan="1" colspan="1">Bile salt sulfotransferase</td><td align="right" rowspan="1" colspan="1">-7.98</td><td align="right" rowspan="1" colspan="1">9.41E-20</td><td align="right" rowspan="1" colspan="1">1.70E-18</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>SPINK2</italic></td><td align="left" rowspan="1" colspan="1">Serine protease inhibitor Kazal-type 2</td><td align="right" rowspan="1" colspan="1">-7.71</td><td align="right" rowspan="1" colspan="1">5.75E-71</td><td align="right" rowspan="1" colspan="1">8.46E-68</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>POU3F3</italic></td><td align="left" rowspan="1" colspan="1">POU domain, class 3, transcription factor 3</td><td align="right" rowspan="1" colspan="1">-7.70</td><td align="right" rowspan="1" colspan="1">4.68E-17</td><td align="right" rowspan="1" colspan="1">5.77E-16</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>LCN1</italic></td><td align="left" rowspan="1" colspan="1">Lipocalin-1</td><td align="right" rowspan="1" colspan="1">-7.66</td><td align="right" rowspan="1" colspan="1">4.18E-08</td><td align="right" rowspan="1" colspan="1">1.56E-07</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>PATE3</italic></td><td align="left" rowspan="1" colspan="1">Prostate and testis expressed protein 3</td><td align="right" rowspan="1" colspan="1">-7.63</td><td align="right" rowspan="1" colspan="1">3.33E-25</td><td align="right" rowspan="1" colspan="1">1.32E-23</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Log<sub>2</sub> fold change describes malignant expression relative to non-malignant expression. P-value is determined by DESeq2 using Wald Statistics and Q-value is the false discovery rate-adjusted P-value.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0145322.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0145322.t003</object-id><label>Table 3</label><caption><title>Twenty largest increases in RNA expression between prostate tumor and non-malignant TCGA samples.</title></caption><alternatives><graphic id="pone.0145322.t003g" xlink:href="pone.0145322.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene Symbol</th><th align="left" rowspan="1" colspan="1">Name</th><th align="left" rowspan="1" colspan="1">Log<sub>2</sub> Fold Change</th><th align="left" rowspan="1" colspan="1">P-value</th><th align="left" rowspan="1" colspan="1">Q-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>ANKRD30A</italic></td><td align="left" rowspan="1" colspan="1">Ankyrin repeat domain-containing protein 30A</td><td align="left" rowspan="1" colspan="1">7.08</td><td align="left" rowspan="1" colspan="1">5.95E-10</td><td align="left" rowspan="1" colspan="1">2.82E-09</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>FEZF2</italic></td><td align="left" rowspan="1" colspan="1">Fez family zinc finger protein 2</td><td align="left" rowspan="1" colspan="1">6.71</td><td align="left" rowspan="1" colspan="1">1.89E-06</td><td align="left" rowspan="1" colspan="1">5.59E-06</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>C6orf10</italic></td><td align="left" rowspan="1" colspan="1">Uncharacterized protein C6orf10</td><td align="left" rowspan="1" colspan="1">5.96</td><td align="left" rowspan="1" colspan="1">2.59E-06</td><td align="left" rowspan="1" colspan="1">7.52E-06</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>FOXG1</italic></td><td align="left" rowspan="1" colspan="1">Forkhead box protein G1</td><td align="left" rowspan="1" colspan="1">5.54</td><td align="left" rowspan="1" colspan="1">2.53E-04</td><td align="left" rowspan="1" colspan="1">5.41E-04</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>GC</italic></td><td align="left" rowspan="1" colspan="1">Vitamin D-binding protein</td><td align="left" rowspan="1" colspan="1">5.47</td><td align="left" rowspan="1" colspan="1">4.70E-04</td><td align="left" rowspan="1" colspan="1">9.67E-04</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>VAX1</italic></td><td align="left" rowspan="1" colspan="1">Ventral anterior homeobox 1</td><td align="left" rowspan="1" colspan="1">5.19</td><td align="left" rowspan="1" colspan="1">3.83E-12</td><td align="left" rowspan="1" colspan="1">2.41E-11</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>SSX2</italic></td><td align="left" rowspan="1" colspan="1">Protein SSX2</td><td align="left" rowspan="1" colspan="1">5.16</td><td align="left" rowspan="1" colspan="1">4.52E-03</td><td align="left" rowspan="1" colspan="1">7.92E-03</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>FGB</italic></td><td align="left" rowspan="1" colspan="1">Fibrinogen beta chain</td><td align="left" rowspan="1" colspan="1">5.14</td><td align="left" rowspan="1" colspan="1">1.52E-03</td><td align="left" rowspan="1" colspan="1">2.88E-03</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>SLC45A2</italic></td><td align="left" rowspan="1" colspan="1">Membrane-associated transporter protein</td><td align="left" rowspan="1" colspan="1">5.09</td><td align="left" rowspan="1" colspan="1">1.10E-51</td><td align="left" rowspan="1" colspan="1">5.99E-49</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>SPINK1</italic></td><td align="left" rowspan="1" colspan="1">Pancreatic secretory trypsin inhibitor</td><td align="left" rowspan="1" colspan="1">5.07</td><td align="left" rowspan="1" colspan="1">3.29E-12</td><td align="left" rowspan="1" colspan="1">2.08E-11</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>HOXC12</italic></td><td align="left" rowspan="1" colspan="1">Homeobox protein Hox-C12</td><td align="left" rowspan="1" colspan="1">5.03</td><td align="left" rowspan="1" colspan="1">1.44E-07</td><td align="left" rowspan="1" colspan="1">4.96E-07</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>SCN1A</italic></td><td align="left" rowspan="1" colspan="1">Sodium channel protein type 1 subunit alpha</td><td align="left" rowspan="1" colspan="1">4.96</td><td align="left" rowspan="1" colspan="1">5.38E-03</td><td align="left" rowspan="1" colspan="1">9.31E-03</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>LOC284661</italic></td><td align="left" rowspan="1" colspan="1">Uncharacterized non-coding RNA</td><td align="left" rowspan="1" colspan="1">4.84</td><td align="left" rowspan="1" colspan="1">4.89E-06</td><td align="left" rowspan="1" colspan="1">1.36E-05</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TFDP3</italic></td><td align="left" rowspan="1" colspan="1">Transcription factor Dp family member 3</td><td align="left" rowspan="1" colspan="1">4.76</td><td align="left" rowspan="1" colspan="1">2.00E-03</td><td align="left" rowspan="1" colspan="1">3.72E-03</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>B3GNT6</italic></td><td align="left" rowspan="1" colspan="1">UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6</td><td align="left" rowspan="1" colspan="1">4.64</td><td align="left" rowspan="1" colspan="1">5.49E-22</td><td align="left" rowspan="1" colspan="1">1.40E-20</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>FOXB2</italic></td><td align="left" rowspan="1" colspan="1">Forkhead box protein B2</td><td align="left" rowspan="1" colspan="1">4.52</td><td align="left" rowspan="1" colspan="1">2.14E-18</td><td align="left" rowspan="1" colspan="1">3.19E-17</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>NR2E1</italic></td><td align="left" rowspan="1" colspan="1">Nuclear receptor subfamily 2 group E member 1</td><td align="left" rowspan="1" colspan="1">4.51</td><td align="left" rowspan="1" colspan="1">1.21E-15</td><td align="left" rowspan="1" colspan="1">1.23E-14</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>XAGE1E</italic></td><td align="left" rowspan="1" colspan="1">X antigen family, member 1E</td><td align="left" rowspan="1" colspan="1">4.51</td><td align="left" rowspan="1" colspan="1">4.00E-03</td><td align="left" rowspan="1" colspan="1">7.07E-03</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TBX10</italic></td><td align="left" rowspan="1" colspan="1">T-box transcription factor TBX10</td><td align="left" rowspan="1" colspan="1">4.43</td><td align="left" rowspan="1" colspan="1">6.47E-17</td><td align="left" rowspan="1" colspan="1">7.81E-16</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>Log<sub>2</sub> fold change describes malignant expression relative to non-malignant expression. P-value is determined by DESeq2 using Wald Statistics and Q-value is the false discovery rate-adjusted P-value.</p></fn></table-wrap-foot></table-wrap><sec id="sec007"><title>Classification and Overrepresentation Analysis</title><p>The 11,115 DEGs were grouped according to PANTHER protein class, GO Molecular Function and GO Biological Process annotations. A total of 6,254 DEGs had either PANTHER protein class, GO Biological Process, or GO Molecular Function annotations and were further classified. Grouping by protein class and GO Biological Process categories proved to be the most informative (<xref rid="pone.0145322.g002" ref-type="fig">Fig 2</xref>). The complete classifications can be found in the Supporting Information (<xref rid="pone.0145322.s008" ref-type="supplementary-material">S5 Table</xref>). The DEGs represent a wide spectrum of protein classes involved in a broad array of processes. The &#x0201c;Nucleic Acid Binding&#x0201d; PANTHER protein class includes both RNA and DNA binding proteins, nucleases, and helicases. The &#x0201c;Transcription Factor&#x0201d; protein class is sub-categorized by structural motif and also contains cofactors and nuclear hormone receptors. Proteases and phosphatases are found within the &#x0201c;Hydrolase&#x0201d; protein class. The types of &#x0201c;Receptor&#x0201d; included are protein kinase receptors, nuclear hormone receptors, cytokine receptors, ligand-gated ion channels, and G-protein coupled receptors. The &#x0201c;Enzyme Modulator&#x0201d; category features G protein, kinase, phosphatase, and protease modulators. Interestingly, the categories were generally not predominantly populated by down-regulated or up-regulated genes or transcripts. For all protein classes except the &#x0201c;Nucleic Acid Binding&#x0201d; class, DEGs were evenly distributed across tumor and non-malignant samples. In the &#x0201c;Nucleic Acid Binding&#x0201d; protein class, there were nearly one and half times as many up-regulated genes as down-regulated. The abundance of nucleic acid binding genes suggests altered transcriptional activity in tumor samples.</p><fig id="pone.0145322.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0145322.g002</object-id><label>Fig 2</label><caption><title>Functional Classification of Differentially Expressed Genes in Human Prostate Cancer According to PANTHER Protein Class (A) and Biological Process Gene Ontology Terms (B).</title><p>(A) &#x0201c;Nucleic Acid Binding&#x0201d; includes RNA and DNA binding, nucleases, and helicases. &#x0201c;Transcription Factor&#x0201d; includes zinc finger, helix-turn-helix, high mobility group box, basic helix-loop-helix, and basic leucine zipper transcription factors; cofactors; and nuclear hormone receptors. &#x0201c;Hydrolase&#x0201d; refers to proteases, phosphatases, esterases, lipases, deaminases, phosphodiesterases, glycosidases, deacetylases, pyrophosphatases, glucosidases, galactosidases, and amylases. &#x0201c;Receptor&#x0201d; includes protein kinase receptors, nuclear hormone receptors, cytokine receptors, ligand-gated ion channels, and G-protein coupled receptors. &#x0201c;Enzyme Modulator&#x0201d; includes G protein, kinase, phosphatase, and protease modulators. (B) &#x0201c;Metabolic Process&#x0201d; features carbohydrate, cellular amino acid, lipid, protein, and nucleobase-containing compound metabolism; and the tricarboxylic acid cycle. &#x0201c;Cellular Process&#x0201d; categories are cell-cell signaling, cell cycle, growth and proliferation, cell component movement, and cytokinesis. &#x0201c;Biological Regulation&#x0201d; includes the regulation of apoptosis, metabolism, cell cycle, translation, catalytic activity, and homeostasis. &#x0201c;Developmental Process&#x0201d; categories are system, ectoderm, mesoderm, and endoderm development; cell differentiation; death; anatomical structure morphogenesis; embryo development; sex determination; and pattern specification processes. &#x0201c;Localization&#x0201d; includes transport proteins, protein and RNA localization processes.</p></caption><graphic xlink:href="pone.0145322.g002"/></fig><p>The two most abundant GO Biological Process groups&#x02014;&#x0201c;Metabolic Process&#x0201d; and &#x0201c;Cellular Process&#x0201d;&#x02014;are not surprising because these contains genes are involved in the most basic of life processes. In fact, metabolic changes have been widely documented in tumors [<xref rid="pone.0145322.ref068" ref-type="bibr">68</xref>&#x02013;<xref rid="pone.0145322.ref070" ref-type="bibr">70</xref>]. The increased energetic and biosynthetic needs of proliferating cancer cells are often met through metabolic dysregulation [<xref rid="pone.0145322.ref071" ref-type="bibr">71</xref>&#x02013;<xref rid="pone.0145322.ref073" ref-type="bibr">73</xref>]. The heading &#x0201c;Metabolic Process&#x0201d; includes carbohydrate metabolism, cellular amino acid metabolism, lipid metabolism, nucleobase-containing compound metabolism, protein metabolism, and the tricarboxylic acid cycle. &#x0201c;Cellular Process&#x0201d; includes cell-cell signaling, cell cycle, growth and proliferation, cell component movement, and cytokinesis. &#x0201c;Biological Regulation&#x0201d; includes the regulation of apoptosis, metabolism, cell cycle, translation, catalytic activity, and homeostasis. The category &#x0201c;Developmental Process&#x0201d; incorporates system, ectoderm, mesoderm, and endoderm development, as well as cell differentiation, death, anatomical structure morphogenesis, embryo development, sex determination, and pattern specification processes. &#x0201c;Localization&#x0201d; refers to general transport proteins and specific protein and RNA localization processes.</p><p>PANTHER&#x02019;s overrepresentation statistic was used to calculate the probability that the highly populated protein classes and GO groupings among the DEGs would occur by random chance. Indeed, many of the most abundant categories are overrepresented in the data when compared to a reference genome (<xref rid="pone.0145322.t004" ref-type="table">Table 4</xref>). The three most abundant protein classes&#x02014;&#x0201c;Nucleic Acid Binding&#x0201d;, &#x0201c;Transcription Factor&#x0201d;, and &#x0201c;Hydrolase&#x0201d;&#x02014;were enriched along with the classes &#x0201c;Transferase&#x0201d; and &#x0201c;Transporter&#x0201d;. The five most populated GO Biological Processes were also enriched: &#x0201c;Metabolic Process&#x0201d;, &#x0201c;Cellular Process&#x0201d;, &#x0201c;Biological Regulation&#x0201d;, &#x0201c;Localization&#x0201d;, and &#x0201c;Developmental Process&#x0201d;. The &#x0201c;Multicellular Organism Process&#x0201d;, &#x0201c;Biological Adhesion&#x0201d;, &#x0201c;Cellular Component Organization or Biogenesis&#x0201d;, and &#x0201c;Immune System Process&#x0201d; GO Biological Processes were also enriched. Finally, five of the top six GO Molecular Functions were enriched: &#x0201c;Binding&#x0201d;, &#x0201c;Catalytic Activity&#x0201d;, &#x0201c;Nucleic Acid Binding Transcription Factor Activity&#x0201d;, &#x0201c;Transporter Activity&#x0201d;, and &#x0201c;Structural Molecule Activity&#x0201d;.</p><table-wrap id="pone.0145322.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0145322.t004</object-id><label>Table 4</label><caption><title>Overrepresented PANTHER protein class and GO ontology categories in TCGA data from malignant and non-malignant prostate.</title></caption><alternatives><graphic id="pone.0145322.t004g" xlink:href="pone.0145322.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>PANTHER Protein Class</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">RNA binding protein (Nucleic Acid Binding)</td><td align="left" rowspan="1" colspan="1">9.08E-05</td></tr><tr><td align="left" rowspan="1" colspan="1">Ribosomal protein (Nucleic Acid Binding)</td><td align="left" rowspan="1" colspan="1">4.67E-04</td></tr><tr><td align="left" rowspan="1" colspan="1">Transcription factor</td><td align="left" rowspan="1" colspan="1">2.04E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Transferase</td><td align="left" rowspan="1" colspan="1">3.41E-04</td></tr><tr><td align="left" rowspan="1" colspan="1">Hydrolase</td><td align="left" rowspan="1" colspan="1">5.75E-04</td></tr><tr><td align="left" rowspan="1" colspan="1">Transporter</td><td align="left" rowspan="1" colspan="1">3.65E-03</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>GO-Biological Process</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sensory perception of chemical stimulus (Multicellular Organism Process)</td><td align="left" rowspan="1" colspan="1">2.96E-10</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein metabolic process (Metabolic Process)</td><td align="left" rowspan="1" colspan="1">6.82E-09</td></tr><tr><td align="left" rowspan="1" colspan="1">Nucleobase-containing compound metabolic process (Metabolic Process)</td><td align="left" rowspan="1" colspan="1">1.64E-08</td></tr><tr><td align="left" rowspan="1" colspan="1">RNA metabolic process (Metabolic Process)</td><td align="left" rowspan="1" colspan="1">6.87E-06</td></tr><tr><td align="left" rowspan="1" colspan="1">Nervous system development (Developmental Process)</td><td align="left" rowspan="1" colspan="1">1.48E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">Cellular protein modification process (Metabolic Process)</td><td align="left" rowspan="1" colspan="1">1.90E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">Translation (Metabolic Process)</td><td align="left" rowspan="1" colspan="1">2.81E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">Natural killer cell activation (Immune System Process)</td><td align="left" rowspan="1" colspan="1">4.06E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">DNA-dependent transcription (Metabolic Process)</td><td align="left" rowspan="1" colspan="1">7.61E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">Ion transport (Localization)</td><td align="left" rowspan="1" colspan="1">1.81E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein phosphorylation (Metabolic Process)</td><td align="left" rowspan="1" colspan="1">3.31E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Cellular component morphogenesis (Cellular Component Organization or Biogenesis)</td><td align="left" rowspan="1" colspan="1">3.85E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Cellular component organization (Cellular Component Organization or Biogenesis)</td><td align="left" rowspan="1" colspan="1">7.58E-04</td></tr><tr><td align="left" rowspan="1" colspan="1">Cell communication (Cellular Process)</td><td align="left" rowspan="1" colspan="1">2.57E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Biological regulation</td><td align="left" rowspan="1" colspan="1">3.03E-05</td></tr><tr><td align="left" rowspan="1" colspan="1">Biological adhesion</td><td align="left" rowspan="1" colspan="1">4.67E-02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>GO-Molecular Function</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Transferase activity (Catalytic Activity)</td><td align="left" rowspan="1" colspan="1">1.67E-06</td></tr><tr><td align="left" rowspan="1" colspan="1">Hydrolase activity (Catalytic Activity)</td><td align="left" rowspan="1" colspan="1">2.87E-04</td></tr><tr><td align="left" rowspan="1" colspan="1">Kinase activity (Catalytic Activity)</td><td align="left" rowspan="1" colspan="1">7.73E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein binding (Binding)</td><td align="left" rowspan="1" colspan="1">2.99E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">DNA binding (Binding)</td><td align="left" rowspan="1" colspan="1">4.19E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">Transmembrane transporter activity (Transporter Activity)</td><td align="left" rowspan="1" colspan="1">3.37E-03</td></tr><tr><td align="left" rowspan="1" colspan="1">Sequence-specific DNA binding transcription factor activity (Nucleic Acid Binding Transcription Factor Activity)</td><td align="left" rowspan="1" colspan="1">1.52E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Structural constituent of ribosome (Structural Molecule Activity)</td><td align="left" rowspan="1" colspan="1">3.59E-02</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>Overrepresentation was determined by calculating the probability that the number of differentially expressed genes belonging to a particular category is larger or smaller than what would be expected based on a reference human genome. P-values are adjusted using a Bonferroni correction.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec008"><title>Gene Set Enrichment Analysis</title><p>One limitation of a class or pathway overrepresentation analysis is that it does not indicate which condition is associated with the overrepresentation; GSEA does. Expressed genes were ranked by their correlation with the malignant phenotype and then this list was compared to sets of genes in a pathway, linking pathway enrichment to a phenotype. The more highly-correlated genes in a gene set, the higher the significance of that gene set. The gene sets with the highest normalized enrichment scores are presented in <xref rid="pone.0145322.t005" ref-type="table">Table 5</xref> and other results are listed in the Supporting Information (<xref rid="pone.0145322.s010" ref-type="supplementary-material">S7 Table</xref>). The FDR cutoff was set at 25% to maximize hypothesis generation. Only one pathway was enriched in the tumor samples, the &#x0201c;RanMS pathway&#x0201d; which includes the genes that regulate the formation of the mitotic spindle during cell division. Ten genes in our list of DEGs belonged to this pathway, each contributing to its enrichment in the malignant phenotype (<xref rid="pone.0145322.t006" ref-type="table">Table 6</xref>). All ten were differentially expressed and up-regulated in the malignant samples. The remaining pathways were enriched in the non-malignant phenotype. The most significant pathway enriched in the non-malignant phenotype was the &#x0201c;calcium signaling&#x0201d; pathway. Enrichment of the calcium signaling pathway was due to 81 DEGs and 19 other genes or transcripts (<xref rid="pone.0145322.s011" ref-type="supplementary-material">S8 Table</xref>). Also enriched in the non-malignant phenotype were several other signaling pathways (oxytocin, prolactin, cAMP, MAPK, cGMP-PKG, TGF-&#x003b2;, Hippo, and Ras) and pathways related to cell-cell and cell-matrix adhesion (extracellular matrix-receptor interaction, actin cytoskeleton regulation, proteoglycans, and focal adhesion).</p><table-wrap id="pone.0145322.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0145322.t005</object-id><label>Table 5</label><caption><title>Significant gene sets enriched in malignant and non-malignant prostate with the largest normalized enrichment scores.</title></caption><alternatives><graphic id="pone.0145322.t005g" xlink:href="pone.0145322.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene Set</th><th align="left" rowspan="1" colspan="1">ES</th><th align="left" rowspan="1" colspan="1">NES</th><th align="left" rowspan="1" colspan="1">P-value</th><th align="left" rowspan="1" colspan="1">Q-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BioCarta: RanMS pathway</td><td align="left" rowspan="1" colspan="1">0.827</td><td align="left" rowspan="1" colspan="1">1.652</td><td align="left" rowspan="1" colspan="1">4.02E-03</td><td align="left" rowspan="1" colspan="1">2.05E-01</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Calcium signaling pathway</td><td align="left" rowspan="1" colspan="1">-0.456</td><td align="left" rowspan="1" colspan="1">-1.714</td><td align="left" rowspan="1" colspan="1">4.89E-03</td><td align="left" rowspan="1" colspan="1">5.75E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Basal cell carcinoma</td><td align="left" rowspan="1" colspan="1">-0.482</td><td align="left" rowspan="1" colspan="1">-1.647</td><td align="left" rowspan="1" colspan="1">6.59E-03</td><td align="left" rowspan="1" colspan="1">6.10E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Oxytocin signaling pathway</td><td align="left" rowspan="1" colspan="1">-0.443</td><td align="left" rowspan="1" colspan="1">-1.603</td><td align="left" rowspan="1" colspan="1">1.66E-02</td><td align="left" rowspan="1" colspan="1">6.26E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Thyroid hormone synthesis</td><td align="left" rowspan="1" colspan="1">-0.466</td><td align="left" rowspan="1" colspan="1">-1.652</td><td align="left" rowspan="1" colspan="1">1.19E-02</td><td align="left" rowspan="1" colspan="1">6.34E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Signaling pathways regulating pluripotency of stem cells</td><td align="left" rowspan="1" colspan="1">-0.432</td><td align="left" rowspan="1" colspan="1">-1.596</td><td align="left" rowspan="1" colspan="1">4.56E-03</td><td align="left" rowspan="1" colspan="1">6.35E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Prolactin signaling pathway</td><td align="left" rowspan="1" colspan="1">-0.461</td><td align="left" rowspan="1" colspan="1">-1.605</td><td align="left" rowspan="1" colspan="1">4.52E-03</td><td align="left" rowspan="1" colspan="1">6.44E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Pathways in cancer</td><td align="left" rowspan="1" colspan="1">-0.433</td><td align="left" rowspan="1" colspan="1">-1.624</td><td align="left" rowspan="1" colspan="1">8.77E-03</td><td align="left" rowspan="1" colspan="1">6.49E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: ECM-receptor interaction</td><td align="left" rowspan="1" colspan="1">-0.517</td><td align="left" rowspan="1" colspan="1">-1.633</td><td align="left" rowspan="1" colspan="1">3.76E-02</td><td align="left" rowspan="1" colspan="1">6.52E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: cAMP signaling pathway</td><td align="left" rowspan="1" colspan="1">-0.434</td><td align="left" rowspan="1" colspan="1">-1.719</td><td align="left" rowspan="1" colspan="1">0.00E+00</td><td align="left" rowspan="1" colspan="1">6.63E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: MAPK signaling pathway</td><td align="left" rowspan="1" colspan="1">-0.417</td><td align="left" rowspan="1" colspan="1">-1.614</td><td align="left" rowspan="1" colspan="1">2.28E-03</td><td align="left" rowspan="1" colspan="1">6.78E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Regulation of actin cytoskeleton</td><td align="left" rowspan="1" colspan="1">-0.449</td><td align="left" rowspan="1" colspan="1">-1.606</td><td align="left" rowspan="1" colspan="1">8.99E-03</td><td align="left" rowspan="1" colspan="1">6.84E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Phosphatidylinositol signaling pathway</td><td align="left" rowspan="1" colspan="1">-0.517</td><td align="left" rowspan="1" colspan="1">-1.653</td><td align="left" rowspan="1" colspan="1">4.38E-03</td><td align="left" rowspan="1" colspan="1">6.93E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: cGMP-PKG signaling pathway</td><td align="left" rowspan="1" colspan="1">-0.469</td><td align="left" rowspan="1" colspan="1">-1.677</td><td align="left" rowspan="1" colspan="1">1.43E-02</td><td align="left" rowspan="1" colspan="1">7.12E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: TGF-beta signaling pathway</td><td align="left" rowspan="1" colspan="1">-0.513</td><td align="left" rowspan="1" colspan="1">-1.654</td><td align="left" rowspan="1" colspan="1">1.11E-02</td><td align="left" rowspan="1" colspan="1">7.73E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Focal adhesion</td><td align="left" rowspan="1" colspan="1">-0.517</td><td align="left" rowspan="1" colspan="1">-1.725</td><td align="left" rowspan="1" colspan="1">1.61E-02</td><td align="left" rowspan="1" colspan="1">7.87E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Hippo signaling pathway</td><td align="left" rowspan="1" colspan="1">-0.482</td><td align="left" rowspan="1" colspan="1">-1.733</td><td align="left" rowspan="1" colspan="1">0.00E+00</td><td align="left" rowspan="1" colspan="1">9.65E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Proteoglycans in cancer</td><td align="left" rowspan="1" colspan="1">-0.492</td><td align="left" rowspan="1" colspan="1">-1.740</td><td align="left" rowspan="1" colspan="1">0.00E+00</td><td align="left" rowspan="1" colspan="1">1.38E-01</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG: Ras signaling pathway</td><td align="left" rowspan="1" colspan="1">-0.460</td><td align="left" rowspan="1" colspan="1">-1.760</td><td align="left" rowspan="1" colspan="1">2.23E-03</td><td align="left" rowspan="1" colspan="1">2.13E-01</td></tr><tr><td align="left" rowspan="1" colspan="1">BioCarta: p38 MAPK pathway</td><td align="left" rowspan="1" colspan="1">-0.527</td><td align="left" rowspan="1" colspan="1">-1.584</td><td align="left" rowspan="1" colspan="1">8.15E-03</td><td align="left" rowspan="1" colspan="1">2.48E-01</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t005fn001"><p>ES = enrichment score, NES = normalized enrichment score, Q-value = false discovery rate-adjusted P-value. Positive enrichment scores correspond to enrichment in the malignant samples. Negative enrichment scores correspond to enrichment in the non-malignant samples.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0145322.t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0145322.t006</object-id><label>Table 6</label><caption><title>Differentially Expressed Ran-Mitotic Spindle Pathway Components in Human Prostate Cancer.</title></caption><alternatives><graphic id="pone.0145322.t006g" xlink:href="pone.0145322.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th colspan="4" align="left" rowspan="1">Ran regulation of mitotic spindle formation pathway</th></tr><tr><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="left" rowspan="1" colspan="1">Symbol</th><th align="left" rowspan="1" colspan="1">Expression</th><th align="left" rowspan="1" colspan="1">Role</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">GTP-binding nuclear protein Ran</td><td align="left" rowspan="1" colspan="1"><italic>RAN</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1">GTPase; nuclear transport; formation of mitotic spindle [<xref rid="pone.0145322.ref074" ref-type="bibr">74</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Regulator of chromosome condensation</td><td align="left" rowspan="1" colspan="1"><italic>RCC1</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1">Guanine nucleotide exchange factor of Ran, produces a RanGTP gradient around chromosomes. [<xref rid="pone.0145322.ref075" ref-type="bibr">75</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Ran GTPase-activating protein 1</td><td align="left" rowspan="1" colspan="1"><italic>RANGAP1</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1">Accelerates RanGTP hydrolysis, helps maintain RanGTP gradient around chromosomes. [<xref rid="pone.0145322.ref075" ref-type="bibr">75</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Ran binding protein 1</td><td align="left" rowspan="1" colspan="1"><italic>RANBP1</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1">Regulates activity of RCC1 and RANGAP [<xref rid="pone.0145322.ref076" ref-type="bibr">76</xref>, <xref rid="pone.0145322.ref077" ref-type="bibr">77</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Importin subunit alpha-1</td><td align="left" rowspan="1" colspan="1"><italic>KPNA2</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1">Nuclear import; KPNB1 adapter protein [<xref rid="pone.0145322.ref078" ref-type="bibr">78</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Importin subunit beta-1</td><td align="left" rowspan="1" colspan="1"><italic>KPNB1</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1">Nuclear import; docking platform [<xref rid="pone.0145322.ref079" ref-type="bibr">79</xref>, <xref rid="pone.0145322.ref080" ref-type="bibr">80</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Targeting protein for Xklp2</td><td align="left" rowspan="1" colspan="1"><italic>TPX2</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1">Spindle assembly factor; microtubule nucleation, separation of bipolar mitotic spindle [<xref rid="pone.0145322.ref081" ref-type="bibr">81</xref>, <xref rid="pone.0145322.ref082" ref-type="bibr">82</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Nuclear mitotic apparatus protein 1</td><td align="left" rowspan="1" colspan="1"><italic>NUMA1</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1">Spindle assembly factor; Establishes, maintains mitotic spindle poles. [<xref rid="pone.0145322.ref083" ref-type="bibr">83</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Kinesin-like protein KIF15</td><td align="left" rowspan="1" colspan="1"><italic>KIF15</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1">Spindle assembly factor; Bipolar spindle maintenance, elongation [<xref rid="pone.0145322.ref082" ref-type="bibr">82</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Aurora kinase A</td><td align="left" rowspan="1" colspan="1"><italic>AURKA</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1">Centrosome maturation, separation, and centrosomal microtubule stabilization and nucleation. [<xref rid="pone.0145322.ref084" ref-type="bibr">84</xref>]</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t006fn001"><p><bold>&#x02191;</bold> = up-regulated expression, <bold>&#x02193;</bold> = down-regulated expression</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec009"><title>Signaling Pathway Impact Analysis</title><p>SPIA considers whether or not the DEGs found in a pathway have a meaningful impact within that pathway and thus addresses the topology of DEGs in pathways [<xref rid="pone.0145322.ref066" ref-type="bibr">66</xref>]. In other words, pathway significance is partly dependent on if the number of DEGs observed in a pathway is larger than that observed by random chance. This is captured in the probability of overrepresentation. Pathway significance is also partly based on whether DEGs in a particular pathway are at crucial junctions and can thus perturb the pathway. This is the probability of perturbation. These two probabilities are combined into a global probability which is adjusted by the false discovery rate. This adjusted metric was used to rank the impact of the pathways. Many of the same pathways were identified as significant in both GSEA and SPIA analysis (<xref rid="pone.0145322.t007" ref-type="table">Table 7</xref>). In fact, the 8 most significant pathway results from SPIA were all significantly enriched in GSEA. However, only the &#x0201c;calcium signaling&#x0201d; pathway was highly ranked in both analyses. The only pathway activated in the malignant condition was the &#x0201c;TGF-&#x003b2; signaling&#x0201d; pathway (<xref rid="pone.0145322.t008" ref-type="table">Table 8</xref>). The other pathways were all inhibited in the malignant condition. Similar to GSEA results, several signaling pathways (oxytocin, cAMP, MAPK, cGMP-PKG, TGF-&#x003b2;, Hippo, Rap1, ErbB, and Ras) and pathways related to cell-cell and cell-matrix adhesion (proteoglycans, focal adhesion, and actin cytoskeleton regulation) were impacted. Images of the pathways with DEGs highlighted can be accessed in the Supporting Information (<xref rid="pone.0145322.s012" ref-type="supplementary-material">S9 Table</xref>).</p><table-wrap id="pone.0145322.t007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0145322.t007</object-id><label>Table 7</label><caption><title>Significantly impacted pathways in human prostate cancer as determined by SPIA.</title></caption><alternatives><graphic id="pone.0145322.t007g" xlink:href="pone.0145322.t007"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Name</th><th align="left" rowspan="1" colspan="1">NDE/pSize</th><th align="left" rowspan="1" colspan="1">pNDE</th><th align="left" rowspan="1" colspan="1">pPERT</th><th align="left" rowspan="1" colspan="1">pG</th><th align="left" rowspan="1" colspan="1">pGFdr</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Proteoglycans in cancer</bold></td><td align="left" rowspan="1" colspan="1">140/201</td><td align="left" rowspan="1" colspan="1">1.75E-05</td><td align="left" rowspan="1" colspan="1">5.00E-06</td><td align="left" rowspan="1" colspan="1">2.11E-09</td><td align="left" rowspan="1" colspan="1">1.86E-07</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Hippo signaling pathway</bold></td><td align="left" rowspan="1" colspan="1">112/153</td><td align="left" rowspan="1" colspan="1">3.12E-06</td><td align="left" rowspan="1" colspan="1">1.60E-02</td><td align="left" rowspan="1" colspan="1">8.90E-07</td><td align="left" rowspan="1" colspan="1">3.91E-05</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Pathways in cancer</bold></td><td align="left" rowspan="1" colspan="1">257/398</td><td align="left" rowspan="1" colspan="1">7.77E-05</td><td align="left" rowspan="1" colspan="1">2.00E-03</td><td align="left" rowspan="1" colspan="1">2.59E-06</td><td align="left" rowspan="1" colspan="1">7.60E-05</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Focal adhesion</bold></td><td align="left" rowspan="1" colspan="1">144/207</td><td align="left" rowspan="1" colspan="1">1.48E-05</td><td align="left" rowspan="1" colspan="1">2.10E-02</td><td align="left" rowspan="1" colspan="1">4.97E-06</td><td align="left" rowspan="1" colspan="1">1.09E-04</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>cGMP-PKG signaling pathway</bold></td><td align="left" rowspan="1" colspan="1">118/167</td><td align="left" rowspan="1" colspan="1">2.80E-05</td><td align="left" rowspan="1" colspan="1">3.07E-01</td><td align="left" rowspan="1" colspan="1">1.09E-04</td><td align="left" rowspan="1" colspan="1">1.92E-03</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Calcium signaling pathway</bold></td><td align="left" rowspan="1" colspan="1">115/180</td><td align="left" rowspan="1" colspan="1">1.08E-02</td><td align="left" rowspan="1" colspan="1">4.00E-03</td><td align="left" rowspan="1" colspan="1">4.78E-04</td><td align="left" rowspan="1" colspan="1">7.01E-03</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ras signaling pathway</bold></td><td align="left" rowspan="1" colspan="1">144/225</td><td align="left" rowspan="1" colspan="1">4.36E-03</td><td align="left" rowspan="1" colspan="1">2.90E-02</td><td align="left" rowspan="1" colspan="1">1.26E-03</td><td align="left" rowspan="1" colspan="1">1.59E-02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TGF-&#x003b2; signaling pathway</bold></td><td align="left" rowspan="1" colspan="1">60/80</td><td align="left" rowspan="1" colspan="1">1.95E-04</td><td align="left" rowspan="1" colspan="1">8.54E-01</td><td align="left" rowspan="1" colspan="1">1.62E-03</td><td align="left" rowspan="1" colspan="1">1.78E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic myeloid leukemia</td><td align="left" rowspan="1" colspan="1">55/73</td><td align="left" rowspan="1" colspan="1">2.93E-04</td><td align="left" rowspan="1" colspan="1">8.74E-01</td><td align="left" rowspan="1" colspan="1">2.37E-03</td><td align="left" rowspan="1" colspan="1">2.32E-02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Basal cell carcinoma</bold></td><td align="left" rowspan="1" colspan="1">36/55</td><td align="left" rowspan="1" colspan="1">8.03E-02</td><td align="left" rowspan="1" colspan="1">6.00E-03</td><td align="left" rowspan="1" colspan="1">4.16E-03</td><td align="left" rowspan="1" colspan="1">3.59E-02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Regulation of actin cytoskeleton</bold></td><td align="left" rowspan="1" colspan="1">135/213</td><td align="left" rowspan="1" colspan="1">9.11E-03</td><td align="left" rowspan="1" colspan="1">6.80E-02</td><td align="left" rowspan="1" colspan="1">5.20E-03</td><td align="left" rowspan="1" colspan="1">3.59E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">ErbB signaling pathway</td><td align="left" rowspan="1" colspan="1">60/87</td><td align="left" rowspan="1" colspan="1">5.98E-03</td><td align="left" rowspan="1" colspan="1">1.07E-01</td><td align="left" rowspan="1" colspan="1">5.34E-03</td><td align="left" rowspan="1" colspan="1">3.59E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Glioma</td><td align="left" rowspan="1" colspan="1">48/65</td><td align="left" rowspan="1" colspan="1">1.50E-03</td><td align="left" rowspan="1" colspan="1">4.51E-01</td><td align="left" rowspan="1" colspan="1">5.60E-03</td><td align="left" rowspan="1" colspan="1">3.59E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Small cell lung cancer</td><td align="left" rowspan="1" colspan="1">58/86</td><td align="left" rowspan="1" colspan="1">1.38E-02</td><td align="left" rowspan="1" colspan="1">5.00E-02</td><td align="left" rowspan="1" colspan="1">5.71E-03</td><td align="left" rowspan="1" colspan="1">3.59E-02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Oxytocin signaling pathway</bold></td><td align="left" rowspan="1" colspan="1">105/157</td><td align="left" rowspan="1" colspan="1">1.82E-03</td><td align="left" rowspan="1" colspan="1">4.53E-01</td><td align="left" rowspan="1" colspan="1">6.69E-03</td><td align="left" rowspan="1" colspan="1">3.87E-02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>MAPK signaling pathway</bold></td><td align="left" rowspan="1" colspan="1">152/254</td><td align="left" rowspan="1" colspan="1">7.51E-02</td><td align="left" rowspan="1" colspan="1">1.30E-02</td><td align="left" rowspan="1" colspan="1">7.75E-03</td><td align="left" rowspan="1" colspan="1">3.87E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Cell cycle</td><td align="left" rowspan="1" colspan="1">85/124</td><td align="left" rowspan="1" colspan="1">1.60E-03</td><td align="left" rowspan="1" colspan="1">6.41E-01</td><td align="left" rowspan="1" colspan="1">8.07E-03</td><td align="left" rowspan="1" colspan="1">3.87E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">MicroRNAs in cancer</td><td align="left" rowspan="1" colspan="1">97/149</td><td align="left" rowspan="1" colspan="1">8.72E-03</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">8.72E-03</td><td align="left" rowspan="1" colspan="1">3.87E-02</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>cAMP signaling pathway</bold></td><td align="left" rowspan="1" colspan="1">132/200</td><td align="left" rowspan="1" colspan="1">1.15E-03</td><td align="left" rowspan="1" colspan="1">9.75E-01</td><td align="left" rowspan="1" colspan="1">8.76E-03</td><td align="left" rowspan="1" colspan="1">3.87E-02</td></tr><tr><td align="left" rowspan="1" colspan="1">Rap1 signaling pathway</td><td align="left" rowspan="1" colspan="1">130/211</td><td align="left" rowspan="1" colspan="1">3.42E-02</td><td align="left" rowspan="1" colspan="1">3.30E-02</td><td align="left" rowspan="1" colspan="1">8.80E-03</td><td align="left" rowspan="1" colspan="1">3.87E-02</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t007fn001"><p>NDE = number of differentially expressed elements, pSize = pathway size, pNDE = overrepresentation probability, pPERT = perturbation probability, pG = global probability, pGFdr = false discovery rate-adjusted global probability. Bold pathways were also significant by Gene Set Enrichment Analysis.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0145322.t008" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0145322.t008</object-id><label>Table 8</label><caption><title>Components of the TGF-&#x003b2; Signaling Pathway Differentially Expressed in Human Prostate Cancer.</title></caption><alternatives><graphic id="pone.0145322.t008g" xlink:href="pone.0145322.t008"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th colspan="4" align="left" rowspan="1">TGF-&#x003b2; Signaling Pathway</th></tr><tr><th align="left" rowspan="1" colspan="1">Gene Name</th><th align="left" rowspan="1" colspan="1">Symbol</th><th align="left" rowspan="1" colspan="1">Expression</th><th align="left" rowspan="1" colspan="1">Role</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Transforming growth factor &#x003b2;-2</td><td align="left" rowspan="1" colspan="1"><italic>TGF-&#x003b2;2</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">Cytokine growth factor [<xref rid="pone.0145322.ref085" ref-type="bibr">85</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Transforming growth factor &#x003b2;-3</td><td align="left" rowspan="1" colspan="1"><italic>TGF-&#x003b2;3</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">Cytokine growth factor [<xref rid="pone.0145322.ref085" ref-type="bibr">85</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">TGF-&#x003b2; receptor type I</td><td align="left" rowspan="1" colspan="1"><italic>TGFBR1</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">transmembrane serine/threonine kinase [<xref rid="pone.0145322.ref086" ref-type="bibr">86</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">TGF-&#x003b2; receptor type II</td><td align="left" rowspan="1" colspan="1"><italic>TGFBR2</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">transmembrane serine/threonine kinase [<xref rid="pone.0145322.ref086" ref-type="bibr">86</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">TGF-&#x003b2; receptor type III</td><td align="left" rowspan="1" colspan="1"><italic>TGFBR3</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">non-signaling receptor, presents TGF-&#x003b2; ligands to TGFBR2 [<xref rid="pone.0145322.ref086" ref-type="bibr">86</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Latent-transforming growth factor &#x003b2;-binding protein 1</td><td align="left" rowspan="1" colspan="1"><italic>LTBP1</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">maintains latency of TGF-&#x003b2; [<xref rid="pone.0145322.ref087" ref-type="bibr">87</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Mothers against decapentaplegic homolog 2</td><td align="left" rowspan="1" colspan="1"><italic>SMAD2</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">receptor SMAD for TGFBR1 [<xref rid="pone.0145322.ref088" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Mothers against decapentaplegic homolog 3</td><td align="left" rowspan="1" colspan="1"><italic>SMAD3</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">receptor SMAD for TGFBR1 [<xref rid="pone.0145322.ref088" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Mothers against decapentaplegic homolog 4</td><td align="left" rowspan="1" colspan="1"><italic>SMAD4</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">complexes with receptor SMADs before nuclear translocation [<xref rid="pone.0145322.ref088" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Mothers against decapentaplegic homolog 7</td><td align="left" rowspan="1" colspan="1"><italic>SMAD7</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">blocks phosphorylation of SMAD 2/3 [<xref rid="pone.0145322.ref089" ref-type="bibr">89</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">E3 ubiquitin-protein ligase RBX1</td><td align="left" rowspan="1" colspan="1"><italic>RBX1</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1">In complex with CUL1 degrades SMAD2/3 [<xref rid="pone.0145322.ref090" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Cullin-1</td><td align="left" rowspan="1" colspan="1"><italic>CUL1</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">In complex with RBX1 degrades SMAD2/3 [<xref rid="pone.0145322.ref090" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Retinoblastoma-like protein 1</td><td align="left" rowspan="1" colspan="1"><italic>RBL1</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">E2F4/5 corepressor of <italic>myc</italic> [<xref rid="pone.0145322.ref091" ref-type="bibr">91</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Transcription factor E2F4</td><td align="left" rowspan="1" colspan="1"><italic>E2F4</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1"><italic>myc</italic> transcription factor [<xref rid="pone.0145322.ref091" ref-type="bibr">91</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Transcription factor E2F5</td><td align="left" rowspan="1" colspan="1"><italic>E2F5</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1"><italic>myc</italic> transcription factor [<xref rid="pone.0145322.ref091" ref-type="bibr">91</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Myc proto-oncogene protein</td><td align="left" rowspan="1" colspan="1"><italic>MYC</italic></td><td align="left" rowspan="1" colspan="1">&#x02191;</td><td align="left" rowspan="1" colspan="1">Influences cell growth, cell cycle, apoptosis, metabolism, energy production, DNA replication and RNA stability and splicing [<xref rid="pone.0145322.ref092" ref-type="bibr">92</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Sp1 Transcription factor</td><td align="left" rowspan="1" colspan="1"><italic>SP1</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">Transcription factor regulating growth factors, DNA synthesis regulators, and cell cycle genes including CDKN2B [<xref rid="pone.0145322.ref093" ref-type="bibr">93</xref>, <xref rid="pone.0145322.ref094" ref-type="bibr">94</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Cyclin-dependent kinase 4 inhibitor B</td><td align="left" rowspan="1" colspan="1"><italic>CDKN2B</italic></td><td align="left" rowspan="1" colspan="1">&#x02193;</td><td align="left" rowspan="1" colspan="1">Mediates cell cycle arrest at G1 [<xref rid="pone.0145322.ref095" ref-type="bibr">95</xref>]</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t008fn001"><p><bold>&#x02191;</bold> = up-regulated, <bold>&#x02193;</bold> = down-regulated</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusions" id="sec010"><title>Discussion</title><p>Global expression studies have documented many differentially expressed genes in human prostate cancer [<xref rid="pone.0145322.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0145322.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0145322.ref013" ref-type="bibr">13</xref>&#x02013;<xref rid="pone.0145322.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0145322.ref096" ref-type="bibr">96</xref>&#x02013;<xref rid="pone.0145322.ref102" ref-type="bibr">102</xref>]. Lucas and Heath compiled a list of differentially expressed genes with reported prognostic significance in prostate cancer [<xref rid="pone.0145322.ref030" ref-type="bibr">30</xref>]. Of the 22 genes listed, 19 were differentially expressed in our TCGA dataset and there was agreement in expression pattern between 12 genes. <italic>PTEN</italic>, <italic>TMPRSS2</italic>, <italic>MYC</italic>, <italic>SMAD4</italic>, <italic>EZH2</italic>, <italic>p53</italic>, <italic>BCL2</italic>, <italic>NPY</italic>, <italic>PLA2G7</italic>, <italic>Ki-67</italic>, <italic>p16</italic>, and <italic>BAX</italic> expression in our findings matched what was presented in the literature. <italic>PTEN</italic>, a tumor suppressor, was down-regulated in malignant samples. The deletion of <italic>PTEN</italic> correlates with higher Gleason grade, risk of progression, and recurrence after therapy, and advanced localized or metastatic disease and death [<xref rid="pone.0145322.ref103" ref-type="bibr">103</xref>, <xref rid="pone.0145322.ref104" ref-type="bibr">104</xref>]. <italic>SMAD</italic>4 was down-regulated in our TCGA prostate cancer data and has also been found to be down-regulated in prostate cancers, including advanced tumors [<xref rid="pone.0145322.ref105" ref-type="bibr">105</xref>, <xref rid="pone.0145322.ref106" ref-type="bibr">106</xref>]. The deletion of this gene has led to invasive, metastatic, and lethal prostate cancers in a mouse model [<xref rid="pone.0145322.ref039" ref-type="bibr">39</xref>]. <italic>TMPRSS2</italic> was up-regulated and this is in agreement with reports of it being more highly expressed in prostate carcinoma compared to normal prostate epithelium [<xref rid="pone.0145322.ref107" ref-type="bibr">107</xref>, <xref rid="pone.0145322.ref108" ref-type="bibr">108</xref>]. <italic>TMPRSS2</italic> contributes to the invasion and metastasis of prostate cancer [<xref rid="pone.0145322.ref109" ref-type="bibr">109</xref>]. Further, <italic>TMPRSS2-ERG</italic> gene fusion holds promise as a potential prostate cancer biomarker [<xref rid="pone.0145322.ref110" ref-type="bibr">110</xref>]. <italic>MYC</italic> was also up-regulated in this dataset and the overexpression (gene amplification, mRNA, and protein increase) of <italic>MYC</italic> in prostate cancer is well-documented [<xref rid="pone.0145322.ref111" ref-type="bibr">111</xref>&#x02013;<xref rid="pone.0145322.ref115" ref-type="bibr">115</xref>]. <italic>MYC</italic> gene amplification was found more often in metastases [<xref rid="pone.0145322.ref116" ref-type="bibr">116</xref>, <xref rid="pone.0145322.ref117" ref-type="bibr">117</xref>] and also correlated with poor prognostic factors like higher Gleason and histopathological scores [<xref rid="pone.0145322.ref118" ref-type="bibr">118</xref>], or greater chance of PSA recurrence [<xref rid="pone.0145322.ref114" ref-type="bibr">114</xref>]. <italic>EZH2</italic> up-regulation is reported here and in the literature where such overexpression led to increased proliferation in prostate cells and is associated with aggressive disease and increased risk of recurrence [<xref rid="pone.0145322.ref119" ref-type="bibr">119</xref>]. The expression of <italic>p53</italic> mRNA was increased in malignant samples in our TCGA data. In a study of prostate cancer patients, <italic>p53</italic> positive expression was seen in the majority (69.1%) of patients with the number of positive patients increasing as stage and Gleason score increased. P53 was also an independent predictor of recurrence [<xref rid="pone.0145322.ref120" ref-type="bibr">120</xref>]. <italic>BCL2</italic> mRNA expression was decreased in TCGA tumor samples. The absence of BCL-2 protein expression is reported in prostate cancer [<xref rid="pone.0145322.ref120" ref-type="bibr">120</xref>, <xref rid="pone.0145322.ref121" ref-type="bibr">121</xref>]. Furthermore, BCL-2 expression is negative in androgen-dependent, but increased in hormone insensitive prostate cancers [<xref rid="pone.0145322.ref122" ref-type="bibr">122</xref>&#x02013;<xref rid="pone.0145322.ref124" ref-type="bibr">124</xref>] and correlated with poor prognosis [<xref rid="pone.0145322.ref125" ref-type="bibr">125</xref>]. Pro-neuropeptide Y was up-regulated in this study and in the literature [<xref rid="pone.0145322.ref126" ref-type="bibr">126</xref>, <xref rid="pone.0145322.ref127" ref-type="bibr">127</xref>]. Pro-neuropeptide Y up-regulation is associated with non-aggressive tumors [<xref rid="pone.0145322.ref128" ref-type="bibr">128</xref>] and regulates proliferation in prostate cancer cell lines [<xref rid="pone.0145322.ref129" ref-type="bibr">129</xref>]. <italic>PLA2G7</italic> was up-regulated in our data. It is reported to be more highly expressed in prostate cancer compared to benign samples [<xref rid="pone.0145322.ref130" ref-type="bibr">130</xref>, <xref rid="pone.0145322.ref131" ref-type="bibr">131</xref>] and the TCGA samples studied here. Levels of <italic>Ki-67</italic> mRNA were increased in tumor versus non-malignant samples from our TCGA data and in the literature compared to normal tissue [<xref rid="pone.0145322.ref132" ref-type="bibr">132</xref>]. Furthermore Ki-67 protein is increased in prostate cancer [<xref rid="pone.0145322.ref133" ref-type="bibr">133</xref>&#x02013;<xref rid="pone.0145322.ref136" ref-type="bibr">136</xref>], prostate cancer metastases [<xref rid="pone.0145322.ref137" ref-type="bibr">137</xref>, <xref rid="pone.0145322.ref138" ref-type="bibr">138</xref>] and is a useful prognostic marker [<xref rid="pone.0145322.ref139" ref-type="bibr">139</xref>]. In our list of DEGs, <italic>p16</italic> was up-regulated. Recently, p16 expression was found in a large majority of prostate tissues [<xref rid="pone.0145322.ref140" ref-type="bibr">140</xref>]. <italic>BAX</italic> mRNA expression was increased in this TCGA dataset and BAX protein had increased expression in prostate cancer [<xref rid="pone.0145322.ref141" ref-type="bibr">141</xref>].</p><p>The remaining 7 DEGs in common with Lucas and Heath&#x02019;s list displayed a discrepancy in expression pattern between our results and the literature. <italic>TGF-&#x003b2;1</italic> was not differentially expressed but <italic>TGF-&#x003b2;2</italic> was down-regulated. Expression of <italic>TGF-&#x003b2;1</italic> and <italic>TGF-&#x003b2;2</italic> was increased in prostate cancer compared to normal or non-malignant tissues [<xref rid="pone.0145322.ref142" ref-type="bibr">142</xref>&#x02013;<xref rid="pone.0145322.ref147" ref-type="bibr">147</xref>]. However, <italic>TGF-&#x003b2;3</italic> was down-regulated in agreement with other reports of <italic>TGF-&#x003b2;3</italic> expression in prostate cancer [<xref rid="pone.0145322.ref097" ref-type="bibr">97</xref>, <xref rid="pone.0145322.ref148" ref-type="bibr">148</xref>]. Both &#x003b1; and &#x003b2; isoforms of <italic>IL-1</italic> and <italic>IL-6</italic> were down-regulated in this TCGA dataset. <italic>IL-1&#x003b1;</italic> and <italic>IL-6</italic> were up-regulated in prostate cancer samples [<xref rid="pone.0145322.ref149" ref-type="bibr">149</xref>&#x02013;<xref rid="pone.0145322.ref153" ref-type="bibr">153</xref>]. <italic>IL-6</italic> stimulated growth of LNCaP cells [<xref rid="pone.0145322.ref154" ref-type="bibr">154</xref>] and elevated <italic>IL-6</italic> was also associated with poor prognosis in prostate cancer [<xref rid="pone.0145322.ref149" ref-type="bibr">149</xref>, <xref rid="pone.0145322.ref155" ref-type="bibr">155</xref>&#x02013;<xref rid="pone.0145322.ref162" ref-type="bibr">162</xref>]. <italic>IL-1&#x003b2;</italic> has been reported both up- and down-regulated in the literature. Protein expression in patient samples was down-regulated [<xref rid="pone.0145322.ref163" ref-type="bibr">163</xref>] but elevated gene and protein expression in human cancer cells and tumors has also been reported [<xref rid="pone.0145322.ref164" ref-type="bibr">164</xref>]. In our list of DEGs, <italic>p21</italic> was down-regulated. Aaltomaa <italic>et al</italic>. reported p21 protein expression in the majority of prostate tumors but not in normal prostate epithelial cells [<xref rid="pone.0145322.ref165" ref-type="bibr">165</xref>] but other studies reported p21 immunostaining in only 20%-35% of cancer samples [<xref rid="pone.0145322.ref166" ref-type="bibr">166</xref>, <xref rid="pone.0145322.ref167" ref-type="bibr">167</xref>]. Both <italic>p21</italic> and <italic>p16</italic> inhibited growth in prostate cancer cell lines [<xref rid="pone.0145322.ref168" ref-type="bibr">168</xref>]. Vascular endothelial growth factor A (<italic>VEGF-A</italic>) was down-regulated in our data. High expression of <italic>VEGF</italic> correlated with poor prognosis [<xref rid="pone.0145322.ref169" ref-type="bibr">169</xref>], but some studies reported that the higher expression of <italic>VEGF-A</italic> correlated with better clinical outcome [<xref rid="pone.0145322.ref170" ref-type="bibr">170</xref>]. <italic>TRAIL/TNFSF10</italic> was up-regulated in our TCGA data. While epithelial expression of TRAIL protein was stronger in tumors, stromal expression of TRAIL was decreased or absent in tumors [<xref rid="pone.0145322.ref171" ref-type="bibr">171</xref>, <xref rid="pone.0145322.ref172" ref-type="bibr">172</xref>]. Only stromal TRAIL expression correlated with recurrence-free survival [<xref rid="pone.0145322.ref171" ref-type="bibr">171</xref>]. <italic>NFKB1</italic> was down-regulated in our data. However, <italic>NFKB1</italic> protein expression progressively increased in normal, benign prostatic hyperplasia and prostate cancer tissues [<xref rid="pone.0145322.ref173" ref-type="bibr">173</xref>]. The other DEGs with prognostic significance in prostate cancer that were not differentially expressed in our list of DEGs include <italic>IL-7</italic>, <italic>CCL-2</italic>, and <italic>CDH1</italic>.</p><p>Comparisons between the DEGs presented herein and DEGs listed in other studies highlight variance from experiment to experiment. Despite such variance a strong underlying correlation between datasets may still sometimes be seen [<xref rid="pone.0145322.ref174" ref-type="bibr">174</xref>]. These correlations would most likely be captured in a pathway approach. Thus our TCGA data was subject to pathway analysis. We found the &#x0201c;Ran regulation of mitotic spindle formation&#x0201d; pathway to be most significant in prostate cancer and the &#x0201c;TGF-&#x003b2; signaling&#x0201d; pathway to be activated in prostate cancer. Additionally, the following pathways were significant across both GSEA and SPIA methods and were associated with the non-malignant samples and were inhibited in the tumor samples: &#x0201c;proteoglycans in cancer&#x0201d;, &#x0201c;Hippo signaling pathway&#x0201d;, &#x0201c;cGMP-PKG signaling pathway&#x0201d;, &#x0201c;Ras signaling pathway&#x0201d;, &#x0201c;MAPK signaling pathway&#x0201d;, &#x0201c;Focal adhesion&#x0201d;, &#x0201c;Regulation of actin cytoskeleton&#x0201d;, &#x0201c;Oxytocin signaling pathway&#x0201d;, and &#x0201c;Pathways in cancer&#x0201d;.</p><sec id="sec011"><title>Ran regulation of mitotic spindle formation pathway</title><p>Ran is a small GTPase of the Ras family known to function in directing nucleocytoplasmic transport, in cell cycle control through regulation of transition to S-phase and mitosis, and in regulating the mitotic spindle during mitosis and the reassembly of the nuclear envelope after mitosis [<xref rid="pone.0145322.ref175" ref-type="bibr">175</xref>]. Ran&#x02019;s control over the mitotic spindle is the pathway that was shown to be significant in prostate cancer in our data. Proper functioning of this pathway assembles spindle microtubules for chromosome alignment and segregation in a way that ensures a single copy of each chromosome is distributed to the daughter cells, thus avoiding aneuploidy [<xref rid="pone.0145322.ref074" ref-type="bibr">74</xref>, <xref rid="pone.0145322.ref075" ref-type="bibr">75</xref>, <xref rid="pone.0145322.ref176" ref-type="bibr">176</xref>]. Each of the genes in this pathway, which include Ran, its regulators, accessory proteins, spindle assembly factors, and import/export factors, was up-regulated (<xref rid="pone.0145322.t006" ref-type="table">Table 6</xref>). Ran&#x02019;s function in mitotic spindle assembly is reviewed by Clarke and Zhang [<xref rid="pone.0145322.ref176" ref-type="bibr">176</xref>]. Ran-GDP is converted to Ran-GTP by the guanine nucleotide-exchange factor RCC1 and is hydrolyzed back to Ran-GDP with the aid of the GTPase activating protein RanGAP1 and RanBP1/2. The specific localization of RCC1 and RanGAP1/RanBP2 results in the formation of Ran-GTP at precise points along spindle assembly. Importin-&#x003b1;/importin-&#x003b2; complexes carry spindle assembly factors such as TPX2 and NuMA into the nucleus where they are released at chromosomes after interaction with Ran-GTP. Spindle assembly factors then interact with other molecules such as Aurora kinase A to form the spindle.</p><p>Ran-GTP overexpression was reported in various human cancers [<xref rid="pone.0145322.ref177" ref-type="bibr">177</xref>&#x02013;<xref rid="pone.0145322.ref181" ref-type="bibr">181</xref>] and multiple cancer cell lines [<xref rid="pone.0145322.ref181" ref-type="bibr">181</xref>, <xref rid="pone.0145322.ref182" ref-type="bibr">182</xref>]. Ran proved critical for epithelial ovarian cancer cell survival [<xref rid="pone.0145322.ref183" ref-type="bibr">183</xref>] and its overexpression caused malignant transformation in rat mammary cells [<xref rid="pone.0145322.ref184" ref-type="bibr">184</xref>]. Silencing of Ran in tumor cell lines, but not normal cells, led to cell death after aberrations in mitotic spindle assembly and mitochondrial function [<xref rid="pone.0145322.ref181" ref-type="bibr">181</xref>]. In agreement with our data, other pathway components and Ran-associated genes are also overexpressed in cancer: Aurora kinase A [<xref rid="pone.0145322.ref185" ref-type="bibr">185</xref>], TPX2 [<xref rid="pone.0145322.ref186" ref-type="bibr">186</xref>&#x02013;<xref rid="pone.0145322.ref188" ref-type="bibr">188</xref>], and HSET [<xref rid="pone.0145322.ref189" ref-type="bibr">189</xref>]. Ran has not been extensively studied in prostate cancer. There are reports of increased Ran expression in prostate tumor tissues [<xref rid="pone.0145322.ref190" ref-type="bibr">190</xref>] and Ran functions as an androgen receptor coactivator [<xref rid="pone.0145322.ref191" ref-type="bibr">191</xref>, <xref rid="pone.0145322.ref192" ref-type="bibr">192</xref>].</p></sec><sec id="sec012"><title>TGF-&#x003b2; Signaling</title><p>The TGF-&#x003b2; signaling pathway was activated in the malignant condition in this TCGA prostate cancer dataset. In general, TGF-&#x003b2; signaling regulates cell proliferation, migration, differentiation, epithelial-mesenchymal transition, immune-suppression, and apoptosis [<xref rid="pone.0145322.ref085" ref-type="bibr">85</xref>, <xref rid="pone.0145322.ref193" ref-type="bibr">193</xref>]. Several components of the TGF-&#x003b2; signaling pathway were differentially expressed (<xref rid="pone.0145322.t008" ref-type="table">Table 8</xref>). The binding of active TGF-&#x003b2; to its receptors begins a phosphorylation cascade that activates Smad transcription factors which translocate to the nucleus. In the nucleus, the Smad complex binds various transcription factors, coactivators, co-repressors, and chromatin remodeling factors to regulate gene expression [<xref rid="pone.0145322.ref194" ref-type="bibr">194</xref>, <xref rid="pone.0145322.ref195" ref-type="bibr">195</xref>]. Ultimately, TGF-&#x003b2; signaling promotes expression of inhibitors of cell cycle progression and suppresses proliferative genes [<xref rid="pone.0145322.ref195" ref-type="bibr">195</xref>, <xref rid="pone.0145322.ref196" ref-type="bibr">196</xref>]. Tumor cells can subvert the suppressive effect of TGF-&#x003b2; signaling seen in normal cells to promote tumorigenesis [<xref rid="pone.0145322.ref194" ref-type="bibr">194</xref>, <xref rid="pone.0145322.ref195" ref-type="bibr">195</xref>].</p><p>Several studies have reported the increase of TGF-&#x003b2; isoforms in prostate cancer [<xref rid="pone.0145322.ref142" ref-type="bibr">142</xref>, <xref rid="pone.0145322.ref145" ref-type="bibr">145</xref>&#x02013;<xref rid="pone.0145322.ref147" ref-type="bibr">147</xref>, <xref rid="pone.0145322.ref197" ref-type="bibr">197</xref>, <xref rid="pone.0145322.ref198" ref-type="bibr">198</xref>], however our study shows a significant decrease in <italic>TGF-&#x003b2;2</italic> and <italic>TGF-&#x003b2;3</italic> gene expression and no differential expression of <italic>TGF-&#x003b2;1</italic>. Our results are, however, corroborated by the work of Dallas <italic>et al</italic>. which showed both latent and active forms of TGF-&#x003b2;2 were decreased in malignant prostate cells compared to normal prostate epithelial cells cultured from the same patient [<xref rid="pone.0145322.ref199" ref-type="bibr">199</xref>]. Our results are also corroborated by studies showing lost or decreased expression of TGF-&#x003b2;3 [<xref rid="pone.0145322.ref143" ref-type="bibr">143</xref>, <xref rid="pone.0145322.ref148" ref-type="bibr">148</xref>]. In our TCGA dataset, all three TGF-&#x003b2; receptors were down-regulated. Loss of TGF-&#x003b2; receptors is consistent with literature [<xref rid="pone.0145322.ref146" ref-type="bibr">146</xref>, <xref rid="pone.0145322.ref200" ref-type="bibr">200</xref>&#x02013;<xref rid="pone.0145322.ref204" ref-type="bibr">204</xref>] and represents a mechanism through which tumors avoid growth suppression by TGF-&#x003b2;, thus facilitating the development of cancer after oncogenic triggers [<xref rid="pone.0145322.ref195" ref-type="bibr">195</xref>]. Additionally, down-regulation of TGF-&#x003b2;1, &#x003b2;2, and &#x003b2;3 is associated with androgen-stimulated growth of prostate cancer cells [<xref rid="pone.0145322.ref205" ref-type="bibr">205</xref>].</p><p>Although TGF-&#x003b2; signaling typically operates through Smad proteins, the pathway signal may also be diverted through other Smad-independent pathways like PI3K/AKT, ERK/MAPK, JNK/p38 MAPK and Rho-like GTPase signaling pathways [<xref rid="pone.0145322.ref151" ref-type="bibr">151</xref>, <xref rid="pone.0145322.ref206" ref-type="bibr">206</xref>]. Since Smad genes were down-regulated, we looked at other effectors and found serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha and beta isoforms (<italic>PPP2R1A</italic>, <italic>PPP2R1B</italic>) to be up-regulated along with the targets ribosomal protein S6 kinase &#x003b2;-1 and &#x003b2;-2 (<italic>RPS6KB1</italic>, <italic>RPS6KB2</italic>), the serine/threonine-protein phosphatase 2A catalytic subunit &#x003b2; isoform (<italic>PPP2CB</italic>) was down-regulated, both <italic>RhoA</italic> and <italic>ROCK1</italic> were down-regulated and <italic>MAPK1</italic> and <italic>MAPK3</italic> were also down-regulated. In our TCGA data, MAPK signaling pathway was significantly different between tumor and non-malignant samples, however it was more associated with non-malignant samples whereas TGF-&#x003b2; was more associated with tumor samples. Erk signaling alters the expression of genes controlling cell motility, and cell-matrix adhesion and interactions [<xref rid="pone.0145322.ref207" ref-type="bibr">207</xref>]. Cell motility and cell-matrix adhesion-related gene sets were also significantly enriched in the non-malignant samples of our TCGA prostate cancer data (<xref rid="pone.0145322.t005" ref-type="table">Table 5</xref>).</p></sec><sec id="sec013"><title>Pathway Comparison</title><p>There were a few surprising results from GSEA analysis&#x02014;namely, the significance of prolactin and oxytocin signaling pathways and thyroid hormone synthesis pathway. The genes contributing to the enrichment of these pathways in non-malignant samples were not the namesake hormones themselves, but the multiple kinases, phosphatases, and calcium or potassium channel proteins that participate in hormone signaling (<xref rid="pone.0145322.s013" ref-type="supplementary-material">S10</xref>&#x02013;<xref rid="pone.0145322.s015" ref-type="supplementary-material">S12</xref> Tables). In the case of oxytocin signaling, the pathway operates through both calcium signaling and MAPK signaling (<xref rid="pone.0145322.s001" ref-type="supplementary-material">S1 Fig</xref>), which were also found to be significant. For the prolactin pathway (<xref rid="pone.0145322.s002" ref-type="supplementary-material">S2 Fig</xref>), the enrichment of MAPK kinases and PI3K kinases is abundant however prolactin itself is not enriched (<xref rid="pone.0145322.s014" ref-type="supplementary-material">S11 Table</xref>). Finally, for thyroid synthesis pathway (<xref rid="pone.0145322.s003" ref-type="supplementary-material">S3 Fig</xref>), none of the hormones or receptors are present but other components through which they operate are (<xref rid="pone.0145322.s015" ref-type="supplementary-material">S12 Table</xref>). Thus it appears these pathways could have been flagged due to substantial overlap with the signaling of other pathways since neither oxytocin, prolactin, or thyroid stimulating hormone nor their receptors were differentially expressed. These results demonstrate the limitation of GSEA discussed previously, the topology of genes in the pathways is unaccounted for. SPIA is a complementary pathway method that does consider the position of genes in the pathway. It is noteworthy that SPIA analysis was able to filter prolactin and thyroid hormone synthesis pathways from significant results.</p><p>Comparison to previous pathway studies which used microarray data or single nucleotide polymorphisms from genome-wide association studies showed that several pathways were identified across experimental platforms. Savli <italic>et al</italic>. looked at gene networks and pathway analysis in prostate cancer [<xref rid="pone.0145322.ref208" ref-type="bibr">208</xref>]. However, that study used microarray to measure gene expression and found 738 up-regulated genes and 515 down-regulated genes. This study used RNA sequencing data and found 5,736 up-regulated genes and 5,379 down-regulated genes. Some advantages of a sequencing method over microarray approach include more extensive transcript identification beyond the coverage of sequence libraries although correlation between some sequencing approaches and microarray platforms has been demonstrated [<xref rid="pone.0145322.ref034" ref-type="bibr">34</xref>]. Additionally, our patient pool was much larger (173 versus 21 tumor and 52 versus 10 non-malignant). The methods for identifying pathways was also different. Savli <italic>et al</italic>. used Ingenuity Pathway Analysis to identify pathways and construct gene networks. &#x0201c;Axonal guidance signaling&#x0201d; (down-regulated) and &#x0201c;acute phase response&#x0201d; (up-regulated) were the most significant pathways among the up- and down-regulated canonical pathways reported by Savli <italic>et al</italic>. but were not found in this study&#x02019;s results. However other important pathways in prostate cancer were found in both studies including &#x0201c;actin cytoskeleton&#x0201d; (down-regulated in both), &#x0201c;calcium signaling&#x0201d; (up-regulated in Savli <italic>et al</italic>., down-regulated in ours), and &#x0201c;MAPK signaling&#x0201d; (down-regulated in both). Jia <italic>et al</italic>. used a combination of GSEA and Plink set-based tests on microarray data and genome-wide association studies to identify thirteen KEGG pathways involved in prostate cancer [<xref rid="pone.0145322.ref209" ref-type="bibr">209</xref>]. In this study, we found five of these KEGG pathways to be important in prostate cancer: regulation of actin cytoskeleton, small cell lung cancer, cell cycle, chronic myeloid leukemia, and TGF-&#x003b2; signaling pathway.</p></sec></sec><sec sec-type="conclusions" id="sec014"><title>Conclusion</title><p>This work presents a comprehensive gene expression profile of human prostate cancer. Differential gene expression was analyzed in the context of gene sets and pathways to identify signature pathways associated with prostate cancer. &#x0201c;TGF-&#x003b2; signaling&#x0201d; and &#x0201c;Ran regulation of mitotic spindle formation&#x0201d; pathways were strongly associated with prostate cancer. Since it is an underexplored area in prostate cancer, we suggest Ran pathway components for further investigation in prostate cancer pathogenesis. Several other significant pathways confirm reported findings from microarray data that suggest actin cytoskeleton regulation, cell cycle, MAPK signaling, and calcium signaling are also altered in prostate cancer. We further observed that none of the most highly altered genes with the largest increases or decreases in expression appeared in the significant pathways. Thus we have demonstrated that both differential expression and pathway analysis are important in extracting meaningful information.</p></sec><sec sec-type="supplementary-material" id="sec015"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0145322.s001"><label>S1 Fig</label><caption><title>KEGG Oxytocin Signaling Pathway.</title><p>Differentially expressed genes are highlighted in red.</p><p>(PNG)</p></caption><media xlink:href="pone.0145322.s001.png"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s002"><label>S2 Fig</label><caption><title>KEGG Prolactin Signaling Pathway.</title><p>Differentially expressed genes are highlighted in red.</p><p>(PNG)</p></caption><media xlink:href="pone.0145322.s002.png"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s003"><label>S3 Fig</label><caption><title>KEGG Thyroid Hormone Synthesis Pathway.</title><p>Differentially expressed genes are highlighted in red.</p><p>(PNG)</p></caption><media xlink:href="pone.0145322.s003.png"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s004"><label>S1 Table</label><caption><title>Age- and stage matched human prostate cancer mRNA expression dataset.</title><p>This file includes the RNAseq expression data for the 225 age- and stage-matched prostate cancer non-malignant and tumor samples downloaded from The Cancer Genome Atlas and used for the analyses presented in this work.</p><p>(XLSX)</p></caption><media xlink:href="pone.0145322.s004.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s005"><label>S2 Table</label><caption><title>Selected KEGG pathways used for all pathway analyses.</title><p>This is the set of KEGG pathways used in Gene Set Enrichment Analysis and Signaling Pathway Impact Analysis. Pathways likely to have little relevance to prostate cancer (<italic>e</italic>.<italic>g</italic>. parasitic, bacterial, and viral infectious diseases, substance dependencies, and specific immune, neurodegenerative, and cardiovascular diseases) have been excluded.</p><p>(XLSX)</p></caption><media xlink:href="pone.0145322.s005.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s006"><label>S3 Table</label><caption><title>Differentially expressed genes in human prostate cancer.</title><p>A total of 11,115 genes and transcripts were differentially expressed according to DESeq2 analysis using Wald statistics. All statistical parameters plus the calculated log<sub>2</sub> fold change are presented.</p><p>(XLSX)</p></caption><media xlink:href="pone.0145322.s006.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s007"><label>S4 Table</label><caption><title>Complete DESeq2 analysis results including all genes and transcripts evaluated.</title><p>Complete results of DESeq2 analysis with statistical parameters and calculated log<sub>2</sub> fold change.</p><p>(XLSX)</p></caption><media xlink:href="pone.0145322.s007.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s008"><label>S5 Table</label><caption><title>Classification of differentially expressed genes by protein class and gene ontology.</title><p>Complete classification based on PANTHER protein class, GO Molecular Function and GO Biological Process terms.</p><p>(XLSX)</p></caption><media xlink:href="pone.0145322.s008.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s009"><label>S6 Table</label><caption><title>PANTHER overrepresentation results for protein class and gene ontology.</title><p>This is the full pathway overrepresentation analysis of protein class and GO Biological Process categories among DEGs from the dataset.</p><p>(XLSX)</p></caption><media xlink:href="pone.0145322.s009.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s010"><label>S7 Table</label><caption><title>Complete GSEA results for BioCarta, Reactome and KEGG gene sets.</title><p>(XLSX)</p></caption><media xlink:href="pone.0145322.s010.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s011"><label>S8 Table</label><caption><title>Genes and Transcripts contributing to KEGG Calcium Signaling Pathway enrichment in GSEA.</title><p>These genes and transcripts from the evaluated TCGA dataset contribute to the enrichment of the KEGG Calcium Signaling Pathway in non-malignant samples.</p><p>(XLSX)</p></caption><media xlink:href="pone.0145322.s011.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s012"><label>S9 Table</label><caption><title>Complete SPIA results for KEGG pathways.</title><p>(XLSX)</p></caption><media xlink:href="pone.0145322.s012.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s013"><label>S10 Table</label><caption><title>Genes contributing to KEGG Oxytocin Signaling Pathway enrichment.</title><p>These genes and transcripts from the evaluated TCGA dataset contribute to the enrichment of the KEGG Calcium Signaling Pathway in non-malignant samples.</p><p>(XLSX)</p></caption><media xlink:href="pone.0145322.s013.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s014"><label>S11 Table</label><caption><title>Genes contributing to KEGG Prolactin Signaling Pathway enrichment.</title><p>These genes and transcripts from the evaluated TCGA dataset contribute to the enrichment of the KEGG Calcium Signaling Pathway in non-malignant samples.</p><p>(XLSX)</p></caption><media xlink:href="pone.0145322.s014.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0145322.s015"><label>S12 Table</label><caption><title>Genes contributing to KEGG Thyroid Hormone Synthesis Pathway enrichment.</title><p>These genes and transcripts from the evaluated TCGA dataset contribute to the enrichment of the KEGG Calcium Signaling Pathway in non-malignant samples.</p><p>(XLSX)</p></caption><media xlink:href="pone.0145322.s015.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors thank Dr. Jinfeng Zhang and Mr. Kaixian Yu in the Departments of Statistics at Florida State University for helpful discussions. This work was in part supported by the Leslie N. Wilson-Delores Auzenne Graduate Assistantship for Minorities awarded to JSM by the Florida State University Graduate School, the Research Experience Program of Women in Math, Science, and Engineering of Florida State University to AKVL, and grants from the Florida State University and an Endowed Chair Professorship in Cancer Research from anonymous donors to QXAS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>PSA</term><def><p>prostate-specific antigen</p></def></def-item><def-item><term>DEGs</term><def><p>differentially expressed genes</p></def></def-item><def-item><term>MAPK</term><def><p>mitogen activated protein kinase</p></def></def-item><def-item><term>TGF-&#x003b2;</term><def><p>transforming growth factor-beta</p></def></def-item><def-item><term>TCGA</term><def><p>The Cancer Genome Atlas</p></def></def-item><def-item><term>FDR</term><def><p>false discovery rate</p></def></def-item><def-item><term>PANTHER</term><def><p>Protein ANalysis THrough Evolutionary Relationships</p></def></def-item><def-item><term>GO</term><def><p>Gene Ontology</p></def></def-item><def-item><term>GSEA</term><def><p>Gene Set Enrichment Analysis</p></def></def-item><def-item><term>KEGG</term><def><p>Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term>SPIA</term><def><p>Signaling Pathway Impact Analysis</p></def></def-item><def-item><term>ES</term><def><p>enrichment score</p></def></def-item><def-item><term>NES</term><def><p>normalized enrichment score</p></def></def-item><def-item><term>pNDE</term><def><p>probability of overrepresentation</p></def></def-item><def-item><term>pPERT</term><def><p>probability of perturbation</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pone.0145322.ref001"><label>1</label><mixed-citation publication-type="other">Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. 2015; 65(1): 5&#x02013;29.</mixed-citation></ref><ref id="pone.0145322.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Draisma</surname><given-names>G</given-names></name>, <name><surname>Etzioni</surname><given-names>R</given-names></name>, <name><surname>Tsodikov</surname><given-names>A</given-names></name>, <name><surname>Mariotto</surname><given-names>A</given-names></name>, <name><surname>Wever</surname><given-names>E</given-names></name>, <name><surname>Gulati</surname><given-names>R</given-names></name>, <etal>et al</etal><article-title>Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context</article-title>. <source>J Natl Cancer Inst</source>. <year>2009</year>; <volume>101</volume>(<issue>6</issue>): <fpage>374</fpage>&#x02013;<lpage>383</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jnci/djp001">10.1093/jnci/djp001</ext-link></comment>
<?supplied-pmid 19276453?><pub-id pub-id-type="pmid">19276453</pub-id></mixed-citation></ref><ref id="pone.0145322.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Hoffman</surname><given-names>RM</given-names></name>. <article-title>Screening for Prostate Cancer</article-title>. <source>N Engl J Med</source>. <year>2011</year>; <volume>365</volume>(<issue>21</issue>): <fpage>2013</fpage>&#x02013;<lpage>2019</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMcp1103642">10.1056/NEJMcp1103642</ext-link></comment>
<?supplied-pmid 22029754?><pub-id pub-id-type="pmid">22029754</pub-id></mixed-citation></ref><ref id="pone.0145322.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Moyer</surname><given-names>VA</given-names></name>, <collab>U.S. Preventive Services Task Force</collab>. <article-title>Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement</article-title>. <source>Ann Intern Med</source>. <year>2012</year>; <volume>157</volume>(<issue>2</issue>): <fpage>120</fpage>&#x02013;<lpage>134</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00459">10.7326/0003-4819-157-2-201207170-00459</ext-link></comment>
<?supplied-pmid 22801674?><pub-id pub-id-type="pmid">22801674</pub-id></mixed-citation></ref><ref id="pone.0145322.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Cazares</surname><given-names>LH</given-names></name>, <name><surname>Adam</surname><given-names>BL</given-names></name>, <name><surname>Ward</surname><given-names>MD</given-names></name>, <name><surname>Nasim</surname><given-names>S</given-names></name>, <name><surname>Schellhammer</surname><given-names>PF</given-names></name>, <name><surname>Semmes</surname><given-names>OJ</given-names></name>, <etal>et al</etal>
<article-title>Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry</article-title>. <source>Clin Cancer Res</source>. <year>2002</year>; <volume>8</volume>(<issue>8</issue>): <fpage>2541</fpage>&#x02013;<lpage>2552</lpage>. <?supplied-pmid 12171882?><pub-id pub-id-type="pmid">12171882</pub-id></mixed-citation></ref><ref id="pone.0145322.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name>, <name><surname>Barrette</surname><given-names>TR</given-names></name>, <name><surname>Ghosh</surname><given-names>D</given-names></name>, <name><surname>Shah</surname><given-names>R</given-names></name>, <name><surname>Varambally</surname><given-names>S</given-names></name>, <name><surname>Kurachi</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Delineation of prognostic biomarkers in prostate cancer</article-title>. <source>Nature</source>. <year>2001</year>; <volume>412</volume>(<issue>6849</issue>): <fpage>822</fpage>&#x02013;<lpage>826</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/35090585">10.1038/35090585</ext-link></comment>
<?supplied-pmid 11518967?><pub-id pub-id-type="pmid">11518967</pub-id></mixed-citation></ref><ref id="pone.0145322.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Ernst</surname><given-names>T</given-names></name>, <name><surname>Hergenhahn</surname><given-names>M</given-names></name>, <name><surname>Kenzelmann</surname><given-names>M</given-names></name>, <name><surname>Cohen</surname><given-names>CD</given-names></name>, <name><surname>Bonrouhi</surname><given-names>M</given-names></name>, <name><surname>Weninger</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue</article-title>. <source>Am J Pathol</source>. <year>2002</year>; <volume>160</volume>(<issue>6</issue>): <fpage>2169</fpage>&#x02013;<lpage>2180</lpage>. <?supplied-pmid 12057920?><pub-id pub-id-type="pmid">12057920</pub-id></mixed-citation></ref><ref id="pone.0145322.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Lapointe</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <name><surname>Higgins</surname><given-names>JP</given-names></name>, <name><surname>van de Rijn</surname><given-names>M</given-names></name>, <name><surname>Bair</surname><given-names>E</given-names></name>, <name><surname>Montgomery</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Gene expression profiling identifies clinically relevant subtypes of prostate cancer</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2004</year>; <volume>101</volume>(<issue>3</issue>): <fpage>811</fpage>&#x02013;<lpage>816</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0304146101">10.1073/pnas.0304146101</ext-link></comment>
<?supplied-pmid 14711987?><pub-id pub-id-type="pmid">14711987</pub-id></mixed-citation></ref><ref id="pone.0145322.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Luo</surname><given-names>J</given-names></name>, <name><surname>Duggan</surname><given-names>DJ</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Sauvageot</surname><given-names>J</given-names></name>, <name><surname>Ewing</surname><given-names>CM</given-names></name>, <name><surname>Bittner</surname><given-names>ML</given-names></name>, <etal>et al</etal>
<article-title>Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling</article-title>. <source>Cancer Res</source>. <year>2001</year>; <volume>61</volume>(<issue>12</issue>): <fpage>4683</fpage>&#x02013;<lpage>4688</lpage>. <?supplied-pmid 11406537?><pub-id pub-id-type="pmid">11406537</pub-id></mixed-citation></ref><ref id="pone.0145322.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Qian</surname><given-names>DZ</given-names></name>, <name><surname>Huang</surname><given-names>CY</given-names></name>, <name><surname>O'Brien</surname><given-names>CA</given-names></name>, <name><surname>Coleman</surname><given-names>IM</given-names></name>, <name><surname>Garzotto</surname><given-names>M</given-names></name>, <name><surname>True</surname><given-names>LD</given-names></name>, <etal>et al</etal>
<article-title>Prostate cancer-associated gene expression alterations determined from needle biopsies</article-title>. <source>Clin Cancer Res</source>. <year>2009</year>; <volume>15</volume>(<issue>9</issue>): <fpage>3135</fpage>&#x02013;<lpage>3142</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-08-1982">10.1158/1078-0432.CCR-08-1982</ext-link></comment>
<?supplied-pmid 19366833?><pub-id pub-id-type="pmid">19366833</pub-id></mixed-citation></ref><ref id="pone.0145322.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Stamey</surname><given-names>TA</given-names></name>, <name><surname>Warrington</surname><given-names>JA</given-names></name>, <name><surname>Caldwell</surname><given-names>MC</given-names></name>, <name><surname>Chen</surname><given-names>Z</given-names></name>, <name><surname>Fan</surname><given-names>Z</given-names></name>, <name><surname>Mahadevappa</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia</article-title>. <source>J Urol</source>. <year>2001</year>; <volume>166</volume>(<issue>6</issue>): <fpage>2171</fpage>&#x02013;<lpage>2177</lpage>. <?supplied-pmid 11696729?><pub-id pub-id-type="pmid">11696729</pub-id></mixed-citation></ref><ref id="pone.0145322.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>YP</given-names></name>, <name><surname>Landsittel</surname><given-names>D</given-names></name>, <name><surname>Jing</surname><given-names>L</given-names></name>, <name><surname>Nelson</surname><given-names>J</given-names></name>, <name><surname>Ren</surname><given-names>B</given-names></name>, <name><surname>Liu</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy</article-title>. <source>J Clin Oncol. 2004</source>; <volume>22</volume>(<issue>14</issue>): <fpage>2790</fpage>&#x02013;<lpage>2799</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2004.05.158">10.1200/JCO.2004.05.158</ext-link></comment></mixed-citation></ref><ref id="pone.0145322.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Welsh</surname><given-names>JB</given-names></name>, <name><surname>Sapinoso</surname><given-names>LM</given-names></name>, <name><surname>Su</surname><given-names>AI</given-names></name>, <name><surname>Kern</surname><given-names>SG</given-names></name>, <name><surname>Wang-Rodriguez</surname><given-names>J</given-names></name>, <name><surname>Moskaluk</surname><given-names>CA</given-names></name>, <etal>et al</etal>
<article-title>Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer</article-title>. <source>Cancer Res</source>. <year>2001</year>; <volume>61</volume>(<issue>16</issue>): <fpage>5974</fpage>&#x02013;<lpage>5978</lpage>. <?supplied-pmid 11507037?><pub-id pub-id-type="pmid">11507037</pub-id></mixed-citation></ref><ref id="pone.0145322.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>D</given-names></name>, <name><surname>Febbo</surname><given-names>PG</given-names></name>, <name><surname>Ross</surname><given-names>K</given-names></name>, <name><surname>Jackson</surname><given-names>DG</given-names></name>, <name><surname>Manola</surname><given-names>J</given-names></name>, <name><surname>Ladd</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Gene expression correlates of clinical prostate cancer behavior</article-title>. <source>Cancer Cell</source>. <year>2002</year>; <volume>1</volume>(<issue>2</issue>): <fpage>203</fpage>&#x02013;<lpage>209</lpage>. <?supplied-pmid 12086878?><pub-id pub-id-type="pmid">12086878</pub-id></mixed-citation></ref><ref id="pone.0145322.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>LaTulippe</surname><given-names>E</given-names></name>, <name><surname>Satagopan</surname><given-names>J</given-names></name>, <name><surname>Smith</surname><given-names>A</given-names></name>, <name><surname>Scher</surname><given-names>H</given-names></name>, <name><surname>Scardino</surname><given-names>P</given-names></name>, <name><surname>Reuter</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease</article-title>. <source>Cancer Res</source>. <year>2002</year>; <volume>62</volume>(<issue>15</issue>): <fpage>4499</fpage>&#x02013;<lpage>4506</lpage>. <?supplied-pmid 12154061?><pub-id pub-id-type="pmid">12154061</pub-id></mixed-citation></ref><ref id="pone.0145322.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Khan</surname><given-names>AP</given-names></name>, <name><surname>Poisson</surname><given-names>LM</given-names></name>, <name><surname>Bhat</surname><given-names>VB</given-names></name>, <name><surname>Fermin</surname><given-names>D</given-names></name>, <name><surname>Zhao</surname><given-names>R</given-names></name>, <name><surname>Kalyana-Sundaram</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer</article-title>. <source>Mol Cell Proteomics</source>. <year>2010</year>; <volume>9</volume>(<issue>2</issue>): <fpage>298</fpage>&#x02013;<lpage>312</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/mcp.M900159-MCP200">10.1074/mcp.M900159-MCP200</ext-link></comment>
<?supplied-pmid 19955085?><pub-id pub-id-type="pmid">19955085</pub-id></mixed-citation></ref><ref id="pone.0145322.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Varambally</surname><given-names>S</given-names></name>, <name><surname>Yu</surname><given-names>J</given-names></name>, <name><surname>Laxman</surname><given-names>B</given-names></name>, <name><surname>Rhodes</surname><given-names>DR</given-names></name>, <name><surname>Mehra</surname><given-names>R</given-names></name>, <name><surname>Tomlins</surname><given-names>SA</given-names></name>, <etal>et al</etal>
<article-title>Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression</article-title>. <source>Cancer Cell</source>. <year>2005</year>; <volume>8</volume>(<issue>5</issue>): <fpage>393</fpage>&#x02013;<lpage>406</lpage>. <?supplied-pmid 16286247?><pub-id pub-id-type="pmid">16286247</pub-id></mixed-citation></ref><ref id="pone.0145322.ref018"><label>18</label><mixed-citation publication-type="other">Lin J, Xu J, Tian H, Gao X, Chen Q, Gu Q, et al. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. 2007; 121(12): 2596&#x02013;2605.</mixed-citation></ref><ref id="pone.0145322.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Alaiya</surname><given-names>AA</given-names></name>, <name><surname>Al-Mohanna</surname><given-names>M</given-names></name>, <name><surname>Aslam</surname><given-names>M</given-names></name>, <name><surname>Shinwari</surname><given-names>Z</given-names></name>, <name><surname>Al-Mansouri</surname><given-names>L</given-names></name>, <name><surname>Al-Rodayan</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma</article-title>. <source>Int J Oncol</source>. <year>2011</year>; <volume>38</volume>(<issue>4</issue>): <fpage>1047</fpage>&#x02013;<lpage>1057</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3892/ijo.2011.937">10.3892/ijo.2011.937</ext-link></comment>
<?supplied-pmid 21305254?><pub-id pub-id-type="pmid">21305254</pub-id></mixed-citation></ref><ref id="pone.0145322.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Ahram</surname><given-names>M</given-names></name>, <name><surname>Best</surname><given-names>CJM</given-names></name>, <name><surname>Flaig</surname><given-names>MJ</given-names></name>, <name><surname>Gillespie</surname><given-names>JW</given-names></name>, <name><surname>Leiva</surname><given-names>IM</given-names></name>, <name><surname>Chuaqui</surname><given-names>RF</given-names></name>, <etal>et al</etal>
<article-title>Proteomic analysis of human prostate cancer</article-title>. <source>Mol Carcinog</source>. <year>2002</year>; <volume>33</volume>(<issue>1</issue>): <fpage>9</fpage>&#x02013;<lpage>15</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mc.10019">10.1002/mc.10019</ext-link></comment>
<?supplied-pmid 11807953?><pub-id pub-id-type="pmid">11807953</pub-id></mixed-citation></ref><ref id="pone.0145322.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Meehan</surname><given-names>KL</given-names></name>, <name><surname>Holland</surname><given-names>JW</given-names></name>, <name><surname>Dawkins</surname><given-names>HJS</given-names></name>. <article-title>Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer</article-title>. <source>Prostate</source>. <year>2002</year>; <volume>50</volume>(<issue>1</issue>): <fpage>54</fpage>&#x02013;<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.10032">10.1002/pros.10032</ext-link></comment>
<?supplied-pmid 11757036?><pub-id pub-id-type="pmid">11757036</pub-id></mixed-citation></ref><ref id="pone.0145322.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Kiprijanovska</surname><given-names>S</given-names></name>, <name><surname>Stavridis</surname><given-names>S</given-names></name>, <name><surname>Stankov</surname><given-names>O</given-names></name>, <name><surname>Komina</surname><given-names>S</given-names></name>, <name><surname>Petrusevska</surname><given-names>G</given-names></name>, <name><surname>Polenakovic</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Mapping and Identification of the Urine Proteome of Prostate Cancer Patients by 2D PAGE/MS</article-title>. <source>Int J Proteomics</source>. <year>2014</year>; <volume>2014</volume>: <fpage>594761</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2014/594761">10.1155/2014/594761</ext-link></comment>
<?supplied-pmid 25215235?><pub-id pub-id-type="pmid">25215235</pub-id></mixed-citation></ref><ref id="pone.0145322.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Davalieva</surname><given-names>K</given-names></name>, <name><surname>Kostovska</surname><given-names>IM</given-names></name>, <name><surname>Kiprijanovska</surname><given-names>S</given-names></name>, <name><surname>Markoska</surname><given-names>K</given-names></name>, <name><surname>Kubelka-Sabit</surname><given-names>K</given-names></name>, <name><surname>Filipovski</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer</article-title>. <source>Prostate</source>. <year>2015</year>; <volume>75</volume>(<issue>14</issue>): <fpage>1586</fpage>&#x02013;<lpage>1600</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.23034">10.1002/pros.23034</ext-link></comment>
<?supplied-pmid 26074449?><pub-id pub-id-type="pmid">26074449</pub-id></mixed-citation></ref><ref id="pone.0145322.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Glinsky</surname><given-names>GV</given-names></name>, <name><surname>Glinskii</surname><given-names>AB</given-names></name>, <name><surname>Stephenson</surname><given-names>AJ</given-names></name>, <name><surname>Hoffman</surname><given-names>RM</given-names></name>, <name><surname>Gerald</surname><given-names>WL</given-names></name>. <article-title>Gene expression profiling predicts clinical outcome of prostate cancer</article-title>. <source>J Clin Invest</source>. <year>2004</year>; <volume>113</volume>(<issue>6</issue>): <fpage>913</fpage>&#x02013;<lpage>923</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI20032">10.1172/JCI20032</ext-link></comment>
<?supplied-pmid 15067324?><pub-id pub-id-type="pmid">15067324</pub-id></mixed-citation></ref><ref id="pone.0145322.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>C</given-names></name>, <name><surname>Chen</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>T</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Ru</surname><given-names>G</given-names></name>, <name><surname>Lang</surname><given-names>J</given-names></name>. <article-title>Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing</article-title>. <source>Prostate</source>. <year>2015</year>; <volume>75</volume>(<issue>5</issue>): <fpage>500</fpage>&#x02013;<lpage>516</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.22936">10.1002/pros.22936</ext-link></comment>
<?supplied-pmid 25597612?><pub-id pub-id-type="pmid">25597612</pub-id></mixed-citation></ref><ref id="pone.0145322.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Gordanpour</surname><given-names>A</given-names></name>, <name><surname>Nam</surname><given-names>RK</given-names></name>, <name><surname>Sugar</surname><given-names>L</given-names></name>, <name><surname>Seth</surname><given-names>A</given-names></name>. <article-title>MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics</article-title>. <source>Prostate Cancer Prostatic Dis</source>. <year>2012</year>; <volume>15</volume>(<issue>4</issue>): <fpage>314</fpage>&#x02013;<lpage>319</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/pcan.2012.3">10.1038/pcan.2012.3</ext-link></comment>
<?supplied-pmid 22333688?><pub-id pub-id-type="pmid">22333688</pub-id></mixed-citation></ref><ref id="pone.0145322.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Mahapatra</surname><given-names>S</given-names></name>, <name><surname>Klee</surname><given-names>EW</given-names></name>, <name><surname>Young</surname><given-names>CY</given-names></name>, <name><surname>Sun</surname><given-names>Z</given-names></name>, <name><surname>Jimenez</surname><given-names>RE</given-names></name>, <name><surname>Klee</surname><given-names>GG</given-names></name>, <etal>et al</etal>
<article-title>Global methylation profiling for risk prediction of prostate cancer</article-title>. <source>Clin Cancer Res</source>. <year>2012</year>; <volume>18</volume>(<issue>10</issue>): <fpage>2882</fpage>&#x02013;<lpage>2895</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-11-2090">10.1158/1078-0432.CCR-11-2090</ext-link></comment>
<?supplied-pmid 22589488?><pub-id pub-id-type="pmid">22589488</pub-id></mixed-citation></ref><ref id="pone.0145322.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Hoque</surname><given-names>MO</given-names></name>, <name><surname>Topaloglu</surname><given-names>O</given-names></name>, <name><surname>Begum</surname><given-names>S</given-names></name>, <name><surname>Henrique</surname><given-names>R</given-names></name>, <name><surname>Rosenbaum</surname><given-names>E</given-names></name>, <name><surname>Van Criekinge</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects</article-title>. <source>J Clin Oncol</source>. <year>2005</year>; <volume>23</volume>(<issue>27</issue>): <fpage>6569</fpage>&#x02013;<lpage>6575</lpage>. <?supplied-pmid 16170165?><pub-id pub-id-type="pmid">16170165</pub-id></mixed-citation></ref><ref id="pone.0145322.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Ozen</surname><given-names>M</given-names></name>, <name><surname>Creighton</surname><given-names>CJ</given-names></name>, <name><surname>Ozdemir</surname><given-names>M</given-names></name>, <name><surname>Ittmann</surname><given-names>M</given-names></name>. <article-title>Widespread deregulation of microRNA expression in human prostate cancer</article-title>. <source>Oncogene</source>. <year>2008</year>; <volume>27</volume>(<issue>12</issue>): <fpage>1788</fpage>&#x02013;<lpage>1793</lpage>. <?supplied-pmid 17891175?><pub-id pub-id-type="pmid">17891175</pub-id></mixed-citation></ref><ref id="pone.0145322.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Lucas</surname><given-names>SM</given-names></name>, <name><surname>Heath</surname><given-names>EI</given-names></name>. <article-title>Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers</article-title>. <source>Prostate Cancer</source>. <year>2012</year>; <volume>2012</volume>: <fpage>640968</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2012/640968">10.1155/2012/640968</ext-link></comment>
<?supplied-pmid 22970379?><pub-id pub-id-type="pmid">22970379</pub-id></mixed-citation></ref><ref id="pone.0145322.ref031"><label>31</label><mixed-citation publication-type="other">Coppola V, De Maria R, Bonci D. MicroRNAs and prostate cancer. 2010; 17(1): F1-F17.</mixed-citation></ref><ref id="pone.0145322.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Arora</surname><given-names>R</given-names></name>, <name><surname>Koch</surname><given-names>MO</given-names></name>, <name><surname>Eble</surname><given-names>JN</given-names></name>, <name><surname>Ulbright</surname><given-names>TM</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Cheng</surname><given-names>L</given-names></name>. <article-title>Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate</article-title>. <source>Cancer</source>. <year>2004</year>; <volume>100</volume>(<issue>11</issue>): <fpage>2362</fpage>&#x02013;<lpage>2366</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/cncr.20243">10.1002/cncr.20243</ext-link></comment>
<?supplied-pmid 15160339?><pub-id pub-id-type="pmid">15160339</pub-id></mixed-citation></ref><ref id="pone.0145322.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Ein-Dor</surname><given-names>L</given-names></name>, <name><surname>Kela</surname><given-names>I</given-names></name>, <name><surname>Getz</surname><given-names>G</given-names></name>, <name><surname>Givol</surname><given-names>D</given-names></name>, <name><surname>Domany</surname><given-names>E</given-names></name>. <article-title>Outcome signature genes in breast cancer: is there a unique set?</article-title>
<source>Bioinformatics</source>. <year>2005</year>; <volume>21</volume>(<issue>2</issue>): <fpage>171</fpage>&#x02013;<lpage>178</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/bth469">10.1093/bioinformatics/bth469</ext-link></comment>
<?supplied-pmid 15308542?><pub-id pub-id-type="pmid">15308542</pub-id></mixed-citation></ref><ref id="pone.0145322.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>F</given-names></name>, <name><surname>Jenssen</surname><given-names>T</given-names></name>, <name><surname>Trimarchi</surname><given-names>J</given-names></name>, <name><surname>Punzo</surname><given-names>C</given-names></name>, <name><surname>Cepko</surname><given-names>CL</given-names></name>, <name><surname>Ohno-Machado</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Comparison of hybridization-based and sequencing-based gene expression technologies on biological replicates</article-title>. <source>BMC Genomics</source>. <year>2007</year>; <volume>8</volume>(<issue>1</issue>): <fpage>153</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2164-8-153">10.1186/1471-2164-8-153</ext-link></comment><pub-id pub-id-type="pmid">17555589</pub-id></mixed-citation></ref><ref id="pone.0145322.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Diamandis</surname><given-names>EP</given-names></name>. <article-title>The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?</article-title>
<source>BMC Med</source>. <year>2012</year>; <volume>10</volume>: 87-7015-10-87. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1741-7015-10-87">10.1186/1741-7015-10-87</ext-link></comment></mixed-citation></ref><ref id="pone.0145322.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Diamandis</surname><given-names>EP</given-names></name>. <article-title>Present and future of cancer biomarkers</article-title>. <source>Clin Chem Lab Med</source>. <year>2014</year>; <volume>52</volume>(<issue>6</issue>): <fpage>791</fpage>&#x02013;<lpage>794</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1515/cclm-2014-0317">10.1515/cclm-2014-0317</ext-link></comment>
<?supplied-pmid 24803613?><pub-id pub-id-type="pmid">24803613</pub-id></mixed-citation></ref><ref id="pone.0145322.ref037"><label>37</label><mixed-citation publication-type="other">Schroten C, Dits NF, Steyerberg EW, Kranse R, van Leenders AGJLH, Bangma CH, et al. The additional value of TGF&#x000df;1 and IL-7 to predict the course of prostate cancer progression. 2011; 61(6): 905&#x02013;910.</mixed-citation></ref><ref id="pone.0145322.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Latil</surname><given-names>A</given-names></name>, <name><surname>Bieche</surname><given-names>I</given-names></name>, <name><surname>Chene</surname><given-names>L</given-names></name>, <name><surname>Laurendeau</surname><given-names>I</given-names></name>, <name><surname>Berthon</surname><given-names>P</given-names></name>, <name><surname>Cussenot</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior</article-title>. <source>Clin Cancer Res</source>. <year>2003</year>; <volume>9</volume>(<issue>15</issue>): <fpage>5477</fpage>&#x02013;<lpage>5485</lpage>. <?supplied-pmid 14654526?><pub-id pub-id-type="pmid">14654526</pub-id></mixed-citation></ref><ref id="pone.0145322.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Ding</surname><given-names>Z</given-names></name>, <name><surname>Wu</surname><given-names>C</given-names></name>, <name><surname>Chu</surname><given-names>GC</given-names></name>, <name><surname>Xiao</surname><given-names>Y</given-names></name>, <name><surname>Ho</surname><given-names>D</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression</article-title>. <source>Nature</source>. <year>2011</year>; <volume>470</volume>(<issue>7333</issue>): <fpage>269</fpage>&#x02013;<lpage>273</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature09677">10.1038/nature09677</ext-link></comment>
<?supplied-pmid 21289624?><pub-id pub-id-type="pmid">21289624</pub-id></mixed-citation></ref><ref id="pone.0145322.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Bibikova</surname><given-names>M</given-names></name>, <name><surname>Chudin</surname><given-names>E</given-names></name>, <name><surname>Arsanjani</surname><given-names>A</given-names></name>, <name><surname>Zhou</surname><given-names>L</given-names></name>, <name><surname>Garcia</surname><given-names>EW</given-names></name>, <name><surname>Modder</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Expression signatures that correlated with Gleason score and relapse in prostate cancer</article-title>. <source>Genomics</source>. <year>2007</year>; <volume>89</volume>(<issue>6</issue>): <fpage>666</fpage>&#x02013;<lpage>672</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ygeno.2007.02.005">10.1016/j.ygeno.2007.02.005</ext-link></comment>
<?supplied-pmid 17459658?><pub-id pub-id-type="pmid">17459658</pub-id></mixed-citation></ref><ref id="pone.0145322.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Blume-Jensen</surname><given-names>P</given-names></name>, <name><surname>Berman</surname><given-names>DM</given-names></name>, <name><surname>Rimm</surname><given-names>DL</given-names></name>, <name><surname>Shipitsin</surname><given-names>M</given-names></name>, <name><surname>Putzi</surname><given-names>M</given-names></name>, <name><surname>Nifong</surname><given-names>TP</given-names></name>, <etal>et al</etal>
<article-title>Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer</article-title>. <source>Clin Cancer Res</source>. <year>2015</year>; <volume>21</volume>(<issue>11</issue>): <fpage>2591</fpage>&#x02013;<lpage>2600</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-14-2603">10.1158/1078-0432.CCR-14-2603</ext-link></comment>
<?supplied-pmid 25733599?><pub-id pub-id-type="pmid">25733599</pub-id></mixed-citation></ref><ref id="pone.0145322.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Knezevic</surname><given-names>D</given-names></name>, <name><surname>Goddard</surname><given-names>AD</given-names></name>, <name><surname>Natraj</surname><given-names>N</given-names></name>, <name><surname>Cherbavaz</surname><given-names>DB</given-names></name>, <name><surname>Clark-Langone</surname><given-names>KM</given-names></name>, <name><surname>Snable</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Analytical validation of the Oncotype DX prostate cancer assay&#x02014;a clinical RT-PCR assay optimized for prostate needle biopsies</article-title>. <source>BMC Genomics</source>. <year>2013</year>; <volume>14</volume>: <fpage>690</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2164-14-690">10.1186/1471-2164-14-690</ext-link></comment>
<?supplied-pmid 24103217?><pub-id pub-id-type="pmid">24103217</pub-id></mixed-citation></ref><ref id="pone.0145322.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Cuzick</surname><given-names>J</given-names></name>, <name><surname>Swanson</surname><given-names>GP</given-names></name>, <name><surname>Fisher</surname><given-names>G</given-names></name>, <name><surname>Brothman</surname><given-names>AR</given-names></name>, <name><surname>Berney</surname><given-names>DM</given-names></name>, <name><surname>Reid</surname><given-names>JE</given-names></name>, <etal>et al</etal>
<article-title>Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study</article-title>. <source>Lancet Oncol</source>. <year>2011</year>; <volume>12</volume>(<issue>3</issue>): <fpage>245</fpage>&#x02013;<lpage>255</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1470-2045(10)70295-3">10.1016/S1470-2045(10)70295-3</ext-link></comment>
<?supplied-pmid 21310658?><pub-id pub-id-type="pmid">21310658</pub-id></mixed-citation></ref><ref id="pone.0145322.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Karnes</surname><given-names>RJ</given-names></name>, <name><surname>Bergstralh</surname><given-names>EJ</given-names></name>, <name><surname>Davicioni</surname><given-names>E</given-names></name>, <name><surname>Ghadessi</surname><given-names>M</given-names></name>, <name><surname>Buerki</surname><given-names>C</given-names></name>, <name><surname>Mitra</surname><given-names>AP</given-names></name>, <etal>et al</etal>
<article-title>Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population</article-title>. <source>J Urol</source>. <year>2013</year>; <volume>190</volume>(<issue>6</issue>): <fpage>2047</fpage>&#x02013;<lpage>2053</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.juro.2013.06.017">10.1016/j.juro.2013.06.017</ext-link></comment>
<?supplied-pmid 23770138?><pub-id pub-id-type="pmid">23770138</pub-id></mixed-citation></ref><ref id="pone.0145322.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Yao</surname><given-names>C</given-names></name>, <name><surname>Guo</surname><given-names>Z</given-names></name>, <name><surname>Zou</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Xiao</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Apparently low reproducibility of true differential expression discoveries in microarray studies</article-title>. <source>Bioinformatics</source>. <year>2008</year>; <volume>24</volume>(<issue>18</issue>): <fpage>2057</fpage>&#x02013;<lpage>2063</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btn365">10.1093/bioinformatics/btn365</ext-link></comment>
<?supplied-pmid 18632747?><pub-id pub-id-type="pmid">18632747</pub-id></mixed-citation></ref><ref id="pone.0145322.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Shen</surname><given-names>B</given-names></name>, <name><surname>Zhang</surname><given-names>D</given-names></name>. <article-title>Molecular signature of cancer at gene level or pathway level? Case studies of colorectal cancer and prostate cancer microarray data</article-title>. <source>Comput Math Methods Med</source>. <year>2013</year>; <volume>2013</volume>: <fpage>909525</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2013/909525">10.1155/2013/909525</ext-link></comment>
<?supplied-pmid 23401724?><pub-id pub-id-type="pmid">23401724</pub-id></mixed-citation></ref><ref id="pone.0145322.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>Q</given-names></name>, <name><surname>Wang</surname><given-names>H</given-names></name>, <name><surname>Liu</surname><given-names>G</given-names></name>, <name><surname>Jing</surname><given-names>Q</given-names></name>, <etal>et al</etal>
<article-title>Identifying novel prostate cancer associated pathways based on integrative microarray data analysis</article-title>. <source>Comput Biol Chem</source>. <year>2011</year>; <volume>35</volume>(<issue>3</issue>): <fpage>151</fpage>&#x02013;<lpage>158</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.compbiolchem.2011.04.003">10.1016/j.compbiolchem.2011.04.003</ext-link></comment>
<?supplied-pmid 21704261?><pub-id pub-id-type="pmid">21704261</pub-id></mixed-citation></ref><ref id="pone.0145322.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Abraham</surname><given-names>G</given-names></name>, <name><surname>Kowalczyk</surname><given-names>A</given-names></name>, <name><surname>Loi</surname><given-names>S</given-names></name>, <name><surname>Haviv</surname><given-names>I</given-names></name>, <name><surname>Zobel</surname><given-names>J</given-names></name>. <article-title>Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context</article-title>. <source>BMC Bioinformatics</source>. <year>2010</year>; <volume>11</volume>(<issue>1</issue>): <fpage>277</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2105-11-277">10.1186/1471-2105-11-277</ext-link></comment><pub-id pub-id-type="pmid">20500821</pub-id></mixed-citation></ref><ref id="pone.0145322.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Tian</surname><given-names>L</given-names></name>, <name><surname>Greenberg</surname><given-names>SA</given-names></name>, <name><surname>Kong</surname><given-names>SW</given-names></name>, <name><surname>Altschuler</surname><given-names>J</given-names></name>, <name><surname>Kohane</surname><given-names>IS</given-names></name>, <name><surname>Park</surname><given-names>PJ</given-names></name>. <article-title>Discovering statistically significant pathways in expression profiling studies</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2005</year>; <volume>102</volume>(<issue>38</issue>): <fpage>13544</fpage>&#x02013;<lpage>13549</lpage>. <?supplied-pmid 16174746?><pub-id pub-id-type="pmid">16174746</pub-id></mixed-citation></ref><ref id="pone.0145322.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>E</given-names></name>, <name><surname>Chuang</surname><given-names>HY</given-names></name>, <name><surname>Kim</surname><given-names>JW</given-names></name>, <name><surname>Ideker</surname><given-names>T</given-names></name>, <name><surname>Lee</surname><given-names>D</given-names></name>. <article-title>Inferring pathway activity toward precise disease classification</article-title>. <source>PLoS Comput Biol</source>. <year>2008</year>; <volume>4</volume>(<issue>11</issue>): <fpage>e1000217</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pcbi.1000217">10.1371/journal.pcbi.1000217</ext-link></comment>
<?supplied-pmid 18989396?><pub-id pub-id-type="pmid">18989396</pub-id></mixed-citation></ref><ref id="pone.0145322.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Chuang</surname><given-names>H</given-names></name>, <name><surname>Lee</surname><given-names>E</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Lee</surname><given-names>D</given-names></name>, <name><surname>Ideker</surname><given-names>T</given-names></name>. <article-title>Network-based classification of breast cancer metastasis</article-title>. <source>Mol Syst Biol</source>. <year>2007</year>; <volume>3</volume>: <fpage>140</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/msb4100180">10.1038/msb4100180</ext-link></comment>
<?supplied-pmid 17940530?><pub-id pub-id-type="pmid">17940530</pub-id></mixed-citation></ref><ref id="pone.0145322.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Basu</surname><given-names>A</given-names></name>, <name><surname>Drame</surname><given-names>A</given-names></name>, <name><surname>Munoz</surname><given-names>R</given-names></name>, <name><surname>Gijsbers</surname><given-names>R</given-names></name>, <name><surname>Debyser</surname><given-names>Z</given-names></name>, <name><surname>De Leon</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Pathway specific gene expression profiling reveals oxidative stress genes potentially regulated by transcription co-activator LEDGF/p75 in prostate cancer cells</article-title>. <source>Prostate</source>. <year>2012</year>; <volume>72</volume>(<issue>6</issue>): <fpage>597</fpage>&#x02013;<lpage>611</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.21463">10.1002/pros.21463</ext-link></comment>
<?supplied-pmid 21796653?><pub-id pub-id-type="pmid">21796653</pub-id></mixed-citation></ref><ref id="pone.0145322.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Bettuzzi</surname><given-names>S</given-names></name>, <name><surname>Davalli</surname><given-names>P</given-names></name>, <name><surname>Astancolle</surname><given-names>S</given-names></name>, <name><surname>Carani</surname><given-names>C</given-names></name>, <name><surname>Madeo</surname><given-names>B</given-names></name>, <name><surname>Tampieri</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens</article-title>. <source>Cancer Res</source>. <year>2000</year>; <volume>60</volume>(<issue>1</issue>): <fpage>28</fpage>&#x02013;<lpage>34</lpage>. <?supplied-pmid 10646846?><pub-id pub-id-type="pmid">10646846</pub-id></mixed-citation></ref><ref id="pone.0145322.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Bettuzzi</surname><given-names>S</given-names></name>, <name><surname>Scaltriti</surname><given-names>M</given-names></name>, <name><surname>Caporali</surname><given-names>A</given-names></name>, <name><surname>Brausi</surname><given-names>M</given-names></name>, <name><surname>D'Arca</surname><given-names>D</given-names></name>, <name><surname>Astancolle</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study</article-title>. <source>Cancer Res</source>. <year>2003</year>; <volume>63</volume>(<issue>13</issue>): <fpage>3469</fpage>&#x02013;<lpage>3472</lpage>. <?supplied-pmid 12839927?><pub-id pub-id-type="pmid">12839927</pub-id></mixed-citation></ref><ref id="pone.0145322.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Mukherjee</surname><given-names>R</given-names></name>, <name><surname>McGuinness</surname><given-names>DH</given-names></name>, <name><surname>McCall</surname><given-names>P</given-names></name>, <name><surname>Underwood</surname><given-names>MA</given-names></name>, <name><surname>Seywright</surname><given-names>M</given-names></name>, <name><surname>Orange</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer</article-title>. <source>Br J Cancer</source>. <year>2011</year>; <volume>104</volume>(<issue>12</issue>): <fpage>1920</fpage>&#x02013;<lpage>1928</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/bjc.2011.163">10.1038/bjc.2011.163</ext-link></comment>
<?supplied-pmid 21559022?><pub-id pub-id-type="pmid">21559022</pub-id></mixed-citation></ref><ref id="pone.0145322.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Waalkes</surname><given-names>S</given-names></name>, <name><surname>Simon</surname><given-names>P</given-names></name>, <name><surname>Hennenlotter</surname><given-names>J</given-names></name>, <name><surname>Knapp</surname><given-names>J</given-names></name>, <name><surname>Tezval</surname><given-names>H</given-names></name>, <name><surname>Serth</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Altered expression of Akt signaling pathway parameters in prostate needle biopsies derived from benign, adjacent and cancerous tissue</article-title>. <source>Oncol Rep</source>. <year>2010</year>; <volume>23</volume>(<issue>5</issue>): <fpage>1257</fpage>&#x02013;<lpage>1260</lpage>. <?supplied-pmid 20372838?><pub-id pub-id-type="pmid">20372838</pub-id></mixed-citation></ref><ref id="pone.0145322.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Campa</surname><given-names>D</given-names></name>, <name><surname>Husing</surname><given-names>A</given-names></name>, <name><surname>Stein</surname><given-names>A</given-names></name>, <name><surname>Dostal</surname><given-names>L</given-names></name>, <name><surname>Boeing</surname><given-names>H</given-names></name>, <name><surname>Pischon</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC)</article-title>. <source>PLoS One</source>. <year>2011</year>; <volume>6</volume>(<issue>2</issue>): <fpage>e16914</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0016914">10.1371/journal.pone.0016914</ext-link></comment>
<?supplied-pmid 21373201?><pub-id pub-id-type="pmid">21373201</pub-id></mixed-citation></ref><ref id="pone.0145322.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Kremer</surname><given-names>CL</given-names></name>, <name><surname>Klein</surname><given-names>RR</given-names></name>, <name><surname>Mendelson</surname><given-names>J</given-names></name>, <name><surname>Browne</surname><given-names>W</given-names></name>, <name><surname>Samadzedeh</surname><given-names>LK</given-names></name>, <name><surname>Vanpatten</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Expression of mTOR signaling pathway markers in prostate cancer progression</article-title>. <source>Prostate</source>. <year>2006</year>; <volume>66</volume>(<issue>11</issue>): <fpage>1203</fpage>&#x02013;<lpage>1212</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.20410">10.1002/pros.20410</ext-link></comment>
<?supplied-pmid 16652388?><pub-id pub-id-type="pmid">16652388</pub-id></mixed-citation></ref><ref id="pone.0145322.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Lowey</surname><given-names>J</given-names></name>, <name><surname>Wiklund</surname><given-names>F</given-names></name>, <name><surname>Sun</surname><given-names>J</given-names></name>, <name><surname>Lindmark</surname><given-names>F</given-names></name>, <name><surname>Hsu</surname><given-names>FC</given-names></name>, <etal>et al</etal>
<article-title>The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2005</year>; <volume>14</volume>(<issue>11 Pt 1</issue>): <fpage>2563</fpage>&#x02013;<lpage>2568</lpage>. <?supplied-pmid 16284379?><pub-id pub-id-type="pmid">16284379</pub-id></mixed-citation></ref><ref id="pone.0145322.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Creighton</surname><given-names>CJ</given-names></name>. <article-title>Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors</article-title>. <source>PLoS One</source>. <year>2008</year>; <volume>3</volume>(<issue>3</issue>): <fpage>e1816</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0001816">10.1371/journal.pone.0001816</ext-link></comment>
<?supplied-pmid 18350153?><pub-id pub-id-type="pmid">18350153</pub-id></mixed-citation></ref><ref id="pone.0145322.ref061"><label>61</label><mixed-citation publication-type="book"><collab>R Core Team</collab>. <chapter-title>R: A language and environment for statistical computing</chapter-title>
<publisher-loc>Vienna, Austria</publisher-loc>:<publisher-name>R Foundation for Statistical Computing</publisher-name>;<year>2014</year>.</mixed-citation></ref><ref id="pone.0145322.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Love</surname><given-names>MI</given-names></name>, <name><surname>Huber</surname><given-names>W</given-names></name>, <name><surname>Anders</surname><given-names>S</given-names></name>. <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol</source>. <year>2014</year>; <volume>15</volume>(<issue>12</issue>): <fpage>550</fpage>&#x02013;<lpage>558</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13059-014-0550-8">10.1186/s13059-014-0550-8</ext-link></comment>
<?supplied-pmid 25516281?><pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation></ref><ref id="pone.0145322.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Mi</surname><given-names>H</given-names></name>, <name><surname>Muruganujan</surname><given-names>A</given-names></name>, <name><surname>Thomas</surname><given-names>PD</given-names></name>. <article-title>PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees</article-title>. <source>Nucleic Acids Research</source>. <year>2013</year>; <volume>41</volume>(<issue>D1</issue>): 08/05/2015-D377-D386. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gks1118">10.1093/nar/gks1118</ext-link></comment></mixed-citation></ref><ref id="pone.0145322.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Subramanian</surname><given-names>A</given-names></name>, <name><surname>Tamayo</surname><given-names>P</given-names></name>, <name><surname>Mootha</surname><given-names>VK</given-names></name>, <name><surname>Mukherjee</surname><given-names>S</given-names></name>, <name><surname>Ebert</surname><given-names>BL</given-names></name>, <name><surname>Gillette</surname><given-names>MA</given-names></name>, <etal>et al</etal>
<article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>PNAS</source>. <year>2005</year>; <volume>102</volume>(<issue>43</issue>): <fpage>15545</fpage>&#x02013;<lpage>15550</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0506580102">10.1073/pnas.0506580102</ext-link></comment>
<?supplied-pmid 16199517?><pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation></ref><ref id="pone.0145322.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Kanehisa</surname><given-names>M</given-names></name>, <name><surname>Goto</surname><given-names>S</given-names></name>, <name><surname>Furumichi</surname><given-names>M</given-names></name>, <name><surname>Tanabe</surname><given-names>M</given-names></name>, <name><surname>Hirakawa</surname><given-names>M</given-names></name>. <article-title>KEGG for representation and analysis of molecular networks involving diseases and drugs</article-title>. <source>Nucleic Acids Res</source>. <year>2010</year>; <volume>38</volume>(Database issue): <fpage>D355</fpage>&#x02013;<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkp896">10.1093/nar/gkp896</ext-link></comment>
<?supplied-pmid 19880382?><pub-id pub-id-type="pmid">19880382</pub-id></mixed-citation></ref><ref id="pone.0145322.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Tarca</surname><given-names>AL</given-names></name>, <name><surname>Draghici</surname><given-names>S</given-names></name>, <name><surname>Khatri</surname><given-names>P</given-names></name>, <name><surname>Hassan</surname><given-names>SS</given-names></name>, <name><surname>Mittal</surname><given-names>P</given-names></name>, <name><surname>Kim</surname><given-names>JS</given-names></name>, <etal>et al</etal>
<article-title>A novel signaling pathway impact analysis</article-title>. <source>Bioinformatics</source>. <year>2009</year>; <volume>25</volume>(<issue>1</issue>): <fpage>75</fpage>&#x02013;<lpage>82</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btn577">10.1093/bioinformatics/btn577</ext-link></comment>
<?supplied-pmid 18990722?><pub-id pub-id-type="pmid">18990722</pub-id></mixed-citation></ref><ref id="pone.0145322.ref067"><label>67</label><mixed-citation publication-type="other">Tarca AL, Kathri P and Draghici S. SPIA: Signaling Pathway Impact Analysis (SPIA) using combined evidence of pathway over-representation and unusual signaling perturbations. 2013.</mixed-citation></ref><ref id="pone.0145322.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Furuta</surname><given-names>E</given-names></name>, <name><surname>Okuda</surname><given-names>H</given-names></name>, <name><surname>Kobayashi</surname><given-names>A</given-names></name>, <name><surname>Watabe</surname><given-names>K</given-names></name>. <article-title>Metabolic genes in cancer: their roles in tumor progression and clinical implications</article-title>. <source>Biochim Biophys Acta</source>. <year>2010</year>; <volume>1805</volume>(<issue>2</issue>): <fpage>141</fpage>&#x02013;<lpage>152</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbcan.2010.01.005">10.1016/j.bbcan.2010.01.005</ext-link></comment>
<?supplied-pmid 20122995?><pub-id pub-id-type="pmid">20122995</pub-id></mixed-citation></ref><ref id="pone.0145322.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Robey</surname><given-names>RB</given-names></name>, <name><surname>Weisz</surname><given-names>J</given-names></name>, <name><surname>Kuemmerle</surname><given-names>NB</given-names></name>, <name><surname>Salzberg</surname><given-names>AC</given-names></name>, <name><surname>Berg</surname><given-names>A</given-names></name>, <name><surname>Brown</surname><given-names>DG</given-names></name>, <etal>et al</etal>
<article-title>Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?</article-title>
<source>Carcinogenesis</source>. <year>2015</year>; <volume>36</volume>(<issue>Suppl 1</issue>): <fpage>S203</fpage>&#x02013;<lpage>S231</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/carcin/bgv037">10.1093/carcin/bgv037</ext-link></comment>
<?supplied-pmid 26106140?><pub-id pub-id-type="pmid">26106140</pub-id></mixed-citation></ref><ref id="pone.0145322.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Dang</surname><given-names>CV</given-names></name>. <article-title>Links between metabolism and cancer</article-title>. <source>Genes Dev</source>. <year>2012</year>; <volume>26</volume>(<issue>9</issue>): <fpage>877</fpage>&#x02013;<lpage>890</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/gad.189365.112">10.1101/gad.189365.112</ext-link></comment>
<?supplied-pmid 22549953?><pub-id pub-id-type="pmid">22549953</pub-id></mixed-citation></ref><ref id="pone.0145322.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name>, <name><surname>Lum</surname><given-names>JJ</given-names></name>, <name><surname>Hatzivassiliou</surname><given-names>G</given-names></name>, <name><surname>Thompson</surname><given-names>CB</given-names></name>. <article-title>The biology of cancer: metabolic reprogramming fuels cell growth and proliferation</article-title>. <source>Cell Metab. 2008</source>; <volume>7</volume>(<issue>1</issue>): <fpage>11</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cmet.2007.10.002">10.1016/j.cmet.2007.10.002</ext-link></comment></mixed-citation></ref><ref id="pone.0145322.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Vander Heiden</surname><given-names>MG</given-names></name>, <name><surname>Cantley</surname><given-names>LC</given-names></name>, <name><surname>Thompson</surname><given-names>CB</given-names></name>. <article-title>Understanding the Warburg effect: the metabolic requirements of cell proliferation</article-title>. <source>Science</source>. <year>2009</year>; <volume>324</volume>(<issue>5930</issue>): <fpage>1029</fpage>&#x02013;<lpage>1033</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1160809">10.1126/science.1160809</ext-link></comment>
<?supplied-pmid 19460998?><pub-id pub-id-type="pmid">19460998</pub-id></mixed-citation></ref><ref id="pone.0145322.ref073"><label>73</label><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>J</given-names></name>, <name><surname>Locasale</surname><given-names>JW</given-names></name>, <name><surname>Bielas</surname><given-names>JH</given-names></name>, <name><surname>O'Sullivan</surname><given-names>J</given-names></name>, <name><surname>Sheahan</surname><given-names>K</given-names></name>, <name><surname>Cantley</surname><given-names>LC</given-names></name>, <etal>et al</etal>
<article-title>Heterogeneity of tumor-induced gene expression changes in the human metabolic network</article-title>. <source>Nat Biotechnol</source>. <year>2013</year>; <volume>31</volume>(<issue>6</issue>): <fpage>522</fpage>&#x02013;<lpage>529</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nbt.2530">10.1038/nbt.2530</ext-link></comment>
<?supplied-pmid 23604282?><pub-id pub-id-type="pmid">23604282</pub-id></mixed-citation></ref><ref id="pone.0145322.ref074"><label>74</label><mixed-citation publication-type="journal"><name><surname>Gruss</surname><given-names>OJ</given-names></name>, <name><surname>Vernos</surname><given-names>I</given-names></name>. <article-title>The mechanism of spindle assembly: functions of Ran and its target TPX2</article-title>. <source>J Cell Biol</source>. <year>2004</year>; <volume>166</volume>(<issue>7</issue>): <fpage>949</fpage>&#x02013;<lpage>955</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1083/jcb.200312112">10.1083/jcb.200312112</ext-link></comment>
<?supplied-pmid 15452138?><pub-id pub-id-type="pmid">15452138</pub-id></mixed-citation></ref><ref id="pone.0145322.ref075"><label>75</label><mixed-citation publication-type="journal"><name><surname>Kalab</surname><given-names>P</given-names></name>, <name><surname>Heald</surname><given-names>R</given-names></name>. <article-title>The RanGTP gradient&#x02014;a GPS for the mitotic spindle</article-title>. <source>J Cell Sci</source>. <year>2008</year>; <volume>121</volume>(<issue>Pt 10</issue>): <fpage>1577</fpage>&#x02013;<lpage>1586</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1242/jcs.005959">10.1242/jcs.005959</ext-link></comment>
<?supplied-pmid 18469014?><pub-id pub-id-type="pmid">18469014</pub-id></mixed-citation></ref><ref id="pone.0145322.ref076"><label>76</label><mixed-citation publication-type="journal"><name><surname>Bischoff</surname><given-names>FR</given-names></name>, <name><surname>Krebber</surname><given-names>H</given-names></name>, <name><surname>Smirnova</surname><given-names>E</given-names></name>, <name><surname>Dong</surname><given-names>W</given-names></name>, <name><surname>Ponstingl</surname><given-names>H</given-names></name>. <article-title>Co-activation of RanGTPase and inhibition of GTP dissociation by Ran-GTP binding protein RanBP1</article-title>. <source>EMBO J</source>. <year>1995</year>; <volume>14</volume>(<issue>4</issue>): <fpage>705</fpage>&#x02013;<lpage>715</lpage>. <?supplied-pmid 7882974?><pub-id pub-id-type="pmid">7882974</pub-id></mixed-citation></ref><ref id="pone.0145322.ref077"><label>77</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>MS</given-names></name>, <name><surname>Arnaoutov</surname><given-names>A</given-names></name>, <name><surname>Dasso</surname><given-names>M</given-names></name>. <article-title>RanBP1 governs spindle assembly by defining mitotic Ran-GTP production</article-title>. <source>Dev Cell</source>. <year>2014</year>; <volume>31</volume>(<issue>4</issue>): <fpage>393</fpage>&#x02013;<lpage>404</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.devcel.2014.10.014">10.1016/j.devcel.2014.10.014</ext-link></comment>
<?supplied-pmid 25458009?><pub-id pub-id-type="pmid">25458009</pub-id></mixed-citation></ref><ref id="pone.0145322.ref078"><label>78</label><mixed-citation publication-type="journal"><name><surname>Ems-McClung</surname><given-names>SC</given-names></name>, <name><surname>Zheng</surname><given-names>Y</given-names></name>, <name><surname>Walczak</surname><given-names>CE</given-names></name>. <article-title>Importin alpha/beta and Ran-GTP regulate XCTK2 microtubule binding through a bipartite nuclear localization signal</article-title>. <source>Mol Biol Cell</source>. <year>2004</year>; <volume>15</volume>(<issue>1</issue>): <fpage>46</fpage>&#x02013;<lpage>57</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1091/mbc.E03-07-0454">10.1091/mbc.E03-07-0454</ext-link></comment>
<?supplied-pmid 13679510?><pub-id pub-id-type="pmid">13679510</pub-id></mixed-citation></ref><ref id="pone.0145322.ref079"><label>79</label><mixed-citation publication-type="journal"><name><surname>Nachury</surname><given-names>MV</given-names></name>, <name><surname>Maresca</surname><given-names>TJ</given-names></name>, <name><surname>Salmon</surname><given-names>WC</given-names></name>, <name><surname>Waterman-Storer</surname><given-names>CM</given-names></name>, <name><surname>Heald</surname><given-names>R</given-names></name>, <name><surname>Weis</surname><given-names>K</given-names></name>. <article-title>Importin &#x000df; Is a Mitotic Target of the Small GTPase Ran in Spindle Assembly</article-title>. <source>Cell</source>. <year>2001</year>; <volume>104</volume>(<issue>1</issue>): <fpage>95</fpage>&#x02013;<lpage>106</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0092-8674(01)00194-5">10.1016/S0092-8674(01)00194-5</ext-link></comment>
<?supplied-pmid 11163243?><pub-id pub-id-type="pmid">11163243</pub-id></mixed-citation></ref><ref id="pone.0145322.ref080"><label>80</label><mixed-citation publication-type="journal"><name><surname>Wiese</surname><given-names>C</given-names></name>, <name><surname>Wilde</surname><given-names>A</given-names></name>, <name><surname>Moore</surname><given-names>MS</given-names></name>, <name><surname>Adam</surname><given-names>SA</given-names></name>, <name><surname>Merdes</surname><given-names>A</given-names></name>, <name><surname>Zheng</surname><given-names>Y</given-names></name>. <article-title>Role of importin-beta in coupling Ran to downstream targets in microtubule assembly</article-title>. <source>Science</source>. <year>2001</year>; <volume>291</volume>(<issue>5504</issue>): <fpage>653</fpage>&#x02013;<lpage>656</lpage>. <?supplied-pmid 11229403?><pub-id pub-id-type="pmid">11229403</pub-id></mixed-citation></ref><ref id="pone.0145322.ref081"><label>81</label><mixed-citation publication-type="journal"><name><surname>Trieselmann</surname><given-names>N</given-names></name>, <name><surname>Armstrong</surname><given-names>S</given-names></name>, <name><surname>Rauw</surname><given-names>J</given-names></name>, <name><surname>Wilde</surname><given-names>A</given-names></name>. <article-title>Ran modulates spindle assembly by regulating a subset of TPX2 and Kid activities including Aurora A activation</article-title>. <source>J Cell Sci</source>. <year>2003</year>; <volume>116</volume>(<issue>Pt 23</issue>): <fpage>4791</fpage>&#x02013;<lpage>4798</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1242/jcs.00798">10.1242/jcs.00798</ext-link></comment>
<?supplied-pmid 14600264?><pub-id pub-id-type="pmid">14600264</pub-id></mixed-citation></ref><ref id="pone.0145322.ref082"><label>82</label><mixed-citation publication-type="journal"><name><surname>Tanenbaum</surname><given-names>ME</given-names></name>, <name><surname>Macurek</surname><given-names>L</given-names></name>, <name><surname>Janssen</surname><given-names>A</given-names></name>, <name><surname>Geers</surname><given-names>EF</given-names></name>, <name><surname>Alvarez-Fernandez</surname><given-names>M</given-names></name>, <name><surname>Medema</surname><given-names>RH</given-names></name>. <article-title>Kif15 cooperates with eg5 to promote bipolar spindle assembly</article-title>. <source>Curr Biol</source>. <year>2009</year>; <volume>19</volume>(<issue>20</issue>): <fpage>1703</fpage>&#x02013;<lpage>1711</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cub.2009.08.027">10.1016/j.cub.2009.08.027</ext-link></comment>
<?supplied-pmid 19818618?><pub-id pub-id-type="pmid">19818618</pub-id></mixed-citation></ref><ref id="pone.0145322.ref083"><label>83</label><mixed-citation publication-type="journal"><name><surname>Silk</surname><given-names>AD</given-names></name>, <name><surname>Holland</surname><given-names>AJ</given-names></name>, <name><surname>Cleveland</surname><given-names>DW</given-names></name>. <article-title>Requirements for NuMA in maintenance and establishment of mammalian spindle poles</article-title>. <source>J Cell Biol</source>. <year>2009</year>; <volume>184</volume>(<issue>5</issue>): <fpage>677</fpage>&#x02013;<lpage>690</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1083/jcb.200810091">10.1083/jcb.200810091</ext-link></comment>
<?supplied-pmid 19255246?><pub-id pub-id-type="pmid">19255246</pub-id></mixed-citation></ref><ref id="pone.0145322.ref084"><label>84</label><mixed-citation publication-type="other">Katayama H, Sasai K, Kloc M, Brinkley BR, Sen S. Aurora kinase-A regulates kinetochore/chromatin associated microtubule assembly in human cells. 2008; 7(17): 2691&#x02013;2704.</mixed-citation></ref><ref id="pone.0145322.ref085"><label>85</label><mixed-citation publication-type="journal"><name><surname>Akhurst</surname><given-names>RJ</given-names></name>, <name><surname>Hata</surname><given-names>A</given-names></name>. <article-title>Targeting the TGFbeta signalling pathway in disease</article-title>. <source>Nat Rev Drug Discov</source>. <year>2012</year>; <volume>11</volume>(<issue>10</issue>): <fpage>790</fpage>&#x02013;<lpage>811</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrd3810">10.1038/nrd3810</ext-link></comment>
<?supplied-pmid 23000686?><pub-id pub-id-type="pmid">23000686</pub-id></mixed-citation></ref><ref id="pone.0145322.ref086"><label>86</label><mixed-citation publication-type="journal"><name><surname>Wrana</surname><given-names>JL</given-names></name>, <name><surname>Attisano</surname><given-names>L</given-names></name>, <name><surname>Wieser</surname><given-names>R</given-names></name>, <name><surname>Ventura</surname><given-names>F</given-names></name>, <name><surname>Massague</surname><given-names>J</given-names></name>. <article-title>Mechanism of activation of the TGF-beta receptor</article-title>. <source>Nature</source>. <year>1994</year>; <volume>370</volume>(<issue>6488</issue>): <fpage>341</fpage>&#x02013;<lpage>347</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/370341a0">10.1038/370341a0</ext-link></comment>
<?supplied-pmid 8047140?><pub-id pub-id-type="pmid">8047140</pub-id></mixed-citation></ref><ref id="pone.0145322.ref087"><label>87</label><mixed-citation publication-type="journal"><name><surname>Hyytiainen</surname><given-names>M</given-names></name>, <name><surname>Penttinen</surname><given-names>C</given-names></name>, <name><surname>Keski-Oja</surname><given-names>J</given-names></name>. <article-title>Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation</article-title>. <source>Crit Rev Clin Lab Sci</source>. <year>2004</year>; <volume>41</volume>(<issue>3</issue>): <fpage>233</fpage>&#x02013;<lpage>264</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/10408360490460933">10.1080/10408360490460933</ext-link></comment>
<?supplied-pmid 15307633?><pub-id pub-id-type="pmid">15307633</pub-id></mixed-citation></ref><ref id="pone.0145322.ref088"><label>88</label><mixed-citation publication-type="journal"><name><surname>Nakao</surname><given-names>A</given-names></name>, <name><surname>Imamura</surname><given-names>T</given-names></name>, <name><surname>Souchelnytskyi</surname><given-names>S</given-names></name>, <name><surname>Kawabata</surname><given-names>M</given-names></name>, <name><surname>Ishisaki</surname><given-names>A</given-names></name>, <name><surname>Oeda</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4</article-title>. <source>EMBO J</source>. <year>1997</year>; <volume>16</volume>(<issue>17</issue>): <fpage>5353</fpage>&#x02013;<lpage>5362</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/emboj/16.17.5353">10.1093/emboj/16.17.5353</ext-link></comment>
<?supplied-pmid 9311995?><pub-id pub-id-type="pmid">9311995</pub-id></mixed-citation></ref><ref id="pone.0145322.ref089"><label>89</label><mixed-citation publication-type="journal"><name><surname>Hayashi</surname><given-names>H</given-names></name>, <name><surname>Abdollah</surname><given-names>S</given-names></name>, <name><surname>Qiu</surname><given-names>Y</given-names></name>, <name><surname>Cai</surname><given-names>J</given-names></name>, <name><surname>Xu</surname><given-names>YY</given-names></name>, <name><surname>Grinnell</surname><given-names>BW</given-names></name>, <etal>et al</etal>
<article-title>The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling</article-title>. <source>Cell</source>. <year>1997</year>; <volume>89</volume>(<issue>7</issue>): <fpage>1165</fpage>&#x02013;<lpage>1173</lpage>. <?supplied-pmid 9215638?><pub-id pub-id-type="pmid">9215638</pub-id></mixed-citation></ref><ref id="pone.0145322.ref090"><label>90</label><mixed-citation publication-type="journal"><name><surname>Fukuchi</surname><given-names>M</given-names></name>, <name><surname>Imamura</surname><given-names>T</given-names></name>, <name><surname>Chiba</surname><given-names>T</given-names></name>, <name><surname>Ebisawa</surname><given-names>T</given-names></name>, <name><surname>Kawabata</surname><given-names>M</given-names></name>, <name><surname>Tanaka</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins</article-title>. <source>Mol Biol Cell</source>. <year>2001</year>; <volume>12</volume>(<issue>5</issue>): <fpage>1431</fpage>&#x02013;<lpage>1443</lpage>. <?supplied-pmid 11359933?><pub-id pub-id-type="pmid">11359933</pub-id></mixed-citation></ref><ref id="pone.0145322.ref091"><label>91</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>CR</given-names></name>, <name><surname>Kang</surname><given-names>Y</given-names></name>, <name><surname>Siegel</surname><given-names>PM</given-names></name>, <name><surname>Massague</surname><given-names>J</given-names></name>. <article-title>E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression</article-title>. <source>Cell</source>. <year>2002</year>; <volume>110</volume>(<issue>1</issue>): <fpage>19</fpage>&#x02013;<lpage>32</lpage>. <?supplied-pmid 12150994?><pub-id pub-id-type="pmid">12150994</pub-id></mixed-citation></ref><ref id="pone.0145322.ref092"><label>92</label><mixed-citation publication-type="journal"><name><surname>Kress</surname><given-names>TR</given-names></name>, <name><surname>Sabo</surname><given-names>A</given-names></name>, <name><surname>Amati</surname><given-names>B</given-names></name>. <article-title>MYC: connecting selective transcriptional control to global RNA production</article-title>. <source>Nat Rev Cancer</source>. <year>2015</year>; <volume>15</volume>(<issue>10</issue>): <fpage>593</fpage>&#x02013;<lpage>607</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrc3984">10.1038/nrc3984</ext-link></comment>
<?supplied-pmid 26383138?><pub-id pub-id-type="pmid">26383138</pub-id></mixed-citation></ref><ref id="pone.0145322.ref093"><label>93</label><mixed-citation publication-type="journal"><name><surname>Feng</surname><given-names>XH</given-names></name>, <name><surname>Lin</surname><given-names>X</given-names></name>, <name><surname>Derynck</surname><given-names>R</given-names></name>. <article-title>Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta</article-title>. <source>EMBO J</source>. <year>2000</year>; <volume>19</volume>(<issue>19</issue>): <fpage>5178</fpage>&#x02013;<lpage>5193</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/emboj/19.19.5178">10.1093/emboj/19.19.5178</ext-link></comment>
<?supplied-pmid 11013220?><pub-id pub-id-type="pmid">11013220</pub-id></mixed-citation></ref><ref id="pone.0145322.ref094"><label>94</label><mixed-citation publication-type="journal"><name><surname>Black</surname><given-names>AR</given-names></name>, <name><surname>Black</surname><given-names>JD</given-names></name>, <name><surname>Azizkhan-Clifford</surname><given-names>J</given-names></name>. <article-title>Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer</article-title>. <source>J Cell Physiol</source>. <year>2001</year>; <volume>188</volume>(<issue>2</issue>): <fpage>143</fpage>&#x02013;<lpage>160</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jcp.1111">10.1002/jcp.1111</ext-link></comment>
<?supplied-pmid 11424081?><pub-id pub-id-type="pmid">11424081</pub-id></mixed-citation></ref><ref id="pone.0145322.ref095"><label>95</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>WY</given-names></name>, <name><surname>Sharpless</surname><given-names>NE</given-names></name>. <article-title>The Regulation of INK4/ARF in Cancer and Aging</article-title>. <source>Cell</source>. <year>2006</year>; <volume>127</volume>(<issue>2</issue>): <fpage>265</fpage>&#x02013;<lpage>275</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2006.10.003">10.1016/j.cell.2006.10.003</ext-link></comment>
<?supplied-pmid 17055429?><pub-id pub-id-type="pmid">17055429</pub-id></mixed-citation></ref><ref id="pone.0145322.ref096"><label>96</label><mixed-citation publication-type="journal"><name><surname>Luo</surname><given-names>J</given-names></name>, <name><surname>Yu</surname><given-names>YP</given-names></name>, <name><surname>Cieply</surname><given-names>K</given-names></name>, <name><surname>Lin</surname><given-names>F</given-names></name>, <name><surname>Deflavia</surname><given-names>P</given-names></name>, <name><surname>Dhir</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Gene expression analysis of prostate cancers</article-title>. <source>Mol Carcinog</source>. <year>2002</year>; <volume>33</volume>(<issue>1</issue>): <fpage>25</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/mc.10018">10.1002/mc.10018</ext-link></comment>
<?supplied-pmid 11807955?><pub-id pub-id-type="pmid">11807955</pub-id></mixed-citation></ref><ref id="pone.0145322.ref097"><label>97</label><mixed-citation publication-type="journal"><name><surname>Chetcuti</surname><given-names>A</given-names></name>, <name><surname>Margan</surname><given-names>S</given-names></name>, <name><surname>Mann</surname><given-names>S</given-names></name>, <name><surname>Russell</surname><given-names>P</given-names></name>, <name><surname>Handelsman</surname><given-names>D</given-names></name>, <name><surname>Rogers</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array</article-title>. <source>Prostate</source>. <year>2001</year>; <volume>47</volume>(<issue>2</issue>): <fpage>132</fpage>&#x02013;<lpage>140</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.1056">10.1002/pros.1056</ext-link></comment>
<?supplied-pmid 11340636?><pub-id pub-id-type="pmid">11340636</pub-id></mixed-citation></ref><ref id="pone.0145322.ref098"><label>98</label><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>H</given-names></name>, <name><surname>Ramos</surname><given-names>CF</given-names></name>, <name><surname>Brooks</surname><given-names>JD</given-names></name>, <name><surname>Peehl</surname><given-names>DM</given-names></name>. <article-title>Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues</article-title>. <source>J Cell Physiol</source>. <year>2007</year>; <volume>210</volume>(<issue>1</issue>): <fpage>111</fpage>&#x02013;<lpage>121</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jcp.20828">10.1002/jcp.20828</ext-link></comment>
<?supplied-pmid 17044071?><pub-id pub-id-type="pmid">17044071</pub-id></mixed-citation></ref><ref id="pone.0145322.ref099"><label>99</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Stolk</surname><given-names>JA</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Silva</surname><given-names>SJ</given-names></name>, <name><surname>Houghton</surname><given-names>RL</given-names></name>, <name><surname>Matsumura</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Identification of differentially expressed genes in human prostate cancer using subtraction and microarray</article-title>. <source>Cancer Res</source>. <year>2000</year>; <volume>60</volume>(<issue>6</issue>): <fpage>1677</fpage>&#x02013;<lpage>1682</lpage>. <?supplied-pmid 10749139?><pub-id pub-id-type="pmid">10749139</pub-id></mixed-citation></ref><ref id="pone.0145322.ref100"><label>100</label><mixed-citation publication-type="journal"><name><surname>Golub</surname><given-names>TR</given-names></name>, <name><surname>Slonim</surname><given-names>DK</given-names></name>, <name><surname>Tamayo</surname><given-names>P</given-names></name>, <name><surname>Huard</surname><given-names>C</given-names></name>, <name><surname>Gaasenbeek</surname><given-names>M</given-names></name>, <name><surname>Mesirov</surname><given-names>JP</given-names></name>, <etal>et al</etal>
<article-title>Molecular classification of cancer: class discovery and class prediction by gene expression monitoring</article-title>. <source>Science</source>. <year>1999</year>; <volume>286</volume>(<issue>5439</issue>): <fpage>531</fpage>&#x02013;<lpage>537</lpage>. <?supplied-pmid 10521349?><pub-id pub-id-type="pmid">10521349</pub-id></mixed-citation></ref><ref id="pone.0145322.ref101"><label>101</label><mixed-citation publication-type="journal"><name><surname>Ramaswamy</surname><given-names>S</given-names></name>, <name><surname>Tamayo</surname><given-names>P</given-names></name>, <name><surname>Rifkin</surname><given-names>R</given-names></name>, <name><surname>Mukherjee</surname><given-names>S</given-names></name>, <name><surname>Yeang</surname><given-names>CH</given-names></name>, <name><surname>Angelo</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Multiclass cancer diagnosis using tumor gene expression signatures</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2001</year>; <volume>98</volume>(<issue>26</issue>): <fpage>15149</fpage>&#x02013;<lpage>15154</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.211566398">10.1073/pnas.211566398</ext-link></comment>
<?supplied-pmid 11742071?><pub-id pub-id-type="pmid">11742071</pub-id></mixed-citation></ref><ref id="pone.0145322.ref102"><label>102</label><mixed-citation publication-type="journal"><name><surname>Gregg</surname><given-names>JL</given-names></name>, <name><surname>Brown</surname><given-names>KE</given-names></name>, <name><surname>Mintz</surname><given-names>EM</given-names></name>, <name><surname>Piontkivska</surname><given-names>H</given-names></name>, <name><surname>Fraizer</surname><given-names>GC</given-names></name>. <article-title>Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection</article-title>. <source>BMC Cancer</source>. <year>2010</year>; <volume>10</volume>: 165-2407-10-165. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2407-10-165">10.1186/1471-2407-10-165</ext-link></comment></mixed-citation></ref><ref id="pone.0145322.ref103"><label>103</label><mixed-citation publication-type="journal"><name><surname>Lotan</surname><given-names>TL</given-names></name>, <name><surname>Gurel</surname><given-names>B</given-names></name>, <name><surname>Sutcliffe</surname><given-names>S</given-names></name>, <name><surname>Esopi</surname><given-names>D</given-names></name>, <name><surname>Liu</surname><given-names>W</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients</article-title>. <source>Clin Cancer Res</source>. <year>2011</year>; <volume>17</volume>(<issue>20</issue>): <fpage>6563</fpage>&#x02013;<lpage>6573</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-11-1244">10.1158/1078-0432.CCR-11-1244</ext-link></comment>
<?supplied-pmid 21878536?><pub-id pub-id-type="pmid">21878536</pub-id></mixed-citation></ref><ref id="pone.0145322.ref104"><label>104</label><mixed-citation publication-type="journal"><name><surname>Chaux</surname><given-names>A</given-names></name>, <name><surname>Peskoe</surname><given-names>SB</given-names></name>, <name><surname>Gonzalez-Roibon</surname><given-names>N</given-names></name>, <name><surname>Schultz</surname><given-names>L</given-names></name>, <name><surname>Albadine</surname><given-names>R</given-names></name>, <name><surname>Hicks</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer</article-title>. <source>Mod Pathol</source>. <year>2012</year>; <volume>25</volume>(<issue>11</issue>): <fpage>1543</fpage>&#x02013;<lpage>1549</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/modpathol.2012.104">10.1038/modpathol.2012.104</ext-link></comment>
<?supplied-pmid 22684219?><pub-id pub-id-type="pmid">22684219</pub-id></mixed-citation></ref><ref id="pone.0145322.ref105"><label>105</label><mixed-citation publication-type="journal"><name><surname>Zeng</surname><given-names>L</given-names></name>, <name><surname>Rowland</surname><given-names>RG</given-names></name>, <name><surname>Lele</surname><given-names>SM</given-names></name>, <name><surname>Kyprianou</surname><given-names>N</given-names></name>. <article-title>Apoptosis incidence and protein expression of p53, TGF-&#x000df; receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate1 1Accepted for publication 0, 2003</article-title>. <source>Hum Pathol</source>. <year>2004</year>; <volume>35</volume>(<issue>3</issue>): <fpage>290</fpage>&#x02013;<lpage>297</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.humpath.2003.11.001">10.1016/j.humpath.2003.11.001</ext-link></comment>
<?supplied-pmid 15017584?><pub-id pub-id-type="pmid">15017584</pub-id></mixed-citation></ref><ref id="pone.0145322.ref106"><label>106</label><mixed-citation publication-type="journal"><name><surname>Aitchison</surname><given-names>AA</given-names></name>, <name><surname>Veerakumarasivam</surname><given-names>A</given-names></name>, <name><surname>Vias</surname><given-names>M</given-names></name>, <name><surname>Kumar</surname><given-names>R</given-names></name>, <name><surname>Hamdy</surname><given-names>FC</given-names></name>, <name><surname>Neal</surname><given-names>DE</given-names></name>, <etal>et al</etal>
<article-title>Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer</article-title>. <source>Prostate</source>. <year>2008</year>; <volume>68</volume>(<issue>6</issue>): <fpage>661</fpage>&#x02013;<lpage>674</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.20730">10.1002/pros.20730</ext-link></comment>
<?supplied-pmid 18213629?><pub-id pub-id-type="pmid">18213629</pub-id></mixed-citation></ref><ref id="pone.0145322.ref107"><label>107</label><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>B</given-names></name>, <name><surname>Ferguson</surname><given-names>C</given-names></name>, <name><surname>White</surname><given-names>JT</given-names></name>, <name><surname>Wang</surname><given-names>S</given-names></name>, <name><surname>Vessella</surname><given-names>R</given-names></name>, <name><surname>True</surname><given-names>LD</given-names></name>, <etal>et al</etal>
<article-title>Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2</article-title>. <source>Cancer Res</source>. <year>1999</year>; <volume>59</volume>(<issue>17</issue>): <fpage>4180</fpage>&#x02013;<lpage>4184</lpage>. <?supplied-pmid 10485450?><pub-id pub-id-type="pmid">10485450</pub-id></mixed-citation></ref><ref id="pone.0145322.ref108"><label>108</label><mixed-citation publication-type="journal"><name><surname>Vaarala</surname><given-names>MH</given-names></name>, <name><surname>Porvari</surname><given-names>K</given-names></name>, <name><surname>Kyllonen</surname><given-names>A</given-names></name>, <name><surname>Lukkarinen</surname><given-names>O</given-names></name>, <name><surname>Vihko</surname><given-names>P</given-names></name>. <article-title>The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease</article-title>. <source>Int J Cancer</source>. <year>2001</year>; <volume>94</volume>(<issue>5</issue>): <fpage>705</fpage>&#x02013;<lpage>710</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.1526">10.1002/ijc.1526</ext-link></comment>
<?supplied-pmid 11745466?><pub-id pub-id-type="pmid">11745466</pub-id></mixed-citation></ref><ref id="pone.0145322.ref109"><label>109</label><mixed-citation publication-type="journal"><name><surname>Lucas</surname><given-names>JM</given-names></name>, <name><surname>Heinlein</surname><given-names>C</given-names></name>, <name><surname>Kim</surname><given-names>T</given-names></name>, <name><surname>Hernandez</surname><given-names>SA</given-names></name>, <name><surname>Malik</surname><given-names>MS</given-names></name>, <name><surname>True</surname><given-names>LD</given-names></name>, <etal>et al</etal>
<article-title>The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis</article-title>. <source>Cancer Discov</source>. <year>2014</year>; <volume>4</volume>(<issue>11</issue>): <fpage>1310</fpage>&#x02013;<lpage>1325</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/2159-8290.CD-13-1010">10.1158/2159-8290.CD-13-1010</ext-link></comment>
<?supplied-pmid 25122198?><pub-id pub-id-type="pmid">25122198</pub-id></mixed-citation></ref><ref id="pone.0145322.ref110"><label>110</label><mixed-citation publication-type="journal"><name><surname>Dijkstra</surname><given-names>S</given-names></name>, <name><surname>Mulders</surname><given-names>PF</given-names></name>, <name><surname>Schalken</surname><given-names>JA</given-names></name>. <article-title>Clinical use of novel urine and blood based prostate cancer biomarkers: a review</article-title>. <source>Clin Biochem</source>. <year>2014</year>; <volume>47</volume>(<issue>10&#x02013;11</issue>): <fpage>889</fpage>&#x02013;<lpage>896</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.clinbiochem.2013.10.023">10.1016/j.clinbiochem.2013.10.023</ext-link></comment>
<?supplied-pmid 24177197?><pub-id pub-id-type="pmid">24177197</pub-id></mixed-citation></ref><ref id="pone.0145322.ref111"><label>111</label><mixed-citation publication-type="journal"><name><surname>Fleming</surname><given-names>WH</given-names></name>, <name><surname>Hamel</surname><given-names>A</given-names></name>, <name><surname>MacDonald</surname><given-names>R</given-names></name>, <name><surname>Ramsey</surname><given-names>E</given-names></name>, <name><surname>Pettigrew</surname><given-names>NM</given-names></name>, <name><surname>Johnston</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Expression of the c-Myc protooncogene in human prostate hyperplasia</article-title>. <source>Cancer research</source>. <year>1986</year>; <volume>46</volume>(<issue>3</issue>): <fpage>1535</fpage>&#x02013;<lpage>1538</lpage>. <?supplied-pmid 2417706?><pub-id pub-id-type="pmid">2417706</pub-id></mixed-citation></ref><ref id="pone.0145322.ref112"><label>112</label><mixed-citation publication-type="journal"><name><surname>Buttyan</surname><given-names>R</given-names></name>, <name><surname>Sawczuk</surname><given-names>IS</given-names></name>, <name><surname>Benson</surname><given-names>MC</given-names></name>, <name><surname>Siegal</surname><given-names>JD</given-names></name>, <name><surname>Olsson</surname><given-names>CA</given-names></name>. <article-title>Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers</article-title>. <source>Prostate</source>. <year>1987</year>; <volume>11</volume>(<issue>4</issue>): <fpage>327</fpage>&#x02013;<lpage>337</lpage>. <?supplied-pmid 2446300?><pub-id pub-id-type="pmid">2446300</pub-id></mixed-citation></ref><ref id="pone.0145322.ref113"><label>113</label><mixed-citation publication-type="journal"><name><surname>Koh</surname><given-names>CM</given-names></name>, <name><surname>Bieberich</surname><given-names>CJ</given-names></name>, <name><surname>Dang</surname><given-names>CV</given-names></name>, <name><surname>Nelson</surname><given-names>WG</given-names></name>, <name><surname>Yegnasubramanian</surname><given-names>S</given-names></name>, <name><surname>De Marzo</surname><given-names>AM</given-names></name>. <article-title>MYC and Prostate Cancer</article-title>. <source>Genes Cancer</source>. <year>2010</year>; <volume>1</volume>(<issue>6</issue>): <fpage>617</fpage>&#x02013;<lpage>628</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/1947601910379132">10.1177/1947601910379132</ext-link></comment>
<?supplied-pmid 21779461?><pub-id pub-id-type="pmid">21779461</pub-id></mixed-citation></ref><ref id="pone.0145322.ref114"><label>114</label><mixed-citation publication-type="journal"><name><surname>Hawksworth</surname><given-names>D</given-names></name>, <name><surname>Ravindranath</surname><given-names>L</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Furusato</surname><given-names>B</given-names></name>, <name><surname>Sesterhenn</surname><given-names>IA</given-names></name>, <name><surname>McLeod</surname><given-names>DG</given-names></name>, <etal>et al</etal>
<article-title>Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence</article-title>. <source>Prostate Cancer Prostatic Dis</source>. <year>2010</year>; <volume>13</volume>(<issue>4</issue>): <fpage>311</fpage>&#x02013;<lpage>315</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/pcan.2010.31">10.1038/pcan.2010.31</ext-link></comment>
<?supplied-pmid 20820186?><pub-id pub-id-type="pmid">20820186</pub-id></mixed-citation></ref><ref id="pone.0145322.ref115"><label>115</label><mixed-citation publication-type="journal"><name><surname>Gurel</surname><given-names>B</given-names></name>, <name><surname>Iwata</surname><given-names>T</given-names></name>, <name><surname>Koh</surname><given-names>CM</given-names></name>, <name><surname>Jenkins</surname><given-names>RB</given-names></name>, <name><surname>Lan</surname><given-names>F</given-names></name>, <name><surname>Van Dang</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis</article-title>. <source>Mod Pathol</source>. <year>2008</year>; <volume>21</volume>(<issue>9</issue>): <fpage>1156</fpage>&#x02013;<lpage>1167</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/modpathol.2008.111">10.1038/modpathol.2008.111</ext-link></comment>
<?supplied-pmid 18567993?><pub-id pub-id-type="pmid">18567993</pub-id></mixed-citation></ref><ref id="pone.0145322.ref116"><label>116</label><mixed-citation publication-type="journal"><name><surname>Bubendorf</surname><given-names>L</given-names></name>, <name><surname>Kononen</surname><given-names>J</given-names></name>, <name><surname>Koivisto</surname><given-names>P</given-names></name>, <name><surname>Schraml</surname><given-names>P</given-names></name>, <name><surname>Moch</surname><given-names>H</given-names></name>, <name><surname>Gasser</surname><given-names>TC</given-names></name>, <etal>et al</etal>
<article-title>Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays</article-title>. <source>Cancer Res</source>. <year>1999</year>; <volume>59</volume>(<issue>4</issue>): <fpage>803</fpage>&#x02013;<lpage>806</lpage>. <?supplied-pmid 10029066?><pub-id pub-id-type="pmid">10029066</pub-id></mixed-citation></ref><ref id="pone.0145322.ref117"><label>117</label><mixed-citation publication-type="journal"><name><surname>Jenkins</surname><given-names>RB</given-names></name>, <name><surname>Qian</surname><given-names>J</given-names></name>, <name><surname>Lieber</surname><given-names>MM</given-names></name>, <name><surname>Bostwick</surname><given-names>DG</given-names></name>. <article-title>Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization</article-title>. <source>Cancer Res</source>. <year>1997</year>; <volume>57</volume>(<issue>3</issue>): <fpage>524</fpage>&#x02013;<lpage>531</lpage>. <?supplied-pmid 9012485?><pub-id pub-id-type="pmid">9012485</pub-id></mixed-citation></ref><ref id="pone.0145322.ref118"><label>118</label><mixed-citation publication-type="journal"><name><surname>Sato</surname><given-names>H</given-names></name>, <name><surname>Minei</surname><given-names>S</given-names></name>, <name><surname>Hachiya</surname><given-names>T</given-names></name>, <name><surname>Yoshida</surname><given-names>T</given-names></name>, <name><surname>Takimoto</surname><given-names>Y</given-names></name>. <article-title>Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients</article-title>. <source>Int J Urol</source>. <year>2006</year>; <volume>13</volume>(<issue>6</issue>): <fpage>761</fpage>&#x02013;<lpage>766</lpage>. <?supplied-pmid 16834657?><pub-id pub-id-type="pmid">16834657</pub-id></mixed-citation></ref><ref id="pone.0145322.ref119"><label>119</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>YA</given-names></name>, <name><surname>Yu</surname><given-names>J</given-names></name>. <article-title>EZH2, an epigenetic driver of prostate cancer</article-title>. <source>Protein Cell</source>. <year>2013</year>; <volume>4</volume>(<issue>5</issue>): <fpage>331</fpage>&#x02013;<lpage>341</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s13238-013-2093-2">10.1007/s13238-013-2093-2</ext-link></comment>
<?supplied-pmid 23636686?><pub-id pub-id-type="pmid">23636686</pub-id></mixed-citation></ref><ref id="pone.0145322.ref120"><label>120</label><mixed-citation publication-type="journal"><name><surname>Moul</surname><given-names>JW</given-names></name>, <name><surname>Bettencourt</surname><given-names>M</given-names></name>, <name><surname>Sesterhenn</surname><given-names>IA</given-names></name>, <name><surname>Mostofi</surname><given-names>FK</given-names></name>, <name><surname>McLeod</surname><given-names>DG</given-names></name>, <name><surname>Srivastava</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer</article-title>. <source>Surgery</source>. <year>1996</year>; <volume>120</volume>(<issue>2</issue>): <fpage>159</fpage>&#x02013;<lpage>167</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0039-6060(96)80283-2">10.1016/S0039-6060(96)80283-2</ext-link></comment>
<?supplied-pmid 8751578?><pub-id pub-id-type="pmid">8751578</pub-id></mixed-citation></ref><ref id="pone.0145322.ref121"><label>121</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>MI</given-names></name>, <name><surname>Robinson</surname><given-names>MC</given-names></name>, <name><surname>Marsh</surname><given-names>C</given-names></name>, <name><surname>Robson</surname><given-names>CN</given-names></name>, <name><surname>Neal</surname><given-names>DE</given-names></name>, <name><surname>Hamdy</surname><given-names>FC</given-names></name>. <article-title>Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation</article-title>. <source>Prostate</source>. <year>1998</year>; <volume>37</volume>(<issue>4</issue>): <fpage>223</fpage>&#x02013;<lpage>229</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/(SICI)1097-0045(19981201)37:4&#x0003c;223::AID-PROS3&#x0003e;3.0.CO;2-O">10.1002/(SICI)1097-0045(19981201)37:4&#x0003c;223::AID-PROS3&#x0003e;3.0.CO;2-O</ext-link></comment>
<?supplied-pmid 9831218?><pub-id pub-id-type="pmid">9831218</pub-id></mixed-citation></ref><ref id="pone.0145322.ref122"><label>122</label><mixed-citation publication-type="journal"><name><surname>McDonnell</surname><given-names>TJ</given-names></name>, <name><surname>Troncoso</surname><given-names>P</given-names></name>, <name><surname>Brisbay</surname><given-names>SM</given-names></name>, <name><surname>Logothetis</surname><given-names>C</given-names></name>, <name><surname>Chung</surname><given-names>LW</given-names></name>, <name><surname>Hsieh</surname><given-names>JT</given-names></name>, <etal>et al</etal>
<article-title>Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer</article-title>. <source>Cancer Res</source>. <year>1992</year>; <volume>52</volume>(<issue>24</issue>): <fpage>6940</fpage>&#x02013;<lpage>6944</lpage>. <?supplied-pmid 1458483?><pub-id pub-id-type="pmid">1458483</pub-id></mixed-citation></ref><ref id="pone.0145322.ref123"><label>123</label><mixed-citation publication-type="journal"><name><surname>Apakama</surname><given-names>I</given-names></name>, <name><surname>Robinson</surname><given-names>M</given-names></name>, <name><surname>Walter</surname><given-names>N</given-names></name>, <name><surname>Charlton</surname><given-names>R</given-names></name>, <name><surname>Royds</surname><given-names>J</given-names></name>, <name><surname>Fuller</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer</article-title>. <source>Br J Cancer</source>. <year>1996</year>; <volume>74</volume>(<issue>8</issue>): <fpage>1258</fpage>&#x02013;<lpage>1262</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/bjc.1996.526">10.1038/bjc.1996.526</ext-link></comment>
<?supplied-pmid 8883414?><pub-id pub-id-type="pmid">8883414</pub-id></mixed-citation></ref><ref id="pone.0145322.ref124"><label>124</label><mixed-citation publication-type="journal"><name><surname>Colombel</surname><given-names>M</given-names></name>, <name><surname>Symmans</surname><given-names>F</given-names></name>, <name><surname>Gil</surname><given-names>S</given-names></name>, <name><surname>O'Toole</surname><given-names>KM</given-names></name>, <name><surname>Chopin</surname><given-names>D</given-names></name>, <name><surname>Benson</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers</article-title>. <source>Am J Pathol</source>. <year>1993</year>; <volume>143</volume>(<issue>2</issue>): <fpage>390</fpage>&#x02013;<lpage>400</lpage>. <?supplied-pmid 7688182?><pub-id pub-id-type="pmid">7688182</pub-id></mixed-citation></ref><ref id="pone.0145322.ref125"><label>125</label><mixed-citation publication-type="journal"><name><surname>Bubendorf</surname><given-names>L</given-names></name>, <name><surname>Sauter</surname><given-names>G</given-names></name>, <name><surname>Moch</surname><given-names>H</given-names></name>, <name><surname>Jordan</surname><given-names>P</given-names></name>, <name><surname>Blochlinger</surname><given-names>A</given-names></name>, <name><surname>Gasser</surname><given-names>TC</given-names></name>, <etal>et al</etal>
<article-title>Prognostic significance of Bcl-2 in clinically localized prostate cancer</article-title>. <source>Am J Pathol</source>. <year>1996</year>; <volume>148</volume>(<issue>5</issue>): <fpage>1557</fpage>&#x02013;<lpage>1565</lpage>. <?supplied-pmid 8623924?><pub-id pub-id-type="pmid">8623924</pub-id></mixed-citation></ref><ref id="pone.0145322.ref126"><label>126</label><mixed-citation publication-type="journal"><name><surname>Mack</surname><given-names>D</given-names></name>, <name><surname>Hacker</surname><given-names>GW</given-names></name>, <name><surname>Hauser-Kronberger</surname><given-names>G</given-names></name>, <name><surname>Frick</surname><given-names>J</given-names></name>, <name><surname>Dietze</surname><given-names>O</given-names></name>. <article-title>Vasoactive Intestinal Polypeptide (VIP) and Neuropeptide Tyrosine (NPY) in Prostate Carcinoma</article-title>. <source>Eur J Cancer</source>. <year>1997</year>; <volume>33</volume>(<issue>2</issue>): <fpage>317</fpage>&#x02013;<lpage>318</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0959-8049(96)00402-9">10.1016/S0959-8049(96)00402-9</ext-link></comment>
<?supplied-pmid 9135509?><pub-id pub-id-type="pmid">9135509</pub-id></mixed-citation></ref><ref id="pone.0145322.ref127"><label>127</label><mixed-citation publication-type="journal"><name><surname>Ueda</surname><given-names>K</given-names></name>, <name><surname>Tatsuguchi</surname><given-names>A</given-names></name>, <name><surname>Saichi</surname><given-names>N</given-names></name>, <name><surname>Toyama</surname><given-names>A</given-names></name>, <name><surname>Tamura</surname><given-names>K</given-names></name>, <name><surname>Furihata</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide</article-title>. <source>J Proteome Res</source>. <year>2013</year>; <volume>12</volume>(<issue>10</issue>): <fpage>4497</fpage>&#x02013;<lpage>4506</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/pr400547s">10.1021/pr400547s</ext-link></comment>
<?supplied-pmid 23991666?><pub-id pub-id-type="pmid">23991666</pub-id></mixed-citation></ref><ref id="pone.0145322.ref128"><label>128</label><mixed-citation publication-type="other">Liu A, Furusato B, Ravindranath L, Chen Y, Srikantan V, Mcleod DG, et al. Quantitative analysis of a panel of gene expression in prostate cancer&#x02014;with emphasis on NPY expression analysis. 2007; 8(12): 853&#x02013;859.</mixed-citation></ref><ref id="pone.0145322.ref129"><label>129</label><mixed-citation publication-type="journal"><name><surname>Ruscica</surname><given-names>M</given-names></name>, <name><surname>Dozio</surname><given-names>E</given-names></name>, <name><surname>Boghossian</surname><given-names>S</given-names></name>, <name><surname>Bovo</surname><given-names>G</given-names></name>, <name><surname>Martos</surname><given-names>Riano V</given-names></name>, <name><surname>Motta</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells</article-title>. <source>Endocrinology</source>. <year>2006</year>; <volume>147</volume>(<issue>3</issue>): <fpage>1466</fpage>&#x02013;<lpage>1473</lpage>. <?supplied-pmid 16339211?><pub-id pub-id-type="pmid">16339211</pub-id></mixed-citation></ref><ref id="pone.0145322.ref130"><label>130</label><mixed-citation publication-type="journal"><name><surname>Vainio</surname><given-names>P</given-names></name>, <name><surname>Gupta</surname><given-names>S</given-names></name>, <name><surname>Ketola</surname><given-names>K</given-names></name>, <name><surname>Mirtti</surname><given-names>T</given-names></name>, <name><surname>Mpindi</surname><given-names>JP</given-names></name>, <name><surname>Kohonen</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer</article-title>. <source>Am J Pathol</source>. <year>2011</year>; <volume>178</volume>(<issue>2</issue>): <fpage>525</fpage>&#x02013;<lpage>536</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ajpath.2010.10.002">10.1016/j.ajpath.2010.10.002</ext-link></comment>
<?supplied-pmid 21281786?><pub-id pub-id-type="pmid">21281786</pub-id></mixed-citation></ref><ref id="pone.0145322.ref131"><label>131</label><mixed-citation publication-type="journal"><name><surname>Vainio</surname><given-names>P</given-names></name>, <name><surname>Lehtinen</surname><given-names>L</given-names></name>, <name><surname>Mirtti</surname><given-names>T</given-names></name>, <name><surname>Hilvo</surname><given-names>M</given-names></name>, <name><surname>Seppanen-Laakso</surname><given-names>T</given-names></name>, <name><surname>Virtanen</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins</article-title>. <source>Oncotarget</source>. <year>2011</year>; <volume>2</volume>(<issue>12</issue>): <fpage>1176</fpage>&#x02013;<lpage>1190</lpage>. <?supplied-pmid 22202492?><pub-id pub-id-type="pmid">22202492</pub-id></mixed-citation></ref><ref id="pone.0145322.ref132"><label>132</label><mixed-citation publication-type="journal"><name><surname>Zhong</surname><given-names>W</given-names></name>, <name><surname>Peng</surname><given-names>J</given-names></name>, <name><surname>He</surname><given-names>H</given-names></name>, <name><surname>Wu</surname><given-names>D</given-names></name>, <name><surname>Han</surname><given-names>Z</given-names></name>, <name><surname>Bi</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia</article-title>. <source>Clin Invest Med</source>. <year>2008</year>; <volume>31</volume>(<issue>1</issue>): <fpage>E8</fpage>&#x02013;<lpage>E15</lpage>. <?supplied-pmid 18312749?><pub-id pub-id-type="pmid">18312749</pub-id></mixed-citation></ref><ref id="pone.0145322.ref133"><label>133</label><mixed-citation publication-type="journal"><name><surname>Thompson</surname><given-names>SJ</given-names></name>, <name><surname>Mellon</surname><given-names>K</given-names></name>, <name><surname>Charlton</surname><given-names>RG</given-names></name>, <name><surname>Marsh</surname><given-names>C</given-names></name>, <name><surname>Robinson</surname><given-names>M</given-names></name>, <name><surname>Neal</surname><given-names>DE</given-names></name>. <article-title>P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia</article-title>. <source>Br J Urol</source>. <year>1992</year>; <volume>69</volume>(<issue>6</issue>): <fpage>609</fpage>&#x02013;<lpage>613</lpage>. <?supplied-pmid 1379102?><pub-id pub-id-type="pmid">1379102</pub-id></mixed-citation></ref><ref id="pone.0145322.ref134"><label>134</label><mixed-citation publication-type="journal"><name><surname>Mucci</surname><given-names>NR</given-names></name>, <name><surname>Rubin</surname><given-names>MA</given-names></name>, <name><surname>Strawderman</surname><given-names>MS</given-names></name>, <name><surname>Montie</surname><given-names>JE</given-names></name>, <name><surname>Smith</surname><given-names>DC</given-names></name>, <name><surname>Pienta</surname><given-names>KJ</given-names></name>. <article-title>Expression of nuclear antigen Ki-67 in prostate cancer needle biopsy and radical prostatectomy specimens</article-title>. <source>J Natl Cancer Inst</source>. <year>2000</year>; <volume>92</volume>(<issue>23</issue>): <fpage>1941</fpage>&#x02013;<lpage>1942</lpage>. <?supplied-pmid 11106686?><pub-id pub-id-type="pmid">11106686</pub-id></mixed-citation></ref><ref id="pone.0145322.ref135"><label>135</label><mixed-citation publication-type="journal"><name><surname>Revelos</surname><given-names>K</given-names></name>, <name><surname>Petraki</surname><given-names>C</given-names></name>, <name><surname>Gregorakis</surname><given-names>A</given-names></name>, <name><surname>Scorilas</surname><given-names>A</given-names></name>, <name><surname>Papanastasiou</surname><given-names>P</given-names></name>, <name><surname>Tenta</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer</article-title>. <source>In Vivo</source>. <year>2005</year>; <volume>19</volume>(<issue>5</issue>): <fpage>911</fpage>&#x02013;<lpage>920</lpage>. <?supplied-pmid 16097446?><pub-id pub-id-type="pmid">16097446</pub-id></mixed-citation></ref><ref id="pone.0145322.ref136"><label>136</label><mixed-citation publication-type="journal"><name><surname>Grover</surname><given-names>SK</given-names></name>, <name><surname>Agarwal</surname><given-names>S</given-names></name>, <name><surname>Gupta</surname><given-names>S</given-names></name>, <name><surname>Wadhwa</surname><given-names>N</given-names></name>, <name><surname>Sharma</surname><given-names>N</given-names></name>. <source>Expression of Estrogen Receptor &#x000df; and Ki 67 in Benign &#x00026; Malignant Human Prostate Lesions by Immunohistochemistry</source>. <year>2015</year>; <volume>21</volume>(<issue>3</issue>): <fpage>651</fpage>&#x02013;<lpage>657</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s12253-014-9870-y">10.1007/s12253-014-9870-y</ext-link></comment></mixed-citation></ref><ref id="pone.0145322.ref137"><label>137</label><mixed-citation publication-type="other">Reis S, Timoszczuk L, Pontes-Junior J, Viana N, Silva I, Dip N, et al. The role of micro RNAs let7c, 100 and 218 expression and their target RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67 in prostate cancer. 2013; 68(5): 652&#x02013;657.</mixed-citation></ref><ref id="pone.0145322.ref138"><label>138</label><mixed-citation publication-type="journal"><name><surname>Tamboli</surname><given-names>P</given-names></name>, <name><surname>Amin</surname><given-names>MB</given-names></name>, <name><surname>Schultz</surname><given-names>DS</given-names></name>, <name><surname>Linden</surname><given-names>MD</given-names></name>, <name><surname>Kubus</surname><given-names>J</given-names></name>. <article-title>Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma</article-title>. <source>Mod Pathol</source>. <year>1996</year>; <volume>9</volume>(<issue>10</issue>): <fpage>1015</fpage>&#x02013;<lpage>1019</lpage>. <?supplied-pmid 8902840?><pub-id pub-id-type="pmid">8902840</pub-id></mixed-citation></ref><ref id="pone.0145322.ref139"><label>139</label><mixed-citation publication-type="journal"><name><surname>Van der Kwast</surname><given-names>TH</given-names></name>. <article-title>Prognostic prostate tissue biomarkers of potential clinical use</article-title>. <source>Virchows Arch</source>. <year>2014</year>; <volume>464</volume>(<issue>3</issue>): <fpage>293</fpage>&#x02013;<lpage>300</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00428-014-1540-7">10.1007/s00428-014-1540-7</ext-link></comment>
<?supplied-pmid 24487790?><pub-id pub-id-type="pmid">24487790</pub-id></mixed-citation></ref><ref id="pone.0145322.ref140"><label>140</label><mixed-citation publication-type="journal"><name><surname>Remo</surname><given-names>A</given-names></name>, <name><surname>Pancione</surname><given-names>M</given-names></name>, <name><surname>Zanella</surname><given-names>C</given-names></name>, <name><surname>Manfrin</surname><given-names>E</given-names></name>. <article-title>p16 Expression in Prostate Cancer and Nonmalignant Lesions: Novel Findings and Review of the Literature</article-title>. <source>Appl Immunohistochem Mol Morphol</source>. <year>2015</year>; <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/PAI.0000000000000171">10.1097/PAI.0000000000000171</ext-link></comment></mixed-citation></ref><ref id="pone.0145322.ref141"><label>141</label><mixed-citation publication-type="journal"><name><surname>Royuela</surname><given-names>M</given-names></name>, <name><surname>De Miguel</surname><given-names>MP</given-names></name>, <name><surname>Bethencourt</surname><given-names>FR</given-names></name>, <name><surname>Fraile</surname><given-names>B</given-names></name>, <name><surname>Arenas</surname><given-names>MI</given-names></name>, <name><surname>Paniagua</surname><given-names>R</given-names></name>. <article-title>IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis</article-title>. <source>Growth Factors</source>. <year>2000</year>; <volume>18</volume>(<issue>2</issue>): <fpage>135</fpage>&#x02013;<lpage>146</lpage>. <?supplied-pmid 11019784?><pub-id pub-id-type="pmid">11019784</pub-id></mixed-citation></ref><ref id="pone.0145322.ref142"><label>142</label><mixed-citation publication-type="journal"><name><surname>Royuela</surname><given-names>M</given-names></name>, <name><surname>De Miguel</surname><given-names>MP</given-names></name>, <name><surname>Bethencourt</surname><given-names>FR</given-names></name>, <name><surname>Sanchez-Chapado</surname><given-names>M</given-names></name>, <name><surname>Fraile</surname><given-names>B</given-names></name>, <name><surname>Paniagua</surname><given-names>R</given-names></name>. <article-title>Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma</article-title>. <source>Growth Factors</source>. <year>1998</year>; <volume>16</volume>(<issue>2</issue>): <fpage>101</fpage>&#x02013;<lpage>110</lpage>. <?supplied-pmid 9932228?><pub-id pub-id-type="pmid">9932228</pub-id></mixed-citation></ref><ref id="pone.0145322.ref143"><label>143</label><mixed-citation publication-type="journal"><name><surname>Cardillo</surname><given-names>MR</given-names></name>, <name><surname>Petrangeli</surname><given-names>E</given-names></name>, <name><surname>Perracchio</surname><given-names>L</given-names></name>, <name><surname>Salvatori</surname><given-names>L</given-names></name>, <name><surname>Ravenna</surname><given-names>L</given-names></name>, <name><surname>Di Silverio</surname><given-names>F</given-names></name>. <article-title>Transforming growth factor-beta expression in prostate neoplasia</article-title>. <source>Anal Quant Cytol Histol</source>. <year>2000</year>; <volume>22</volume>(<issue>1</issue>): <fpage>1</fpage>&#x02013;<lpage>10</lpage>. <?supplied-pmid 10696454?><pub-id pub-id-type="pmid">10696454</pub-id></mixed-citation></ref><ref id="pone.0145322.ref144"><label>144</label><mixed-citation publication-type="journal"><name><surname>Shariat</surname><given-names>SF</given-names></name>, <name><surname>Menesses-Diaz</surname><given-names>A</given-names></name>, <name><surname>Kim</surname><given-names>IY</given-names></name>, <name><surname>Muramoto</surname><given-names>M</given-names></name>, <name><surname>Wheeler</surname><given-names>TM</given-names></name>, <name><surname>Slawin</surname><given-names>KM</given-names></name>. <article-title>Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy</article-title>. <source>Urology</source>. <year>2004</year>; <volume>63</volume>(<issue>6</issue>): <fpage>1191</fpage>&#x02013;<lpage>1197</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.urology.2003.12.015">10.1016/j.urology.2003.12.015</ext-link></comment>
<?supplied-pmid 15183988?><pub-id pub-id-type="pmid">15183988</pub-id></mixed-citation></ref><ref id="pone.0145322.ref145"><label>145</label><mixed-citation publication-type="journal"><name><surname>Perry</surname><given-names>KT</given-names></name>, <name><surname>Anthony</surname><given-names>CT</given-names></name>, <name><surname>Steiner</surname><given-names>MS</given-names></name>. <article-title>Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate</article-title>. <source>Prostate</source>. <year>1997</year>; <volume>33</volume>(<issue>2</issue>): <fpage>133</fpage>&#x02013;<lpage>140</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/(SICI)1097-0045(19971001)33:2&#x0003c;133::AID-PROS7&#x0003e;3.0.CO;2-L">10.1002/(SICI)1097-0045(19971001)33:2&#x0003c;133::AID-PROS7&#x0003e;3.0.CO;2-L</ext-link></comment>
<?supplied-pmid 9316654?><pub-id pub-id-type="pmid">9316654</pub-id></mixed-citation></ref><ref id="pone.0145322.ref146"><label>146</label><mixed-citation publication-type="journal"><name><surname>Gerdes</surname><given-names>MJ</given-names></name>, <name><surname>Larsen</surname><given-names>M</given-names></name>, <name><surname>McBride</surname><given-names>L</given-names></name>, <name><surname>Dang</surname><given-names>TD</given-names></name>, <name><surname>Lu</surname><given-names>B</given-names></name>, <name><surname>Rowley</surname><given-names>DR</given-names></name>. <article-title>Localization of transforming growth factor-beta1 and type II receptor in developing normal human prostate and carcinoma tissues</article-title>. <source>J Histochem Cytochem</source>. <year>1998</year>; <volume>46</volume>(<issue>3</issue>): <fpage>379</fpage>&#x02013;<lpage>388</lpage>. <?supplied-pmid 9487120?><pub-id pub-id-type="pmid">9487120</pub-id></mixed-citation></ref><ref id="pone.0145322.ref147"><label>147</label><mixed-citation publication-type="journal"><name><surname>Truong</surname><given-names>LD</given-names></name>, <name><surname>Kadmon</surname><given-names>D</given-names></name>, <name><surname>McCune</surname><given-names>BK</given-names></name>, <name><surname>Flanders</surname><given-names>KC</given-names></name>, <name><surname>Scardino</surname><given-names>PT</given-names></name>, <name><surname>Thompson</surname><given-names>TC</given-names></name>. <article-title>Association of transforming growth factor-&#x000df;1 with prostate cancer: An immunohistochemical study</article-title>. <source>Hum Pathol</source>. <year>1993</year>; <volume>24</volume>(<issue>1</issue>): <fpage>4</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0046-8177(93)90055-L">10.1016/0046-8177(93)90055-L</ext-link></comment>
<?supplied-pmid 7678092?><pub-id pub-id-type="pmid">7678092</pub-id></mixed-citation></ref><ref id="pone.0145322.ref148"><label>148</label><mixed-citation publication-type="journal"><name><surname>Djonov</surname><given-names>V</given-names></name>, <name><surname>Ball</surname><given-names>RK</given-names></name>, <name><surname>Graf</surname><given-names>S</given-names></name>, <name><surname>Mottaz</surname><given-names>AE</given-names></name>, <name><surname>Arnold</surname><given-names>AM</given-names></name>, <name><surname>Flanders</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Transforming growth factor-beta 3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma</article-title>. <source>Prostate</source>. <year>1997</year>; <volume>31</volume>(<issue>2</issue>): <fpage>103</fpage>&#x02013;<lpage>109</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/(SICI)1097-0045(19970501)31:2&#x0003c;103::AID-PROS5&#x0003e;3.0.CO;2-O">10.1002/(SICI)1097-0045(19970501)31:2&#x0003c;103::AID-PROS5&#x0003e;3.0.CO;2-O</ext-link></comment>
<?supplied-pmid 9140123?><pub-id pub-id-type="pmid">9140123</pub-id></mixed-citation></ref><ref id="pone.0145322.ref149"><label>149</label><mixed-citation publication-type="journal"><name><surname>Twillie</surname><given-names>DA</given-names></name>, <name><surname>Eisenberger</surname><given-names>MA</given-names></name>, <name><surname>Carducci</surname><given-names>MA</given-names></name>, <name><surname>Hseih</surname><given-names>W</given-names></name>, <name><surname>Kim</surname><given-names>WY</given-names></name>, <name><surname>Simons</surname><given-names>JW</given-names></name>. <article-title>Interleukin-6: A candidate mediator of human prostate cancer morbidity</article-title>. <source>Urology</source>. <year>1995</year>; <volume>45</volume>(<issue>3</issue>): <fpage>542</fpage>&#x02013;<lpage>549</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0090-4295(99)80034-X">10.1016/S0090-4295(99)80034-X</ext-link></comment>
<?supplied-pmid 7879350?><pub-id pub-id-type="pmid">7879350</pub-id></mixed-citation></ref><ref id="pone.0145322.ref150"><label>150</label><mixed-citation publication-type="journal"><name><surname>Hobisch</surname><given-names>A</given-names></name>, <name><surname>Rogatsch</surname><given-names>H</given-names></name>, <name><surname>Hittmair</surname><given-names>A</given-names></name>, <name><surname>Fuchs</surname><given-names>D</given-names></name>, <name><surname>Bartsch</surname><given-names>G</given-names><suffix>Jr</suffix></name>, <name><surname>Klocker</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue</article-title>. <source>J Pathol</source>. <year>2000</year>; <volume>191</volume>(<issue>3</issue>): <fpage>239</fpage>&#x02013;<lpage>244</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/1096-9896(2000)9999:9999&#x0003c;::AID-PATH633&#x0003e;3.0.CO;2-X">10.1002/1096-9896(2000)9999:9999&#x0003c;::AID-PATH633&#x0003e;3.0.CO;2-X</ext-link></comment>
<?supplied-pmid 10878544?><pub-id pub-id-type="pmid">10878544</pub-id></mixed-citation></ref><ref id="pone.0145322.ref151"><label>151</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>JI</given-names></name>, <name><surname>Lee</surname><given-names>MG</given-names></name>, <name><surname>Cho</surname><given-names>K</given-names></name>, <name><surname>Park</surname><given-names>BJ</given-names></name>, <name><surname>Chae</surname><given-names>KS</given-names></name>, <name><surname>Byun</surname><given-names>DS</given-names></name>, <etal>et al</etal>
<article-title>Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways</article-title>. <source>Oncogene</source>. <year>2003</year>; <volume>22</volume>(<issue>28</issue>): <fpage>4314</fpage>&#x02013;<lpage>4332</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.onc.1206478">10.1038/sj.onc.1206478</ext-link></comment>
<?supplied-pmid 12853969?><pub-id pub-id-type="pmid">12853969</pub-id></mixed-citation></ref><ref id="pone.0145322.ref152"><label>152</label><mixed-citation publication-type="journal"><name><surname>Bouraoui</surname><given-names>Y</given-names></name>, <name><surname>Ricote</surname><given-names>M</given-names></name>, <name><surname>Garcia-Tunon</surname><given-names>I</given-names></name>, <name><surname>Rodriguez-Berriguete</surname><given-names>G</given-names></name>, <name><surname>Touffehi</surname><given-names>M</given-names></name>, <name><surname>Rais</surname><given-names>NB</given-names></name>, <etal>et al</etal>
<article-title>Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer</article-title>. <source>Cancer Detect Prev</source>. <year>2008</year>; <volume>32</volume>(<issue>1</issue>): <fpage>23</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cdp.2008.02.007">10.1016/j.cdp.2008.02.007</ext-link></comment>
<?supplied-pmid 18400418?><pub-id pub-id-type="pmid">18400418</pub-id></mixed-citation></ref><ref id="pone.0145322.ref153"><label>153</label><mixed-citation publication-type="journal"><name><surname>Mechergui</surname><given-names>YB</given-names></name>, <name><surname>Ben Jemaa</surname><given-names>A</given-names></name>, <name><surname>Mezigh</surname><given-names>C</given-names></name>, <name><surname>Fraile</surname><given-names>B</given-names></name>, <name><surname>Ben Rais</surname><given-names>N</given-names></name>, <name><surname>Paniagua</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>The profile of prostate epithelial cytokines and its impact on sera prostate specific antigen levels</article-title>. <source>Inflammation</source>. <year>2009</year>; <volume>32</volume>(<issue>3</issue>): <fpage>202</fpage>&#x02013;<lpage>210</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10753-009-9121-7">10.1007/s10753-009-9121-7</ext-link></comment>
<?supplied-pmid 19399601?><pub-id pub-id-type="pmid">19399601</pub-id></mixed-citation></ref><ref id="pone.0145322.ref154"><label>154</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>SO</given-names></name>, <name><surname>Lou</surname><given-names>W</given-names></name>, <name><surname>Hou</surname><given-names>M</given-names></name>, <name><surname>de Miguel</surname><given-names>F</given-names></name>, <name><surname>Gerber</surname><given-names>L</given-names></name>, <name><surname>Gao</surname><given-names>AC</given-names></name>. <article-title>Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells</article-title>. <source>Clin Cancer Res</source>. <year>2003</year>; <volume>9</volume>(<issue>1</issue>): <fpage>370</fpage>&#x02013;<lpage>376</lpage>. <?supplied-pmid 12538490?><pub-id pub-id-type="pmid">12538490</pub-id></mixed-citation></ref><ref id="pone.0145322.ref155"><label>155</label><mixed-citation publication-type="journal"><name><surname>D E Drachenberg</surname><given-names>A.-A.A.</given-names></name>
<article-title>Elgamal,R Rowbotham,M Peterson,G P Murphy. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer</article-title>. <source>The Prostate</source>. <year>1999</year>; <volume>41</volume>(<issue>2</issue>): <fpage>127</fpage>&#x02013;<lpage>133</lpage>.<pub-id pub-id-type="pmid">10477909</pub-id></mixed-citation></ref><ref id="pone.0145322.ref156"><label>156</label><mixed-citation publication-type="journal"><name><surname>Akimoto</surname><given-names>S</given-names></name>, <name><surname>Okumura</surname><given-names>A</given-names></name>, <name><surname>Fuse</surname><given-names>H</given-names></name>. <article-title>Relationship between serum levels of interleukin-6, tumor necrosis factor-a and bone turnover markers in prostate cancer patients</article-title>. <source>Endocrine journal</source>. <year>1998</year>; <volume>45</volume>(<issue>2</issue>): <fpage>183</fpage>&#x02013;<lpage>189</lpage>. <?supplied-pmid 9700471?><pub-id pub-id-type="pmid">9700471</pub-id></mixed-citation></ref><ref id="pone.0145322.ref157"><label>157</label><mixed-citation publication-type="journal"><name><surname>Adler</surname><given-names>HL</given-names></name>, <name><surname>Mccurdy</surname><given-names>MA</given-names></name>, <name><surname>Kattan</surname><given-names>MW</given-names></name>, <name><surname>Timme</surname><given-names>TL</given-names></name>, <name><surname>Scardino</surname><given-names>PT</given-names></name>, <name><surname>Thompson</surname><given-names>TC</given-names></name>. <article-title>Elevated Levels of Circulating Interleukin-6 and Transforming Growth Factor-Beta 1 in Patients with Metastatic Prostatic Carcinoma</article-title>. <source>J Urol</source>. <year>1999</year>; <volume>161</volume>(<issue>1</issue>): <fpage>182</fpage>&#x02013;<lpage>187</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0022-5347(01)62092-5">10.1016/S0022-5347(01)62092-5</ext-link></comment>
<?supplied-pmid 10037394?><pub-id pub-id-type="pmid">10037394</pub-id></mixed-citation></ref><ref id="pone.0145322.ref158"><label>158</label><mixed-citation publication-type="journal"><name><surname>Wise</surname><given-names>GJ</given-names></name>, <name><surname>Marella</surname><given-names>VK</given-names></name>, <name><surname>Talluri</surname><given-names>G</given-names></name>, <name><surname>Shirazian</surname><given-names>D</given-names></name>. <article-title>Cytokine variations in patients with hormone treated prostate cancer</article-title>. <source>J Urol</source>. <year>2000</year>; <volume>164</volume>(<issue>3 Pt 1</issue>): <fpage>722</fpage>&#x02013;<lpage>725</lpage>. <?supplied-pmid 10953133?><pub-id pub-id-type="pmid">10953133</pub-id></mixed-citation></ref><ref id="pone.0145322.ref159"><label>159</label><mixed-citation publication-type="journal"><name><surname>Shariat</surname><given-names>SF</given-names></name>, <name><surname>Andrews</surname><given-names>B</given-names></name>, <name><surname>Kattan</surname><given-names>MW</given-names></name>, <name><surname>Kim</surname><given-names>J</given-names></name>, <name><surname>Wheeler</surname><given-names>TM</given-names></name>, <name><surname>Slawin</surname><given-names>KM</given-names></name>. <article-title>Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis</article-title>. <source>Urology</source>. <year>2001</year>; <volume>58</volume>(<issue>6</issue>): <fpage>1008</fpage>&#x02013;<lpage>1015</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0090-4295(01)01405-4">10.1016/S0090-4295(01)01405-4</ext-link></comment>
<?supplied-pmid 11744478?><pub-id pub-id-type="pmid">11744478</pub-id></mixed-citation></ref><ref id="pone.0145322.ref160"><label>160</label><mixed-citation publication-type="journal"><name><surname>Michalaki</surname><given-names>V</given-names></name>, <name><surname>Syrigos</surname><given-names>K</given-names></name>, <name><surname>Charles</surname><given-names>P</given-names></name>, <name><surname>Waxman</surname><given-names>J</given-names></name>. <article-title>Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer</article-title>. <source>Br J Cancer</source>. <year>2004</year>; <volume>90</volume>(<issue>12</issue>): <fpage>2312</fpage>&#x02013;<lpage>2316</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/sj.bjc.6601814">10.1038/sj.bjc.6601814</ext-link></comment>
<?supplied-pmid 15150588?><pub-id pub-id-type="pmid">15150588</pub-id></mixed-citation></ref><ref id="pone.0145322.ref161"><label>161</label><mixed-citation publication-type="journal"><name><surname>George</surname><given-names>DJ</given-names></name>, <name><surname>Halabi</surname><given-names>S</given-names></name>, <name><surname>Shepard</surname><given-names>TF</given-names></name>, <name><surname>Sanford</surname><given-names>B</given-names></name>, <name><surname>Vogelzang</surname><given-names>NJ</given-names></name>, <name><surname>Small</surname><given-names>EJ</given-names></name>, <etal>et al</etal>
<article-title>The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480</article-title>. <source>Clin Cancer Res</source>. <year>2005</year>; <volume>11</volume>(<issue>5</issue>): <fpage>1815</fpage>&#x02013;<lpage>1820</lpage>. <?supplied-pmid 15756004?><pub-id pub-id-type="pmid">15756004</pub-id></mixed-citation></ref><ref id="pone.0145322.ref162"><label>162</label><mixed-citation publication-type="journal"><name><surname>Nakashima</surname><given-names>J</given-names></name>, <name><surname>Tachibana</surname><given-names>M</given-names></name>, <name><surname>Horiguchi</surname><given-names>Y</given-names></name>, <name><surname>Oya</surname><given-names>M</given-names></name>, <name><surname>Ohigashi</surname><given-names>T</given-names></name>, <name><surname>Asakura</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Serum interleukin 6 as a prognostic factor in patients with prostate cancer</article-title>. <source>Clin Cancer Res</source>. <year>2000</year>; <volume>6</volume>(<issue>7</issue>): <fpage>2702</fpage>&#x02013;<lpage>2706</lpage>. <?supplied-pmid 10914713?><pub-id pub-id-type="pmid">10914713</pub-id></mixed-citation></ref><ref id="pone.0145322.ref163"><label>163</label><mixed-citation publication-type="journal"><name><surname>Ricote</surname><given-names>M</given-names></name>, <name><surname>Garcia-Tunon</surname><given-names>I</given-names></name>, <name><surname>Bethencourt</surname><given-names>FR</given-names></name>, <name><surname>Fraile</surname><given-names>B</given-names></name>, <name><surname>Paniagua</surname><given-names>R</given-names></name>, <name><surname>Royuela</surname><given-names>M</given-names></name>. <article-title>Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma</article-title>. <source>Cancer</source>. <year>2004</year>; <volume>100</volume>(<issue>7</issue>): <fpage>1388</fpage>&#x02013;<lpage>1396</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/cncr.20142">10.1002/cncr.20142</ext-link></comment>
<?supplied-pmid 15042672?><pub-id pub-id-type="pmid">15042672</pub-id></mixed-citation></ref><ref id="pone.0145322.ref164"><label>164</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Q</given-names></name>, <name><surname>Russell</surname><given-names>MR</given-names></name>, <name><surname>Shahriari</surname><given-names>K</given-names></name>, <name><surname>Jernigan</surname><given-names>DL</given-names></name>, <name><surname>Lioni</surname><given-names>MI</given-names></name>, <name><surname>Garcia</surname><given-names>FU</given-names></name>, <etal>et al</etal>
<article-title>Interleukin-1 Promotes Skeletal Colonization and Progression of Metastatic Prostate Cancer Cells with Neuroendocrine Features</article-title>. <source>Cancer Res</source>. <year>2013</year>; <volume>73</volume>(<issue>11</issue>): <fpage>3297</fpage>&#x02013;<lpage>3305</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-12-3970">10.1158/0008-5472.CAN-12-3970</ext-link></comment>
<?supplied-pmid 23536554?><pub-id pub-id-type="pmid">23536554</pub-id></mixed-citation></ref><ref id="pone.0145322.ref165"><label>165</label><mixed-citation publication-type="journal"><name><surname>Aaltomaa</surname><given-names>S</given-names></name>, <name><surname>Lipponen</surname><given-names>P</given-names></name>, <name><surname>Eskelinen</surname><given-names>M</given-names></name>, <name><surname>Ala-Opas</surname><given-names>M</given-names></name>, <name><surname>Kosma</surname><given-names>VM</given-names></name>. <article-title>Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer</article-title>. <source>Prostate</source>. <year>1999</year>; <volume>39</volume>(<issue>1</issue>): <fpage>8</fpage>&#x02013;<lpage>15</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/(SICI)1097-0045(19990401)39:1&#x0003c;8::AID-PROS2&#x0003e;3.0.CO;2-N">10.1002/(SICI)1097-0045(19990401)39:1&#x0003c;8::AID-PROS2&#x0003e;3.0.CO;2-N</ext-link></comment>
<?supplied-pmid 10221260?><pub-id pub-id-type="pmid">10221260</pub-id></mixed-citation></ref><ref id="pone.0145322.ref166"><label>166</label><mixed-citation publication-type="journal"><name><surname>Omar</surname><given-names>EA</given-names></name>, <name><surname>Behlouli</surname><given-names>H</given-names></name>, <name><surname>Chevalier</surname><given-names>S</given-names></name>, <name><surname>Aprikian</surname><given-names>AG</given-names></name>. <article-title>Relationship of p21(WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation</article-title>. <source>Prostate</source>. <year>2001</year>; <volume>49</volume>(<issue>3</issue>): <fpage>191</fpage>&#x02013;<lpage>199</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.1134">10.1002/pros.1134</ext-link></comment>
<?supplied-pmid 11746264?><pub-id pub-id-type="pmid">11746264</pub-id></mixed-citation></ref><ref id="pone.0145322.ref167"><label>167</label><mixed-citation publication-type="journal"><name><surname>Rigaud</surname><given-names>J</given-names></name>, <name><surname>Tiguert</surname><given-names>R</given-names></name>, <name><surname>Decobert</surname><given-names>M</given-names></name>, <name><surname>Hovington</surname><given-names>H</given-names></name>, <name><surname>Latulippe</surname><given-names>E</given-names></name>, <name><surname>Laverdiere</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy</article-title>. <source>Prostate</source>. <year>2004</year>; <volume>58</volume>(<issue>3</issue>): <fpage>269</fpage>&#x02013;<lpage>276</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.10329">10.1002/pros.10329</ext-link></comment>
<?supplied-pmid 14743466?><pub-id pub-id-type="pmid">14743466</pub-id></mixed-citation></ref><ref id="pone.0145322.ref168"><label>168</label><mixed-citation publication-type="journal"><name><surname>Gotoh</surname><given-names>A</given-names></name>, <name><surname>Kao</surname><given-names>C</given-names></name>, <name><surname>Ko</surname><given-names>S</given-names></name>, <name><surname>Hamada</surname><given-names>K</given-names></name>, <name><surname>Liu</surname><given-names>T</given-names></name>, <name><surname>Chung</surname><given-names>LWK</given-names></name>. <article-title>Cytotoxic Effects of Recombinant Adenovirus p53 and Cell Cycle Regulator Genes (p21 sup WAF1/CIP1 and p16 sup CDKN4) in Human Prostate Cancers</article-title>. <source>J Urol</source>. <year>1997</year>; <volume>158</volume>(<issue>2</issue>): <fpage>636</fpage>&#x02013;<lpage>641</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0022-5347(01)64574-9">10.1016/S0022-5347(01)64574-9</ext-link></comment>
<?supplied-pmid 9224383?><pub-id pub-id-type="pmid">9224383</pub-id></mixed-citation></ref><ref id="pone.0145322.ref169"><label>169</label><mixed-citation publication-type="journal"><name><surname>Green</surname><given-names>MM</given-names></name>, <name><surname>Hiley</surname><given-names>CT</given-names></name>, <name><surname>Shanks</surname><given-names>JH</given-names></name>, <name><surname>Bottomley</surname><given-names>IC</given-names></name>, <name><surname>West</surname><given-names>CM</given-names></name>, <name><surname>Cowan</surname><given-names>RA</given-names></name>, <etal>et al</etal>
<article-title>Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2007</year>; <volume>67</volume>(<issue>1</issue>): <fpage>84</fpage>&#x02013;<lpage>90</lpage>. <?supplied-pmid 17189065?><pub-id pub-id-type="pmid">17189065</pub-id></mixed-citation></ref><ref id="pone.0145322.ref170"><label>170</label><mixed-citation publication-type="journal"><name><surname>Mori</surname><given-names>R</given-names></name>, <name><surname>Dorff</surname><given-names>TB</given-names></name>, <name><surname>Xiong</surname><given-names>S</given-names></name>, <name><surname>Tarabolous</surname><given-names>CJ</given-names></name>, <name><surname>Ye</surname><given-names>W</given-names></name>, <name><surname>Groshen</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes</article-title>. <source>Prostate</source>. <year>2010</year>; <volume>70</volume>(<issue>15</issue>): <fpage>1692</fpage>&#x02013;<lpage>1700</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/pros.21204">10.1002/pros.21204</ext-link></comment>
<?supplied-pmid 20564320?><pub-id pub-id-type="pmid">20564320</pub-id></mixed-citation></ref><ref id="pone.0145322.ref171"><label>171</label><mixed-citation publication-type="journal"><name><surname>Anees</surname><given-names>M</given-names></name>, <name><surname>Horak</surname><given-names>P</given-names></name>, <name><surname>El-Gazzar</surname><given-names>A</given-names></name>, <name><surname>Susani</surname><given-names>M</given-names></name>, <name><surname>Heinze</surname><given-names>G</given-names></name>, <name><surname>Perco</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression</article-title>. <source>Cancer</source>. <year>2011</year>; <volume>117</volume>(<issue>6</issue>): <fpage>1172</fpage>&#x02013;<lpage>1182</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/cncr.25504">10.1002/cncr.25504</ext-link></comment>
<?supplied-pmid 21381010?><pub-id pub-id-type="pmid">21381010</pub-id></mixed-citation></ref><ref id="pone.0145322.ref172"><label>172</label><mixed-citation publication-type="journal"><name><surname>Sanlioglu</surname><given-names>AD</given-names></name>, <name><surname>Koksal</surname><given-names>IT</given-names></name>, <name><surname>Ciftcioglu</surname><given-names>A</given-names></name>, <name><surname>Baykara</surname><given-names>M</given-names></name>, <name><surname>Luleci</surname><given-names>G</given-names></name>, <name><surname>Sanlioglu</surname><given-names>S</given-names></name>. <article-title>Differential Expression of TRAIL and its Receptors in Benign and Malignant Prostate Tissues</article-title>. <source>J Urol</source>. <year>2007</year>; <volume>177</volume>(<issue>1</issue>): <fpage>359</fpage>&#x02013;<lpage>364</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.juro.2006.08.087">10.1016/j.juro.2006.08.087</ext-link></comment>
<?supplied-pmid 17162091?><pub-id pub-id-type="pmid">17162091</pub-id></mixed-citation></ref><ref id="pone.0145322.ref173"><label>173</label><mixed-citation publication-type="journal"><name><surname>Nunez</surname><given-names>C</given-names></name>, <name><surname>Cansino</surname><given-names>JR</given-names></name>, <name><surname>Bethencourt</surname><given-names>F</given-names></name>, <name><surname>Perez-Utrilla</surname><given-names>M</given-names></name>, <name><surname>Fraile</surname><given-names>B</given-names></name>, <name><surname>Martinez-Onsurbe</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma)</article-title>. <source>Histopathology</source>. <year>2008</year>; <volume>53</volume>(<issue>2</issue>): <fpage>166</fpage>&#x02013;<lpage>176</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2559.2008.03092.x">10.1111/j.1365-2559.2008.03092.x</ext-link></comment>
<?supplied-pmid 18752500?><pub-id pub-id-type="pmid">18752500</pub-id></mixed-citation></ref><ref id="pone.0145322.ref174"><label>174</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Zou</surname><given-names>J</given-names></name>, <name><surname>Yao</surname><given-names>C</given-names></name>, <name><surname>Xiao</surname><given-names>H</given-names></name>, <name><surname>Liu</surname><given-names>Q</given-names></name>, <etal>et al</etal>
<article-title>Evaluating reproducibility of differential expression discoveries in microarray studies by considering correlated molecular changes</article-title>. <source>Bioinformatics</source>. <year>2009</year>; <volume>25</volume>(<issue>13</issue>): <fpage>1662</fpage>&#x02013;<lpage>1668</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btp295">10.1093/bioinformatics/btp295</ext-link></comment>
<?supplied-pmid 19417058?><pub-id pub-id-type="pmid">19417058</pub-id></mixed-citation></ref><ref id="pone.0145322.ref175"><label>175</label><mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>JD</given-names></name>. <article-title>The Ran-GTPase and cell-cycle control</article-title>. <source>Bioessays</source>. <year>2001</year>; <volume>23</volume>(<issue>1</issue>): <fpage>77</fpage>&#x02013;<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/1521-1878(200101)23:1&#x0003c;77::AID-BIES1010&#x0003e;3.0.CO;2-E">10.1002/1521-1878(200101)23:1&#x0003c;77::AID-BIES1010&#x0003e;3.0.CO;2-E</ext-link></comment>
<?supplied-pmid 11135312?><pub-id pub-id-type="pmid">11135312</pub-id></mixed-citation></ref><ref id="pone.0145322.ref176"><label>176</label><mixed-citation publication-type="journal"><name><surname>Clarke</surname><given-names>PR</given-names></name>, <name><surname>Zhang</surname><given-names>C</given-names></name>. <article-title>Spatial and temporal coordination of mitosis by Ran GTPase</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2008</year>; <volume>9</volume>(<issue>6</issue>): <fpage>464</fpage>&#x02013;<lpage>477</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrm2410">10.1038/nrm2410</ext-link></comment>
<?supplied-pmid 18478030?><pub-id pub-id-type="pmid">18478030</pub-id></mixed-citation></ref><ref id="pone.0145322.ref177"><label>177</label><mixed-citation publication-type="journal"><name><surname>Abe</surname><given-names>H</given-names></name>, <name><surname>Kamai</surname><given-names>T</given-names></name>, <name><surname>Shirataki</surname><given-names>H</given-names></name>, <name><surname>Oyama</surname><given-names>T</given-names></name>, <name><surname>Arai</surname><given-names>K</given-names></name>, <name><surname>Yoshida</surname><given-names>K</given-names></name>. <article-title>High expression of Ran GTPase is associated with local invasion and metastasis of human clear cell renal cell carcinoma</article-title>. <source>Int J Cancer</source>. <year>2008</year>; <volume>122</volume>(<issue>10</issue>): <fpage>2391</fpage>&#x02013;<lpage>2397</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.23400">10.1002/ijc.23400</ext-link></comment>
<?supplied-pmid 18241036?><pub-id pub-id-type="pmid">18241036</pub-id></mixed-citation></ref><ref id="pone.0145322.ref178"><label>178</label><mixed-citation publication-type="journal"><name><surname>Ouellet</surname><given-names>V</given-names></name>, <name><surname>Provencher</surname><given-names>DM</given-names></name>, <name><surname>Maugard</surname><given-names>CM</given-names></name>, <name><surname>Le Page</surname><given-names>C</given-names></name>, <name><surname>Ren</surname><given-names>F</given-names></name>, <name><surname>Lussier</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling</article-title>. <source>Oncogene</source>. <year>2005</year>; <volume>24</volume>(<issue>29</issue>): <fpage>4672</fpage>&#x02013;<lpage>4687</lpage>. <?supplied-pmid 15940270?><pub-id pub-id-type="pmid">15940270</pub-id></mixed-citation></ref><ref id="pone.0145322.ref179"><label>179</label><mixed-citation publication-type="journal"><name><surname>Ouellet</surname><given-names>V</given-names></name>, <name><surname>Guyot</surname><given-names>MC</given-names></name>, <name><surname>Le Page</surname><given-names>C</given-names></name>, <name><surname>Filali-Mouhim</surname><given-names>A</given-names></name>, <name><surname>Lussier</surname><given-names>C</given-names></name>, <name><surname>Tonin</surname><given-names>PN</given-names></name>, <etal>et al</etal>
<article-title>Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer</article-title>. <source>Int J Cancer</source>. <year>2006</year>; <volume>119</volume>(<issue>3</issue>): <fpage>599</fpage>&#x02013;<lpage>607</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.21902">10.1002/ijc.21902</ext-link></comment>
<?supplied-pmid 16572426?><pub-id pub-id-type="pmid">16572426</pub-id></mixed-citation></ref><ref id="pone.0145322.ref180"><label>180</label><mixed-citation publication-type="journal"><name><surname>Hung</surname><given-names>KE</given-names></name>, <name><surname>Faca</surname><given-names>V</given-names></name>, <name><surname>Song</surname><given-names>K</given-names></name>, <name><surname>Sarracino</surname><given-names>DA</given-names></name>, <name><surname>Richard</surname><given-names>LG</given-names></name>, <name><surname>Krastins</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis</article-title>. <source>Cancer Prev Res (Phila)</source>. <year>2009</year>; <volume>2</volume>(<issue>3</issue>): <fpage>224</fpage>&#x02013;<lpage>233</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1940-6207.CAPR-08-0153">10.1158/1940-6207.CAPR-08-0153</ext-link></comment><pub-id pub-id-type="pmid">19240248</pub-id></mixed-citation></ref><ref id="pone.0145322.ref181"><label>181</label><mixed-citation publication-type="journal"><name><surname>Xia</surname><given-names>F</given-names></name>, <name><surname>Lee</surname><given-names>CW</given-names></name>, <name><surname>Altieri</surname><given-names>DC</given-names></name>. <article-title>Tumor cell dependence on Ran-GTP-directed mitosis</article-title>. <source>Cancer Res</source>. <year>2008</year>; <volume>68</volume>(<issue>6</issue>): <fpage>1826</fpage>&#x02013;<lpage>1833</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-07-5279">10.1158/0008-5472.CAN-07-5279</ext-link></comment>
<?supplied-pmid 18339863?><pub-id pub-id-type="pmid">18339863</pub-id></mixed-citation></ref><ref id="pone.0145322.ref182"><label>182</label><mixed-citation publication-type="journal"><name><surname>Azuma</surname><given-names>K</given-names></name>, <name><surname>Sasada</surname><given-names>T</given-names></name>, <name><surname>Takedatsu</surname><given-names>H</given-names></name>, <name><surname>Shomura</surname><given-names>H</given-names></name>, <name><surname>Koga</surname><given-names>M</given-names></name>, <name><surname>Maeda</surname><given-names>Y</given-names></name>, <etal>et al</etal> Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) <article-title>epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients</article-title>. <source>Clin Cancer Res</source>. <year>2004</year>; <volume>10</volume>(<issue>19</issue>): <fpage>6695</fpage>&#x02013;<lpage>6702</lpage>. <?supplied-pmid 15475460?><pub-id pub-id-type="pmid">15475460</pub-id></mixed-citation></ref><ref id="pone.0145322.ref183"><label>183</label><mixed-citation publication-type="journal"><name><surname>Barres</surname><given-names>V</given-names></name>, <name><surname>Ouellet</surname><given-names>V</given-names></name>, <name><surname>Lafontaine</surname><given-names>J</given-names></name>, <name><surname>Tonin</surname><given-names>PN</given-names></name>, <name><surname>Provencher</surname><given-names>DM</given-names></name>, <name><surname>Mes-Masson</surname><given-names>AM</given-names></name>. <article-title>An essential role for Ran GTPase in epithelial ovarian cancer cell survival</article-title>. <source>Mol Cancer</source>. <year>2010</year>; <volume>9</volume>: <fpage>272</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1476-4598-9-272">10.1186/1476-4598-9-272</ext-link></comment>
<?supplied-pmid 20942967?><pub-id pub-id-type="pmid">20942967</pub-id></mixed-citation></ref><ref id="pone.0145322.ref184"><label>184</label><mixed-citation publication-type="journal"><name><surname>Kurisetty</surname><given-names>VV</given-names></name>, <name><surname>Johnston</surname><given-names>PG</given-names></name>, <name><surname>Johnston</surname><given-names>N</given-names></name>, <name><surname>Erwin</surname><given-names>P</given-names></name>, <name><surname>Crowe</surname><given-names>P</given-names></name>, <name><surname>Fernig</surname><given-names>DG</given-names></name>, <etal>et al</etal>
<article-title>RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin</article-title>. <source>Oncogene</source>. <year>2008</year>; <volume>27</volume>(<issue>57</issue>): <fpage>7139</fpage>&#x02013;<lpage>7149</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/onc.2008.325">10.1038/onc.2008.325</ext-link></comment>
<?supplied-pmid 18794800?><pub-id pub-id-type="pmid">18794800</pub-id></mixed-citation></ref><ref id="pone.0145322.ref185"><label>185</label><mixed-citation publication-type="journal"><name><surname>Katayama</surname><given-names>H</given-names></name>, <name><surname>Brinkley</surname><given-names>WR</given-names></name>, <name><surname>Sen</surname><given-names>S</given-names></name>. <article-title>The Aurora kinases: role in cell transformation and tumorigenesis</article-title>. <source>Cancer Metastasis Rev</source>. <year>2003</year>; <volume>22</volume>(<issue>4</issue>): <fpage>451</fpage>&#x02013;<lpage>464</lpage>. <?supplied-pmid 12884918?><pub-id pub-id-type="pmid">12884918</pub-id></mixed-citation></ref><ref id="pone.0145322.ref186"><label>186</label><mixed-citation publication-type="journal"><name><surname>Vainio</surname><given-names>P</given-names></name>, <name><surname>Mpindi</surname><given-names>JP</given-names></name>, <name><surname>Kohonen</surname><given-names>P</given-names></name>, <name><surname>Fey</surname><given-names>V</given-names></name>, <name><surname>Mirtti</surname><given-names>T</given-names></name>, <name><surname>Alanen</surname><given-names>KA</given-names></name>, <etal>et al</etal>
<article-title>High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer</article-title>. <source>PLoS One</source>. <year>2012</year>; <volume>7</volume>(<issue>6</issue>): <fpage>e39801</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0039801">10.1371/journal.pone.0039801</ext-link></comment>
<?supplied-pmid 22761906?><pub-id pub-id-type="pmid">22761906</pub-id></mixed-citation></ref><ref id="pone.0145322.ref187"><label>187</label><mixed-citation publication-type="journal"><name><surname>Neumayer</surname><given-names>G</given-names></name>, <name><surname>Belzil</surname><given-names>C</given-names></name>, <name><surname>Gruss</surname><given-names>OJ</given-names></name>, <name><surname>Nguyen</surname><given-names>MD</given-names></name>. <article-title>TPX2: of spindle assembly, DNA damage response, and cancer</article-title>. <source>Cell Mol Life Sci</source>. <year>2014</year>; <volume>71</volume>(<issue>16</issue>): <fpage>3027</fpage>&#x02013;<lpage>3047</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00018-014-1582-7">10.1007/s00018-014-1582-7</ext-link></comment>
<?supplied-pmid 24556998?><pub-id pub-id-type="pmid">24556998</pub-id></mixed-citation></ref><ref id="pone.0145322.ref188"><label>188</label><mixed-citation publication-type="journal"><name><surname>Carter</surname><given-names>SL</given-names></name>, <name><surname>Eklund</surname><given-names>AC</given-names></name>, <name><surname>Kohane</surname><given-names>IS</given-names></name>, <name><surname>Harris</surname><given-names>LN</given-names></name>, <name><surname>Szallasi</surname><given-names>Z</given-names></name>. <article-title>A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers</article-title>. <source>Nat Genet</source>. <year>2006</year>; <volume>38</volume>(<issue>9</issue>): <fpage>1043</fpage>&#x02013;<lpage>1048</lpage>. <?supplied-pmid 16921376?><pub-id pub-id-type="pmid">16921376</pub-id></mixed-citation></ref><ref id="pone.0145322.ref189"><label>189</label><mixed-citation publication-type="journal"><name><surname>Pannu</surname><given-names>V</given-names></name>, <name><surname>Rida</surname><given-names>PC</given-names></name>, <name><surname>Ogden</surname><given-names>A</given-names></name>, <name><surname>Turaga</surname><given-names>RC</given-names></name>, <name><surname>Donthamsetty</surname><given-names>S</given-names></name>, <name><surname>Bowen</surname><given-names>NJ</given-names></name>, <etal>et al</etal>
<article-title>HSET overexpression fuels tumor progression via centrosome clustering-independent mechanisms in breast cancer patients</article-title>. <source>Oncotarget</source>. <year>2015</year>; <volume>6</volume>(<issue>8</issue>): <fpage>6076</fpage>&#x02013;<lpage>6091</lpage>. <?supplied-pmid 25788277?><pub-id pub-id-type="pmid">25788277</pub-id></mixed-citation></ref><ref id="pone.0145322.ref190"><label>190</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>P</given-names></name>, <name><surname>Yu</surname><given-names>X</given-names></name>, <name><surname>Ge</surname><given-names>K</given-names></name>, <name><surname>Melamed</surname><given-names>J</given-names></name>, <name><surname>Roeder</surname><given-names>RG</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>. <source>Heterogeneous Expression and Functions of Androgen Receptor Co-Factors in Primary Prostate Cancer</source>. <year>2002</year>; <volume>161</volume>(<issue>4</issue>): <fpage>1467</fpage>&#x02013;<lpage>1474</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0002-9440(10)64422-7">10.1016/S0002-9440(10)64422-7</ext-link></comment></mixed-citation></ref><ref id="pone.0145322.ref191"><label>191</label><mixed-citation publication-type="journal"><name><surname>Hsiao</surname><given-names>P-</given-names></name>, <name><surname>Lin</surname><given-names>D-</given-names></name>, <name><surname>Nakao</surname><given-names>R</given-names></name>, <name><surname>Chang</surname><given-names>C</given-names></name>. <article-title>The Linkage of Kennedy's Neuron Disease to ARA24, the First Identified Androgen Receptor Polyglutamine Region-associated Coactivator</article-title>. <source>J Biol Chem</source>. <year>1999</year>; <volume>274</volume>(<issue>29</issue>): <fpage>20229</fpage>&#x02013;<lpage>20234</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.274.29.20229">10.1074/jbc.274.29.20229</ext-link></comment>
<?supplied-pmid 10400640?><pub-id pub-id-type="pmid">10400640</pub-id></mixed-citation></ref><ref id="pone.0145322.ref192"><label>192</label><mixed-citation publication-type="journal"><name><surname>Harada</surname><given-names>N</given-names></name>, <name><surname>Ohmori</surname><given-names>Y</given-names></name>, <name><surname>Yamaji</surname><given-names>R</given-names></name>, <name><surname>Higashimura</surname><given-names>Y</given-names></name>, <name><surname>Okamoto</surname><given-names>K</given-names></name>, <name><surname>Isohashi</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>ARA24/Ran enhances the androgen-dependent NH2- and COOH-terminal interaction of the androgen receptor</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2008</year>; <volume>373</volume>(<issue>3</issue>): <fpage>373</fpage>&#x02013;<lpage>377</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbrc.2008.06.024">10.1016/j.bbrc.2008.06.024</ext-link></comment>
<?supplied-pmid 18565325?><pub-id pub-id-type="pmid">18565325</pub-id></mixed-citation></ref><ref id="pone.0145322.ref193"><label>193</label><mixed-citation publication-type="journal"><name><surname>Heldin</surname><given-names>CH</given-names></name>, <name><surname>Landstrom</surname><given-names>M</given-names></name>, <name><surname>Moustakas</surname><given-names>A</given-names></name>. <article-title>Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition</article-title>. <source>Curr Opin Cell Biol</source>. <year>2009</year>; <volume>21</volume>(<issue>2</issue>): <fpage>166</fpage>&#x02013;<lpage>176</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ceb.2009.01.021">10.1016/j.ceb.2009.01.021</ext-link></comment>
<?supplied-pmid 19237272?><pub-id pub-id-type="pmid">19237272</pub-id></mixed-citation></ref><ref id="pone.0145322.ref194"><label>194</label><mixed-citation publication-type="journal"><name><surname>Blobe</surname><given-names>GC</given-names></name>, <name><surname>Schiemann</surname><given-names>WP</given-names></name>, <name><surname>Lodish</surname><given-names>HF</given-names></name>. <article-title>Role of transforming growth factor beta in human disease</article-title>. <source>N Engl J Med</source>. <year>2000</year>; <volume>342</volume>(<issue>18</issue>): <fpage>1350</fpage>&#x02013;<lpage>1358</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJM200005043421807">10.1056/NEJM200005043421807</ext-link></comment>
<?supplied-pmid 10793168?><pub-id pub-id-type="pmid">10793168</pub-id></mixed-citation></ref><ref id="pone.0145322.ref195"><label>195</label><mixed-citation publication-type="journal"><name><surname>Massague</surname><given-names>J</given-names></name>. <article-title>TGFbeta in Cancer</article-title>. <source>Cell</source>. <year>2008</year>; <volume>134</volume>(<issue>2</issue>): <fpage>215</fpage>&#x02013;<lpage>230</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2008.07.001">10.1016/j.cell.2008.07.001</ext-link></comment>
<?supplied-pmid 18662538?><pub-id pub-id-type="pmid">18662538</pub-id></mixed-citation></ref><ref id="pone.0145322.ref196"><label>196</label><mixed-citation publication-type="journal"><name><surname>Ravitz</surname><given-names>MJ</given-names></name>, <name><surname>Wenner</surname><given-names>CE</given-names></name>. <article-title>Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta</article-title>. <source>Adv Cancer Res</source>. <year>1997</year>; <volume>71</volume>: <fpage>165</fpage>&#x02013;<lpage>207</lpage>. <?supplied-pmid 9111866?><pub-id pub-id-type="pmid">9111866</pub-id></mixed-citation></ref><ref id="pone.0145322.ref197"><label>197</label><mixed-citation publication-type="journal"><name><surname>Aalinkeel</surname><given-names>R</given-names></name>, <name><surname>Nair</surname><given-names>MP</given-names></name>, <name><surname>Sufrin</surname><given-names>G</given-names></name>, <name><surname>Mahajan</surname><given-names>SD</given-names></name>, <name><surname>Chadha</surname><given-names>KC</given-names></name>, <name><surname>Chawda</surname><given-names>RP</given-names></name>, <etal>et al</etal>
<article-title>Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells</article-title>. <source>Cancer Res</source>. <year>2004</year>; <volume>64</volume>(<issue>15</issue>): <fpage>5311</fpage>&#x02013;<lpage>5321</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-2506-2">10.1158/0008-5472.CAN-2506-2</ext-link></comment>
<?supplied-pmid 15289337?><pub-id pub-id-type="pmid">15289337</pub-id></mixed-citation></ref><ref id="pone.0145322.ref198"><label>198</label><mixed-citation publication-type="journal"><name><surname>Wan</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>M</given-names></name>, <name><surname>Kolattukudy</surname><given-names>S</given-names></name>, <name><surname>Stark</surname><given-names>GR</given-names></name>, <name><surname>Lu</surname><given-names>T</given-names></name>. <article-title>Activation of cAMP-responsive-element-binding protein by PI3 kinase and p38 MAPK is essential for elevated expression of transforming growth factor beta2 in cancer cells</article-title>. <source>J Interferon Cytokine Res</source>. <year>2010</year>; <volume>30</volume>(<issue>9</issue>): <fpage>677</fpage>&#x02013;<lpage>681</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1089/jir.2009.0117">10.1089/jir.2009.0117</ext-link></comment>
<?supplied-pmid 20629536?><pub-id pub-id-type="pmid">20629536</pub-id></mixed-citation></ref><ref id="pone.0145322.ref199"><label>199</label><mixed-citation publication-type="journal"><name><surname>Dallas</surname><given-names>SL</given-names></name>, <name><surname>Zhao</surname><given-names>S</given-names></name>, <name><surname>Cramer</surname><given-names>SD</given-names></name>, <name><surname>Chen</surname><given-names>Z</given-names></name>, <name><surname>Peehl</surname><given-names>DM</given-names></name>, <name><surname>Bonewald</surname><given-names>LF</given-names></name>. <article-title>Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen</article-title>. <source>J Cell Physiol</source>. <year>2005</year>; <volume>202</volume>(<issue>2</issue>): <fpage>361</fpage>&#x02013;<lpage>370</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jcp.20147">10.1002/jcp.20147</ext-link></comment>
<?supplied-pmid 15389580?><pub-id pub-id-type="pmid">15389580</pub-id></mixed-citation></ref><ref id="pone.0145322.ref200"><label>200</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>IY</given-names></name>, <name><surname>Ahn</surname><given-names>HJ</given-names></name>, <name><surname>Zelner</surname><given-names>DJ</given-names></name>, <name><surname>Shaw</surname><given-names>JW</given-names></name>, <name><surname>Lang</surname><given-names>S</given-names></name>, <name><surname>Kato</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues</article-title>. <source>Clin Cancer Res</source>. <year>1996</year>; <volume>2</volume>(<issue>8</issue>): <fpage>1255</fpage>&#x02013;<lpage>1261</lpage>. <?supplied-pmid 9816295?><pub-id pub-id-type="pmid">9816295</pub-id></mixed-citation></ref><ref id="pone.0145322.ref201"><label>201</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>IY</given-names></name>, <name><surname>Ahn</surname><given-names>HJ</given-names></name>, <name><surname>Lang</surname><given-names>S</given-names></name>, <name><surname>Oefelein</surname><given-names>MG</given-names></name>, <name><surname>Oyasu</surname><given-names>R</given-names></name>, <name><surname>Kozlowski</surname><given-names>JM</given-names></name>, <etal>et al</etal>
<article-title>Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients</article-title>. <source>Clin Cancer Res</source>. <year>1998</year>; <volume>4</volume>(<issue>7</issue>): <fpage>1625</fpage>&#x02013;<lpage>1630</lpage>. <?supplied-pmid 9676836?><pub-id pub-id-type="pmid">9676836</pub-id></mixed-citation></ref><ref id="pone.0145322.ref202"><label>202</label><mixed-citation publication-type="journal"><name><surname>Wikstrom</surname><given-names>P</given-names></name>, <name><surname>Stattin</surname><given-names>P</given-names></name>, <name><surname>Franck-Lissbrant</surname><given-names>I</given-names></name>, <name><surname>Damber</surname><given-names>JE</given-names></name>, <name><surname>Bergh</surname><given-names>A</given-names></name>. <article-title>Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer</article-title>. <source>Prostate</source>. <year>1998</year>; <volume>37</volume>(<issue>1</issue>): <fpage>19</fpage>&#x02013;<lpage>29</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/(SICI)1097-0045(19980915)37:1&#x0003c;19::AID-PROS4&#x0003e;3.0.CO;2&#x02013;3">10.1002/(SICI)1097-0045(19980915)37:1&#x0003c;19::AID-PROS4&#x0003e;3.0.CO;2&#x02013;3</ext-link></comment>
<?supplied-pmid 9721065?><pub-id pub-id-type="pmid">9721065</pub-id></mixed-citation></ref><ref id="pone.0145322.ref203"><label>203</label><mixed-citation publication-type="journal"><name><surname>Shariat</surname><given-names>SF</given-names></name>, <name><surname>Kattan</surname><given-names>MW</given-names></name>, <name><surname>Traxel</surname><given-names>E</given-names></name>, <name><surname>Andrews</surname><given-names>B</given-names></name>, <name><surname>Zhu</surname><given-names>K</given-names></name>, <name><surname>Wheeler</surname><given-names>TM</given-names></name>, <etal>et al</etal>
<article-title>Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression</article-title>. <source>Clin Cancer Res</source>. <year>2004</year>; <volume>10</volume>(<issue>6</issue>): <fpage>1992</fpage>&#x02013;<lpage>1999</lpage>. <?supplied-pmid 15041717?><pub-id pub-id-type="pmid">15041717</pub-id></mixed-citation></ref><ref id="pone.0145322.ref204"><label>204</label><mixed-citation publication-type="journal"><name><surname>Ajiboye</surname><given-names>S</given-names></name>, <name><surname>Sissung</surname><given-names>TM</given-names></name>, <name><surname>Sharifi</surname><given-names>N</given-names></name>, <name><surname>Figg</surname><given-names>WD</given-names></name>. <article-title>More than an accessory: implications of type III transforming growth factor-&#x000df; receptor loss in prostate cancer</article-title>. <source>BJU Int</source>. <year>2010</year>; <volume>105</volume>(<issue>7</issue>): <fpage>913</fpage>&#x02013;<lpage>916</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1464-410X.2009.08999.x">10.1111/j.1464-410X.2009.08999.x</ext-link></comment>
<?supplied-pmid 20067462?><pub-id pub-id-type="pmid">20067462</pub-id></mixed-citation></ref><ref id="pone.0145322.ref205"><label>205</label><mixed-citation publication-type="journal"><name><surname>Lucia</surname><given-names>MS</given-names></name>, <name><surname>Sporn</surname><given-names>MB</given-names></name>, <name><surname>Roberts</surname><given-names>AB</given-names></name>, <name><surname>Stewart</surname><given-names>LV</given-names></name>, <name><surname>Danielpour</surname><given-names>D</given-names></name>. <article-title>The role of transforming growth factor-beta1, -beta2, and -beta3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells</article-title>. <source>J Cell Physiol</source>. <year>1998</year>; <volume>175</volume>(<issue>2</issue>): <fpage>184</fpage>&#x02013;<lpage>192</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/(SICI)1097-4652(199805)175:2&#x0003c;184::AID-JCP8&#x0003e;3.0.CO;2-K">10.1002/(SICI)1097-4652(199805)175:2&#x0003c;184::AID-JCP8&#x0003e;3.0.CO;2-K</ext-link></comment>
<?supplied-pmid 9525477?><pub-id pub-id-type="pmid">9525477</pub-id></mixed-citation></ref><ref id="pone.0145322.ref206"><label>206</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>YE</given-names></name>. <article-title>Non-Smad pathways in TGF-beta signaling</article-title>. <source>Cell Res</source>. <year>2009</year>; <volume>19</volume>(<issue>1</issue>): <fpage>128</fpage>&#x02013;<lpage>139</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/cr.2008.328">10.1038/cr.2008.328</ext-link></comment>
<?supplied-pmid 19114990?><pub-id pub-id-type="pmid">19114990</pub-id></mixed-citation></ref><ref id="pone.0145322.ref207"><label>207</label><mixed-citation publication-type="journal"><name><surname>Zavadil</surname><given-names>J</given-names></name>, <name><surname>Bitzer</surname><given-names>M</given-names></name>, <name><surname>Liang</surname><given-names>D</given-names></name>, <name><surname>Yang</surname><given-names>YC</given-names></name>, <name><surname>Massimi</surname><given-names>A</given-names></name>, <name><surname>Kneitz</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2001</year>; <volume>98</volume>(<issue>12</issue>): <fpage>6686</fpage>&#x02013;<lpage>6691</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.111614398">10.1073/pnas.111614398</ext-link></comment>
<?supplied-pmid 11390996?><pub-id pub-id-type="pmid">11390996</pub-id></mixed-citation></ref><ref id="pone.0145322.ref208"><label>208</label><mixed-citation publication-type="journal"><name><surname>Savli</surname><given-names>H</given-names></name>, <name><surname>Szendroi</surname><given-names>A</given-names></name>, <name><surname>Romics</surname><given-names>I</given-names></name>, <name><surname>Nagy</surname><given-names>B</given-names></name>. <article-title>Gene network and canonical pathway analysis in prostate cancer: a microarray study</article-title>. <source>Exp Mol Med</source>. <year>2008</year>; <volume>40</volume>(<issue>2</issue>): <fpage>176</fpage>&#x02013;<lpage>185</lpage>. <?supplied-pmid 18446056?><pub-id pub-id-type="pmid">18446056</pub-id></mixed-citation></ref><ref id="pone.0145322.ref209"><label>209</label><mixed-citation publication-type="journal"><name><surname>Jia</surname><given-names>P</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Zhao</surname><given-names>Z</given-names></name>. <article-title>Integrative pathway analysis of genome-wide association studies and gene expression data in prostate cancer</article-title>. <source>BMC Syst Biol</source>. <year>2012</year>; <volume>6</volume>
<issue>Suppl 3</issue>: <fpage>S3</fpage>&#x02013;<lpage>S13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1752-0509-6-S3-S13">10.1186/1752-0509-6-S3-S13</ext-link></comment>
<?supplied-pmid 23281744?><pub-id pub-id-type="pmid">23281744</pub-id></mixed-citation></ref></ref-list></back></article>